Intravenous	O
azithromycin	B-DRUG
-	O
induced	O
ototoxicity	B-ADVEFFECT
.	O
Immobilization	O
,	O
while	O
Paget	O
's	O
bone	O
disease	O
was	O
present	O
,	O
and	O
perhaps	O
enhanced	O
activation	O
of	O
dihydrotachysterol	B-DRUG
by	O
rifampicin	O
,	O
could	O
have	O
led	O
to	O
increased	B-ADVEFFECT
calcium	I-ADVEFFECT
-	I-ADVEFFECT
release	I-ADVEFFECT
into	O
the	O
circulation	O
.	O
Unaccountable	O
severe	O
hypercalcemia	B-ADVEFFECT
in	O
a	O
patient	O
treated	O
for	O
hypoparathyroidism	O
with	O
dihydrotachysterol	B-DRUG
.	O
METHODS	O
:	O
We	O
report	O
two	O
cases	O
of	O
pseudoporphyria	B-ADVEFFECT
caused	O
by	O
naproxen	B-DRUG
and	O
oxaprozin	B-DRUG
.	O
METHODS	O
:	O
We	O
report	O
two	O
cases	O
of	O
pseudoporphyria	B-ADVEFFECT
caused	O
by	O
naproxen	B-DRUG
and	O
oxaprozin	B-DRUG
.	O
Naproxen	B-DRUG
,	O
the	O
most	O
common	O
offender	O
,	O
has	O
been	O
associated	O
with	O
a	O
dimorphic	O
clinical	O
pattern	O
:	O
a	O
PCT	O
-	O
like	O
presentation	O
and	O
one	O
simulating	O
erythropoietic	B-ADVEFFECT
protoporphyria	I-ADVEFFECT
in	O
the	O
pediatric	O
population	O
.	O
RESULTS	O
:	O
A	O
44-year	O
-	O
old	O
man	O
taking	O
naproxen	B-DRUG
for	O
chronic	O
low	O
back	O
pain	O
and	O
a	O
20-year	O
-	O
old	O
woman	O
on	O
oxaprozin	B-DRUG
for	O
rheumatoid	O
arthritis	O
presented	O
with	O
tense	B-ADVEFFECT
bullae	I-ADVEFFECT
and	O
cutaneous	B-ADVEFFECT
fragility	I-ADVEFFECT
on	O
the	O
face	O
and	O
the	O
back	O
of	O
the	O
hands	O
.	O
RESULTS	O
:	O
A	O
44-year	O
-	O
old	O
man	O
taking	O
naproxen	B-DRUG
for	O
chronic	O
low	O
back	O
pain	O
and	O
a	O
20-year	O
-	O
old	O
woman	O
on	O
oxaprozin	B-DRUG
for	O
rheumatoid	O
arthritis	O
presented	O
with	O
tense	B-ADVEFFECT
bullae	I-ADVEFFECT
and	O
cutaneous	B-ADVEFFECT
fragility	I-ADVEFFECT
on	O
the	O
face	O
and	O
the	O
back	O
of	O
the	O
hands	O
.	O
RESULTS	O
:	O
A	O
44-year	O
-	O
old	O
man	O
taking	O
naproxen	B-DRUG
for	O
chronic	O
low	O
back	O
pain	O
and	O
a	O
20-year	O
-	O
old	O
woman	O
on	O
oxaprozin	B-DRUG
for	O
rheumatoid	O
arthritis	O
presented	O
with	O
tense	B-ADVEFFECT
bullae	I-ADVEFFECT
and	O
cutaneous	B-ADVEFFECT
fragility	I-ADVEFFECT
on	O
the	O
face	O
and	O
the	O
back	O
of	O
the	O
hands	O
.	O
RESULTS	O
:	O
A	O
44-year	O
-	O
old	O
man	O
taking	O
naproxen	B-DRUG
for	O
chronic	O
low	O
back	O
pain	O
and	O
a	O
20-year	O
-	O
old	O
woman	O
on	O
oxaprozin	B-DRUG
for	O
rheumatoid	O
arthritis	O
presented	O
with	O
tense	B-ADVEFFECT
bullae	I-ADVEFFECT
and	O
cutaneous	B-ADVEFFECT
fragility	I-ADVEFFECT
on	O
the	O
face	O
and	O
the	O
back	O
of	O
the	O
hands	O
.	O
BACKGROUND	O
:	O
How	O
to	O
best	O
treat	O
psychotic	O
patients	O
who	O
have	O
had	O
past	O
clozapine	B-DRUG
-	O
induced	O
agranulocytosis	O
or	O
granulocytopenia	B-ADVEFFECT
remains	O
a	O
problem	O
.	O
CONCLUSION	O
:	O
The	O
results	O
suggest	O
that	O
olanzapine	O
may	O
be	O
useful	O
in	O
treating	O
patients	O
with	O
clozapine	B-DRUG
-	O
induced	O
granulocytopenia	B-ADVEFFECT
without	O
the	O
risk	O
of	O
recurrence	O
of	O
hematologic	O
side	O
effects	O
.	O
Prolonged	O
severe	O
5-fluorouracil	B-DRUG
-	O
associated	O
neurotoxicity	B-ADVEFFECT
in	O
a	O
patient	O
with	O
dihydropyrimidine	O
dehydrogenase	O
deficiency	O
.	O
We	O
describe	O
the	O
side	O
effects	O
of	O
5-FU	B-DRUG
in	O
a	O
colon	O
cancer	O
patient	O
who	O
suffered	O
severe	B-ADVEFFECT
mucositis	I-ADVEFFECT
,	O
desquamating	O
dermatitis	O
,	O
prolonged	B-ADVEFFECT
myelosuppression	I-ADVEFFECT
,	O
and	O
neurologic	B-ADVEFFECT
toxicity	I-ADVEFFECT
that	O
required	O
admission	O
to	O
the	O
intensive	O
care	O
unit	O
.	O
We	O
describe	O
the	O
side	O
effects	O
of	O
5-FU	B-DRUG
in	O
a	O
colon	O
cancer	O
patient	O
who	O
suffered	O
severe	B-ADVEFFECT
mucositis	I-ADVEFFECT
,	O
desquamating	O
dermatitis	O
,	O
prolonged	B-ADVEFFECT
myelosuppression	I-ADVEFFECT
,	O
and	O
neurologic	B-ADVEFFECT
toxicity	I-ADVEFFECT
that	O
required	O
admission	O
to	O
the	O
intensive	O
care	O
unit	O
.	O
We	O
describe	O
the	O
side	O
effects	O
of	O
5-FU	B-DRUG
in	O
a	O
colon	O
cancer	O
patient	O
who	O
suffered	O
severe	B-ADVEFFECT
mucositis	I-ADVEFFECT
,	O
desquamating	O
dermatitis	O
,	O
prolonged	B-ADVEFFECT
myelosuppression	I-ADVEFFECT
,	O
and	O
neurologic	B-ADVEFFECT
toxicity	I-ADVEFFECT
that	O
required	O
admission	O
to	O
the	O
intensive	O
care	O
unit	O
.	O
This	O
case	O
suggests	O
that	O
BH	B-DRUG
-	I-DRUG
AC	I-DRUG
,	O
a	O
derivative	O
of	O
cytosine	O
arabinoside	O
(	O
1-beta	O
-	O
D	O
-	O
arabinofuranosylcytosine	O
)	O
could	O
be	O
a	O
cause	O
of	O
reversible	O
encephalopathy	B-ADVEFFECT
syndrome	I-ADVEFFECT
.	O
We	O
report	O
a	O
case	O
of	O
reversible	O
encephalopathy	B-ADVEFFECT
syndrome	I-ADVEFFECT
in	O
a	O
16-year	O
-	O
old	O
girl	O
with	O
acute	O
myelogenous	O
leukemia	O
(	O
AML	O
)	O
,	O
who	O
is	O
undergoing	O
during	O
consolidation	O
chemotherapy	O
composed	O
of	O
BH	B-DRUG
-	I-DRUG
AC	I-DRUG
(	O
N4-behenoyl-1-beta	O
-	O
D	O
-	O
arabinofuranosyl	O
cytosine	O
)	O
and	O
idarubicin	B-DRUG
.	O
We	O
report	O
a	O
case	O
of	O
reversible	O
encephalopathy	B-ADVEFFECT
syndrome	I-ADVEFFECT
in	O
a	O
16-year	O
-	O
old	O
girl	O
with	O
acute	O
myelogenous	O
leukemia	O
(	O
AML	O
)	O
,	O
who	O
is	O
undergoing	O
during	O
consolidation	O
chemotherapy	O
composed	O
of	O
BH	B-DRUG
-	I-DRUG
AC	I-DRUG
(	O
N4-behenoyl-1-beta	O
-	O
D	O
-	O
arabinofuranosyl	O
cytosine	O
)	O
and	O
idarubicin	B-DRUG
.	O
In	O
one	O
case	O
,	O
the	O
readministration	O
of	O
riluzole	B-DRUG
was	O
followed	O
by	O
the	O
relapse	O
of	O
hepatitis	B-ADVEFFECT
.	O
We	O
report	O
the	O
cases	O
of	O
two	O
patients	O
who	O
developed	O
acute	O
hepatitis	B-ADVEFFECT
after	O
taking	O
riluzole	B-DRUG
at	O
the	O
recommended	O
dose	O
(	O
100	O
mg	O
daily	O
)	O
for	O
7	O
and	O
4	O
weeks	O
,	O
respectively	O
.	O
Lupus	B-ADVEFFECT
-	I-ADVEFFECT
like	I-ADVEFFECT
syndrome	I-ADVEFFECT
caused	O
by	O
5-aminosalicylic	B-DRUG
acid	I-DRUG
in	O
patients	O
with	O
inflammatory	O
bowel	O
disease	O
.	O
Although	O
the	O
two	O
local	O
anesthetics	O
usually	O
do	O
not	O
cause	O
methemoglobinemia	B-ADVEFFECT
,	O
we	O
suspect	O
that	O
the	O
displacement	O
of	O
lidocaine	B-DRUG
from	O
protein	O
binding	O
by	O
bupivacaine	B-DRUG
,	O
in	O
combination	O
with	O
metabolic	O
acidosis	O
and	O
treatment	O
with	O
other	O
oxidants	O
,	O
was	O
the	O
reason	O
for	O
the	O
development	O
of	O
methemoglobinemia	B-ADVEFFECT
.	O
Methemoglobinemia	B-ADVEFFECT
after	O
axillary	O
block	O
with	O
bupivacaine	B-DRUG
and	O
additional	O
injection	O
of	O
lidocaine	B-DRUG
in	O
the	O
operative	O
field	O
.	O
Methemoglobinemia	B-ADVEFFECT
after	O
axillary	O
block	O
with	O
bupivacaine	B-DRUG
and	O
additional	O
injection	O
of	O
lidocaine	B-DRUG
in	O
the	O
operative	O
field	O
.	O
We	O
report	O
a	O
patient	O
with	O
chronic	O
renal	O
failure	O
and	O
ischemic	O
heart	O
disease	O
who	O
developed	O
clinically	O
significant	O
methemoglobinemia	B-ADVEFFECT
after	O
an	O
axillary	O
block	O
with	O
bupivacaine	B-DRUG
and	O
additional	O
injection	O
of	O
lidocaine	B-DRUG
in	O
the	O
operative	O
field	O
.	O
We	O
report	O
a	O
patient	O
with	O
chronic	O
renal	O
failure	O
and	O
ischemic	O
heart	O
disease	O
who	O
developed	O
clinically	O
significant	O
methemoglobinemia	B-ADVEFFECT
after	O
an	O
axillary	O
block	O
with	O
bupivacaine	B-DRUG
and	O
additional	O
injection	O
of	O
lidocaine	B-DRUG
in	O
the	O
operative	O
field	O
.	O
Detection	O
of	O
activated	O
eosinophils	O
in	O
nasal	O
polyps	O
of	O
an	O
aspirin	B-DRUG
-	O
induced	O
asthma	B-ADVEFFECT
patient	O
.	O
An	O
episode	O
of	O
subacute	O
encephalopathy	B-ADVEFFECT
after	O
the	O
infusion	O
of	O
a	O
moderate	O
dose	O
of	O
methotrexate	B-DRUG
(	O
1500	O
mg	O
/	O
m2	O
)	O
(	O
MTX	O
)	O
is	O
reported	O
in	O
a	O
young	O
adult	O
with	O
metastastic	O
gastric	O
cancer	O
.	O
We	O
believe	O
that	O
this	O
represents	O
an	O
unusual	O
case	O
of	O
moderate	O
-	O
dose	O
MTX	B-DRUG
-	O
induced	O
neurotoxicity	B-ADVEFFECT
in	O
a	O
patient	O
with	O
gastric	O
cancer	O
,	O
which	O
has	O
not	O
previously	O
been	O
reported	O
.	O
We	O
describe	O
a	O
life	O
threatening	O
side	O
effect	O
of	O
acute	O
epoprostenol	B-DRUG
infusion	O
(	O
pulmonary	B-ADVEFFECT
edema	I-ADVEFFECT
)	O
in	O
a	O
patient	O
with	O
pulmonary	O
hypertension	O
associated	O
with	O
limited	O
scleroderma	O
and	O
discuss	O
its	O
management	O
and	O
potential	O
etiology	O
.	O
A	O
14-year	O
-	O
old	O
girl	O
with	O
newly	O
diagnosed	O
SLE	O
developed	O
a	O
pruritic	B-ADVEFFECT
bullous	I-ADVEFFECT
eruption	I-ADVEFFECT
while	O
on	O
prednisone	B-DRUG
.	O
Hydroxyurea	B-DRUG
-	O
induced	O
acute	B-ADVEFFECT
interstitial	I-ADVEFFECT
pneumonitis	I-ADVEFFECT
in	O
a	O
patient	O
with	O
essential	O
thrombocythemia	O
.	O
The	O
clinical	O
course	O
suggests	O
that	O
the	O
interstitial	B-ADVEFFECT
pneumonitis	I-ADVEFFECT
was	O
induced	O
by	O
hydroxyurea	B-DRUG
.	O
This	O
is	O
the	O
first	O
case	O
of	O
hydroxyurea	B-DRUG
-	O
induced	O
acute	B-ADVEFFECT
interstitial	I-ADVEFFECT
pneumonitis	I-ADVEFFECT
reported	O
in	O
the	O
literature	O
.	O
Allergic	O
and	O
irritant	B-ADVEFFECT
contact	I-ADVEFFECT
dermatitis	I-ADVEFFECT
to	O
calcipotriol	B-DRUG
.	O
Calcipotriol	B-DRUG
(	O
Daivonex	O
R	O
;	O
Leo	O
Pharmaceuticals	O
,	O
Zurich	O
,	O
Switzerland	O
)	O
may	O
cause	O
irritation	B-ADVEFFECT
of	I-ADVEFFECT
the	I-ADVEFFECT
skin	I-ADVEFFECT
,	O
whereas	O
allergic	B-ADVEFFECT
reactions	I-ADVEFFECT
are	O
less	O
common	O
.	O
Calcipotriol	B-DRUG
(	O
Daivonex	O
R	O
;	O
Leo	O
Pharmaceuticals	O
,	O
Zurich	O
,	O
Switzerland	O
)	O
may	O
cause	O
irritation	B-ADVEFFECT
of	I-ADVEFFECT
the	I-ADVEFFECT
skin	I-ADVEFFECT
,	O
whereas	O
allergic	B-ADVEFFECT
reactions	I-ADVEFFECT
are	O
less	O
common	O
.	O
The	O
present	O
observation	O
suggests	O
,	O
that	O
a	O
batch	O
of	O
different	O
testing	O
doses	O
,	O
including	O
lower	O
testing	O
doses	O
may	O
help	O
to	O
differentiate	O
between	O
an	O
allergic	O
type	O
of	O
contact	O
dermatitis	O
and	O
an	O
irritant	B-ADVEFFECT
type	I-ADVEFFECT
of	I-ADVEFFECT
reaction	I-ADVEFFECT
after	O
treatment	O
with	O
calcipotriol	B-DRUG
.	O
Myotonia	B-ADVEFFECT
associated	O
with	O
sarcoidosis	O
:	O
marked	O
exacerbation	O
with	O
pravastatin	B-DRUG
.	O
Pravastatin	B-DRUG
is	O
associated	O
with	O
myotonia	B-ADVEFFECT
in	O
animals	O
.	O
This	O
case	O
suggests	O
that	O
sarcoidosis	O
and	O
pravastatin	B-DRUG
,	O
two	O
entities	O
not	O
frequently	O
associated	O
with	O
myotonia	B-ADVEFFECT
,	O
may	O
interact	O
in	O
a	O
synergistic	O
manner	O
to	O
produce	O
severe	O
clinical	O
myotonia	B-ADVEFFECT
in	O
humans	O
.	O
Hypersensitivity	O
to	O
aspirin	B-DRUG
can	O
be	O
manifested	O
as	O
acute	O
asthma	O
,	O
urticaria	B-ADVEFFECT
and/or	O
angioedema	B-ADVEFFECT
,	O
or	O
a	O
systemic	B-ADVEFFECT
anaphylactoid	I-ADVEFFECT
reaction	I-ADVEFFECT
.	O
Hypersensitivity	O
to	O
aspirin	B-DRUG
can	O
be	O
manifested	O
as	O
acute	O
asthma	O
,	O
urticaria	B-ADVEFFECT
and/or	O
angioedema	B-ADVEFFECT
,	O
or	O
a	O
systemic	B-ADVEFFECT
anaphylactoid	I-ADVEFFECT
reaction	I-ADVEFFECT
.	O
Hypersensitivity	O
to	O
aspirin	B-DRUG
can	O
be	O
manifested	O
as	O
acute	O
asthma	O
,	O
urticaria	B-ADVEFFECT
and/or	O
angioedema	B-ADVEFFECT
,	O
or	O
a	O
systemic	B-ADVEFFECT
anaphylactoid	I-ADVEFFECT
reaction	I-ADVEFFECT
.	O
CONCLUSION	O
:	O
Fixed	O
drug	O
eruption	B-ADVEFFECT
is	O
associated	O
with	O
many	O
drugs	O
but	O
this	O
is	O
the	O
first	O
such	O
report	O
with	O
omeprazole	B-DRUG
.	O
Fixed	O
drug	O
eruption	B-ADVEFFECT
in	O
hands	O
caused	O
by	O
omeprazole	B-DRUG
.	O
The	O
objective	O
of	O
this	O
report	O
is	O
to	O
describe	O
a	O
case	O
of	O
fixed	O
drug	O
eruption	B-ADVEFFECT
that	O
occurred	O
during	O
omeprazole	B-DRUG
treatment	O
.	O
A	O
26-year	O
-	O
old	O
Japanese	O
man	O
,	O
who	O
had	O
been	O
receiving	O
medical	O
attention	O
for	O
ulcerative	O
colitis	O
for	O
one	O
year	O
,	O
presented	O
with	O
diffuse	B-ADVEFFECT
erythema	I-ADVEFFECT
and	O
pustules	B-ADVEFFECT
on	O
his	O
face	O
and	O
trunk	O
,	O
malaise	B-ADVEFFECT
,	O
and	O
fever	B-ADVEFFECT
up	I-ADVEFFECT
to	I-ADVEFFECT
39	I-ADVEFFECT
degrees	I-ADVEFFECT
C	I-ADVEFFECT
one	O
day	O
after	O
the	O
administration	O
of	O
salazosulfapyridine	B-DRUG
.	O
A	O
26-year	O
-	O
old	O
Japanese	O
man	O
,	O
who	O
had	O
been	O
receiving	O
medical	O
attention	O
for	O
ulcerative	O
colitis	O
for	O
one	O
year	O
,	O
presented	O
with	O
diffuse	B-ADVEFFECT
erythema	I-ADVEFFECT
and	O
pustules	B-ADVEFFECT
on	O
his	O
face	O
and	O
trunk	O
,	O
malaise	B-ADVEFFECT
,	O
and	O
fever	B-ADVEFFECT
up	I-ADVEFFECT
to	I-ADVEFFECT
39	I-ADVEFFECT
degrees	I-ADVEFFECT
C	I-ADVEFFECT
one	O
day	O
after	O
the	O
administration	O
of	O
salazosulfapyridine	B-DRUG
.	O
A	O
26-year	O
-	O
old	O
Japanese	O
man	O
,	O
who	O
had	O
been	O
receiving	O
medical	O
attention	O
for	O
ulcerative	O
colitis	O
for	O
one	O
year	O
,	O
presented	O
with	O
diffuse	B-ADVEFFECT
erythema	I-ADVEFFECT
and	O
pustules	B-ADVEFFECT
on	O
his	O
face	O
and	O
trunk	O
,	O
malaise	B-ADVEFFECT
,	O
and	O
fever	B-ADVEFFECT
up	I-ADVEFFECT
to	I-ADVEFFECT
39	I-ADVEFFECT
degrees	I-ADVEFFECT
C	I-ADVEFFECT
one	O
day	O
after	O
the	O
administration	O
of	O
salazosulfapyridine	B-DRUG
.	O
A	O
26-year	O
-	O
old	O
Japanese	O
man	O
,	O
who	O
had	O
been	O
receiving	O
medical	O
attention	O
for	O
ulcerative	O
colitis	O
for	O
one	O
year	O
,	O
presented	O
with	O
diffuse	B-ADVEFFECT
erythema	I-ADVEFFECT
and	O
pustules	B-ADVEFFECT
on	O
his	O
face	O
and	O
trunk	O
,	O
malaise	B-ADVEFFECT
,	O
and	O
fever	B-ADVEFFECT
up	I-ADVEFFECT
to	I-ADVEFFECT
39	I-ADVEFFECT
degrees	I-ADVEFFECT
C	I-ADVEFFECT
one	O
day	O
after	O
the	O
administration	O
of	O
salazosulfapyridine	B-DRUG
.	O
Acute	B-ADVEFFECT
generalized	I-ADVEFFECT
exanthematous	I-ADVEFFECT
pustulosis	I-ADVEFFECT
induced	O
by	O
salazosulfapyridine	B-DRUG
in	O
a	O
patient	O
with	O
ulcerative	O
colitis	O
.	O
We	O
report	O
a	O
case	O
of	O
acute	B-ADVEFFECT
generalized	I-ADVEFFECT
exanthematous	I-ADVEFFECT
pustulosis	I-ADVEFFECT
(	O
AGEP	O
)	O
induced	O
by	O
salazosulfapyridine	B-DRUG
in	O
a	O
patient	O
with	O
ulcerative	O
colitis	O
.	O
CASE	O
SUMMARY	O
:	O
A	O
39-year	O
-	O
old	O
white	O
Jewish	O
schizophrenic	O
man	O
treated	O
with	O
olanzapine	B-DRUG
developed	O
an	O
elevated	B-ADVEFFECT
serum	I-ADVEFFECT
CK	I-ADVEFFECT
concentration	I-ADVEFFECT
with	O
a	O
peak	O
concentration	O
of	O
4000	O
IU	O
/	O
L	O
(	O
normal	O
<	O
230	O
)	O
.	O
DISCUSSION	O
:	O
Olanzapine	B-DRUG
,	O
like	O
other	O
atypical	O
antipsychotic	O
drugs	O
,	O
may	O
cause	O
muscle	B-ADVEFFECT
injury	I-ADVEFFECT
with	I-ADVEFFECT
concomitant	I-ADVEFFECT
elevations	I-ADVEFFECT
of	I-ADVEFFECT
serum	I-ADVEFFECT
CK	I-ADVEFFECT
of	O
muscle	O
origin	O
.	O
Marked	O
elevation	B-ADVEFFECT
of	I-ADVEFFECT
serum	I-ADVEFFECT
creatine	I-ADVEFFECT
kinase	I-ADVEFFECT
associated	O
with	O
olanzapine	B-DRUG
therapy	O
.	O
OBJECTIVE	O
:	O
To	O
report	O
a	O
case	O
of	O
marked	O
elevation	B-ADVEFFECT
of	I-ADVEFFECT
serum	I-ADVEFFECT
creatine	I-ADVEFFECT
kinase	I-ADVEFFECT
(	O
CK	O
)	O
associated	O
with	O
olanzapine	B-DRUG
therapy	O
.	O
Diclofenac	B-DRUG
-	O
associated	O
hepatitis	B-ADVEFFECT
.	O
This	O
patient	O
,	O
who	O
had	O
a	O
history	O
of	O
osteoarthritis	O
,	O
had	O
severe	O
hepatitis	B-ADVEFFECT
5	O
weeks	O
after	O
being	O
started	O
on	O
diclofenac	B-DRUG
for	O
increasing	O
pain	O
in	O
the	O
joints	O
.	O
2-CdA	B-DRUG
induces	O
lymphocytopenia	B-ADVEFFECT
,	O
which	O
may	O
explain	O
the	O
improvement	O
in	O
this	O
patient	O
's	O
psoriasis	O
.	O
One	O
case	O
of	O
priapism	B-ADVEFFECT
occurred	O
during	O
heparin	B-DRUG
therapy	O
for	O
a	O
previous	O
surgical	O
operation	O
to	O
the	O
knee	O
is	O
reported	O
.	O
Priapism	B-ADVEFFECT
as	O
a	O
complication	O
of	O
heparin	B-DRUG
therapy	O
.	O
The	O
association	O
between	O
heparin	B-DRUG
and	O
priapism	B-ADVEFFECT
is	O
often	O
recognized	O
;	O
abnormal	B-ADVEFFECT
platelet	I-ADVEFFECT
aggregation	I-ADVEFFECT
could	O
play	O
a	O
role	O
in	O
the	O
pathogenesis	O
of	O
this	O
side	O
effect	O
.	O
The	O
association	O
between	O
heparin	B-DRUG
and	O
priapism	B-ADVEFFECT
is	O
often	O
recognized	O
;	O
abnormal	B-ADVEFFECT
platelet	I-ADVEFFECT
aggregation	I-ADVEFFECT
could	O
play	O
a	O
role	O
in	O
the	O
pathogenesis	O
of	O
this	O
side	O
effect	O
.	O
It	O
carries	O
a	O
well	O
-	O
known	O
risk	O
of	O
neutropenia	B-ADVEFFECT
and	O
agranulocytosis	B-ADVEFFECT
,	O
which	O
necessitates	O
the	O
immediate	O
discontinuation	O
of	O
clozapine	B-DRUG
.	O
It	O
carries	O
a	O
well	O
-	O
known	O
risk	O
of	O
neutropenia	B-ADVEFFECT
and	O
agranulocytosis	B-ADVEFFECT
,	O
which	O
necessitates	O
the	O
immediate	O
discontinuation	O
of	O
clozapine	B-DRUG
.	O
OBJECTIVE	O
:	O
We	O
report	O
a	O
patient	O
who	O
developed	O
neutropenia	B-ADVEFFECT
on	O
clozapine	B-DRUG
,	O
but	O
behind	O
the	O
cell	O
count	O
decrease	O
showed	O
to	O
be	O
a	O
diurnal	B-ADVEFFECT
variation	I-ADVEFFECT
of	I-ADVEFFECT
the	I-ADVEFFECT
white	I-ADVEFFECT
blood	I-ADVEFFECT
cells	I-ADVEFFECT
(	O
WBC	O
)	O
.	O
Acute	B-ADVEFFECT
neutrophilic	I-ADVEFFECT
dermatosis	I-ADVEFFECT
induced	O
by	O
all	B-DRUG
-	I-DRUG
trans	I-DRUG
-	I-DRUG
retinoic	I-DRUG
acid	I-DRUG
treatment	O
for	O
acute	O
promyelocytic	O
leukemia	O
.	O
Findings	O
on	O
discontinuation	O
and	O
rechallenge	O
supported	O
the	O
assumption	O
that	O
the	O
hair	B-ADVEFFECT
loss	I-ADVEFFECT
was	O
a	O
side	O
effect	O
of	O
the	O
paroxetine	B-DRUG
.	O
Hair	B-ADVEFFECT
loss	I-ADVEFFECT
associated	O
with	O
paroxetine	B-DRUG
treatment	O
:	O
a	O
case	O
report	O
.	O
We	O
report	O
on	O
a	O
37-year	O
-	O
old	O
female	O
who	O
complained	O
of	O
moderate	O
hair	B-ADVEFFECT
loss	I-ADVEFFECT
during	O
paroxetine	B-DRUG
treatment	O
.	O
CONCLUSION	O
:	O
Patients	O
with	O
insulin	B-DRUG
allergy	O
may	O
not	O
have	O
complete	O
resolution	O
of	O
their	O
symptoms	O
after	O
standard	O
desensitization	O
,	O
particularly	O
those	O
patients	O
with	O
concomitant	O
protamine	B-ADVEFFECT
allergy	I-ADVEFFECT
.	O
METHODS	O
:	O
The	O
patient	O
required	O
insulin	O
desensitization	O
for	O
severe	B-ADVEFFECT
urticaria	I-ADVEFFECT
,	O
angioedema	B-ADVEFFECT
,	O
and	O
occasional	O
wheezing	B-ADVEFFECT
resulting	O
from	O
her	O
insulin	B-DRUG
dose	O
.	O
METHODS	O
:	O
The	O
patient	O
required	O
insulin	O
desensitization	O
for	O
severe	B-ADVEFFECT
urticaria	I-ADVEFFECT
,	O
angioedema	B-ADVEFFECT
,	O
and	O
occasional	O
wheezing	B-ADVEFFECT
resulting	O
from	O
her	O
insulin	B-DRUG
dose	O
.	O
METHODS	O
:	O
The	O
patient	O
required	O
insulin	O
desensitization	O
for	O
severe	B-ADVEFFECT
urticaria	I-ADVEFFECT
,	O
angioedema	B-ADVEFFECT
,	O
and	O
occasional	O
wheezing	B-ADVEFFECT
resulting	O
from	O
her	O
insulin	B-DRUG
dose	O
.	O
METHODS	O
:	O
The	O
patient	O
required	O
insulin	O
desensitization	O
for	O
severe	B-ADVEFFECT
urticaria	I-ADVEFFECT
,	O
angioedema	B-ADVEFFECT
,	O
and	O
occasional	O
wheezing	B-ADVEFFECT
resulting	O
from	O
her	O
insulin	B-DRUG
dose	O
.	O
METHODS	O
:	O
The	O
patient	O
required	O
insulin	O
desensitization	O
for	O
severe	B-ADVEFFECT
urticaria	I-ADVEFFECT
,	O
angioedema	B-ADVEFFECT
,	O
and	O
occasional	O
wheezing	B-ADVEFFECT
resulting	O
from	O
her	O
insulin	B-DRUG
dose	O
.	O
METHODS	O
:	O
The	O
patient	O
required	O
insulin	O
desensitization	O
for	O
severe	B-ADVEFFECT
urticaria	I-ADVEFFECT
,	O
angioedema	B-ADVEFFECT
,	O
and	O
occasional	O
wheezing	B-ADVEFFECT
resulting	O
from	O
her	O
insulin	B-DRUG
dose	O
.	O
OBJECTIVE	O
:	O
The	O
purpose	O
of	O
this	O
study	O
was	O
to	O
determine	O
whether	O
desensitization	O
to	O
NPH	B-DRUG
insulin	I-DRUG
,	O
as	O
well	O
as	O
standard	O
insulin	B-DRUG
desensitization	O
,	O
could	O
control	O
allergic	B-ADVEFFECT
symptoms	I-ADVEFFECT
in	O
a	O
patient	O
allergic	O
to	O
both	O
NPH	B-DRUG
and	O
regular	O
insulin	B-DRUG
.	O
OBJECTIVE	O
:	O
The	O
purpose	O
of	O
this	O
study	O
was	O
to	O
determine	O
whether	O
desensitization	O
to	O
NPH	B-DRUG
insulin	I-DRUG
,	O
as	O
well	O
as	O
standard	O
insulin	B-DRUG
desensitization	O
,	O
could	O
control	O
allergic	B-ADVEFFECT
symptoms	I-ADVEFFECT
in	O
a	O
patient	O
allergic	O
to	O
both	O
NPH	B-DRUG
and	O
regular	O
insulin	B-DRUG
.	O
Patients	O
receiving	O
neutral	B-DRUG
protamine	I-DRUG
Hagedorn	I-DRUG
(	O
NPH	B-DRUG
)	O
insulin	B-DRUG
are	O
at	O
increased	O
risk	O
for	O
the	O
development	O
of	O
protamine	B-ADVEFFECT
hypersensitivity	I-ADVEFFECT
.	O
Protamine	B-ADVEFFECT
allergy	I-ADVEFFECT
as	O
a	O
complication	O
of	O
insulin	B-DRUG
hypersensitivity	O
:	O
A	O
case	O
report	O
.	O
She	O
continued	O
to	O
receive	O
regular	O
insulin	B-DRUG
4	O
times	O
per	O
day	O
over	O
the	O
following	O
3	O
years	O
with	O
only	O
occasional	O
hives	B-ADVEFFECT
.	O
The	O
patient	O
had	O
recurrence	O
of	O
urticaria	B-ADVEFFECT
and	O
angioedema	B-ADVEFFECT
a	O
year	O
and	O
a	O
half	O
later	O
,	O
at	O
which	O
point	O
the	O
NPH	B-DRUG
was	O
stopped	O
and	O
she	O
was	O
desensitized	O
to	O
regular	O
insulin	B-DRUG
.	O
The	O
patient	O
had	O
recurrence	O
of	O
urticaria	B-ADVEFFECT
and	O
angioedema	B-ADVEFFECT
a	O
year	O
and	O
a	O
half	O
later	O
,	O
at	O
which	O
point	O
the	O
NPH	B-DRUG
was	O
stopped	O
and	O
she	O
was	O
desensitized	O
to	O
regular	O
insulin	B-DRUG
.	O
The	O
patient	O
had	O
recurrence	O
of	O
urticaria	B-ADVEFFECT
and	O
angioedema	B-ADVEFFECT
a	O
year	O
and	O
a	O
half	O
later	O
,	O
at	O
which	O
point	O
the	O
NPH	B-DRUG
was	O
stopped	O
and	O
she	O
was	O
desensitized	O
to	O
regular	O
insulin	B-DRUG
.	O
The	O
patient	O
had	O
recurrence	O
of	O
urticaria	B-ADVEFFECT
and	O
angioedema	B-ADVEFFECT
a	O
year	O
and	O
a	O
half	O
later	O
,	O
at	O
which	O
point	O
the	O
NPH	B-DRUG
was	O
stopped	O
and	O
she	O
was	O
desensitized	O
to	O
regular	O
insulin	B-DRUG
.	O
A	O
5-month	O
-	O
old	O
infant	O
became	O
lethargic	B-ADVEFFECT
and	O
poorly	B-ADVEFFECT
responsive	I-ADVEFFECT
after	O
receiving	O
1	O
drop	O
of	O
brimonidine	B-DRUG
in	O
each	O
eye	O
.	O
A	O
5-month	O
-	O
old	O
infant	O
became	O
lethargic	B-ADVEFFECT
and	O
poorly	B-ADVEFFECT
responsive	I-ADVEFFECT
after	O
receiving	O
1	O
drop	O
of	O
brimonidine	B-DRUG
in	O
each	O
eye	O
.	O
An	O
11-day	O
-	O
old	O
infant	O
became	O
lethargic	B-ADVEFFECT
and	O
apneic	B-ADVEFFECT
after	O
a	O
single	O
drop	O
of	O
brimonidine	B-DRUG
.	O
An	O
11-day	O
-	O
old	O
infant	O
became	O
lethargic	B-ADVEFFECT
and	O
apneic	B-ADVEFFECT
after	O
a	O
single	O
drop	O
of	O
brimonidine	B-DRUG
.	O
Apparent	O
central	B-ADVEFFECT
nervous	I-ADVEFFECT
system	I-ADVEFFECT
depression	I-ADVEFFECT
in	O
infants	O
after	O
the	O
use	O
of	O
topical	O
brimonidine	B-DRUG
.	O
CONCLUSIONS	O
:	O
Topical	O
brimonidine	B-DRUG
may	O
be	O
associated	O
with	O
central	B-ADVEFFECT
nervous	I-ADVEFFECT
system	I-ADVEFFECT
depression	I-ADVEFFECT
in	O
infants	O
.	O
PURPOSE	O
:	O
To	O
report	O
two	O
cases	O
in	O
which	O
topical	O
brimonidine	B-DRUG
resulted	O
in	O
apparent	O
central	B-ADVEFFECT
nervous	I-ADVEFFECT
system	I-ADVEFFECT
depression	I-ADVEFFECT
and	O
unresponsiveness	O
in	O
an	O
infant	O
.	O
Ceftriaxone	B-DRUG
was	O
approved	O
in	O
1997	O
for	O
the	O
treatment	O
of	O
otitis	O
media	O
despite	O
previous	O
studies	O
that	O
documented	O
an	O
association	O
of	O
ceftriaxone	B-DRUG
with	O
elevated	B-ADVEFFECT
hepato	I-ADVEFFECT
-	I-ADVEFFECT
biliary	I-ADVEFFECT
enzymes	I-ADVEFFECT
and	O
transient	B-ADVEFFECT
biliary	I-ADVEFFECT
stasis	I-ADVEFFECT
.	O
Ceftriaxone	B-DRUG
was	O
approved	O
in	O
1997	O
for	O
the	O
treatment	O
of	O
otitis	O
media	O
despite	O
previous	O
studies	O
that	O
documented	O
an	O
association	O
of	O
ceftriaxone	B-DRUG
with	O
elevated	B-ADVEFFECT
hepato	I-ADVEFFECT
-	I-ADVEFFECT
biliary	I-ADVEFFECT
enzymes	I-ADVEFFECT
and	O
transient	B-ADVEFFECT
biliary	I-ADVEFFECT
stasis	O
.	O
Hepato	B-ADVEFFECT
-	I-ADVEFFECT
biliary	I-ADVEFFECT
abnormalities	I-ADVEFFECT
secondary	O
to	O
ceftriaxone	B-DRUG
use	O
:	O
a	O
case	O
report	O
.	O
Anterior	B-ADVEFFECT
lumbosacral	I-ADVEFFECT
radiculopathy	I-ADVEFFECT
after	O
intrathecal	O
methotrexate	B-DRUG
treatment	O
.	O
Reported	O
are	O
three	O
children	O
who	O
developed	O
progressive	B-ADVEFFECT
paraparesis	I-ADVEFFECT
after	O
intrathecal	O
methotrexate	B-DRUG
administration	O
followed	O
by	O
complete	O
or	O
partial	O
recovery	O
.	O
During	O
the	O
first	O
days	O
of	O
arsenic	B-DRUG
trioxide	I-DRUG
treatment	O
a	O
rapid	O
decrease	B-ADVEFFECT
in	I-ADVEFFECT
the	I-ADVEFFECT
D	I-ADVEFFECT
-	I-ADVEFFECT
dimers	I-ADVEFFECT
was	O
seen	O
(	O
normal	O
values	O
reached	O
until	O
day	O
7	O
)	O
,	O
together	O
with	O
a	O
slight	B-ADVEFFECT
decrease	I-ADVEFFECT
in	I-ADVEFFECT
peripheral	I-ADVEFFECT
blood	I-ADVEFFECT
leukocytes	I-ADVEFFECT
.	O
During	O
the	O
first	O
days	O
of	O
arsenic	B-DRUG
trioxide	I-DRUG
treatment	O
a	O
rapid	O
decrease	B-ADVEFFECT
in	O
the	O
D	O
-	O
dimers	O
was	O
seen	O
(	O
normal	O
values	O
reached	O
until	O
day	O
7	O
)	O
,	O
together	O
with	O
a	O
slight	B-ADVEFFECT
decrease	I-ADVEFFECT
in	I-ADVEFFECT
peripheral	I-ADVEFFECT
blood	I-ADVEFFECT
leukocytes	I-ADVEFFECT
.	O
A	O
22-year	O
-	O
old	O
black	O
man	O
developed	O
fever	B-ADVEFFECT
,	O
chills	B-ADVEFFECT
,	O
fatigue	B-ADVEFFECT
,	O
night	B-ADVEFFECT
sweats	B-ADVEFFECT
,	O
tender	O
lymphadenopathy	O
,	O
and	O
a	O
generalized	B-ADVEFFECT
,	I-ADVEFFECT
pruritic	I-ADVEFFECT
,	I-ADVEFFECT
macular	I-ADVEFFECT
eruption	I-ADVEFFECT
3	O
weeks	O
after	O
starting	O
minocycline	B-DRUG
therapy	O
for	O
acne	O
.	O
A	O
22-year	O
-	O
old	O
black	O
man	O
developed	O
fever	B-ADVEFFECT
,	O
chills	B-ADVEFFECT
,	O
fatigue	B-ADVEFFECT
,	O
night	B-ADVEFFECT
sweats	I-ADVEFFECT
,	O
tender	O
lymphadenopathy	O
,	O
and	O
a	O
generalized	B-ADVEFFECT
,	I-ADVEFFECT
pruritic	I-ADVEFFECT
,	I-ADVEFFECT
macular	I-ADVEFFECT
eruption	I-ADVEFFECT
3	O
weeks	O
after	O
starting	O
minocycline	B-DRUG
therapy	O
for	O
acne	O
.	O
A	O
22-year	O
-	O
old	O
black	O
man	O
developed	O
fever	B-ADVEFFECT
,	O
chills	B-ADVEFFECT
,	O
fatigue	B-ADVEFFECT
,	O
night	B-ADVEFFECT
sweats	I-ADVEFFECT
,	O
tender	O
lymphadenopathy	O
,	O
and	O
a	O
generalized	B-ADVEFFECT
,	I-ADVEFFECT
pruritic	I-ADVEFFECT
,	I-ADVEFFECT
macular	I-ADVEFFECT
eruption	I-ADVEFFECT
3	O
weeks	O
after	O
starting	O
minocycline	B-DRUG
therapy	O
for	O
acne	O
.	O
A	O
22-year	O
-	O
old	O
black	O
man	O
developed	O
fever	B-ADVEFFECT
,	O
chills	B-ADVEFFECT
,	O
fatigue	B-ADVEFFECT
,	O
night	B-ADVEFFECT
sweats	I-ADVEFFECT
,	O
tender	O
lymphadenopathy	O
,	O
and	O
a	O
generalized	B-ADVEFFECT
,	I-ADVEFFECT
pruritic	I-ADVEFFECT
,	I-ADVEFFECT
macular	I-ADVEFFECT
eruption	I-ADVEFFECT
3	O
weeks	O
after	O
starting	O
minocycline	B-DRUG
therapy	O
for	O
acne	O
.	O
A	O
22-year	O
-	O
old	O
black	O
man	O
developed	O
fever	B-ADVEFFECT
,	O
chills	B-ADVEFFECT
,	O
fatigue	B-ADVEFFECT
,	O
night	B-ADVEFFECT
sweats	I-ADVEFFECT
,	O
tender	O
lymphadenopathy	O
,	O
and	O
a	O
generalized	B-ADVEFFECT
,	I-ADVEFFECT
pruritic	I-ADVEFFECT
,	I-ADVEFFECT
macular	I-ADVEFFECT
eruption	I-ADVEFFECT
3	O
weeks	O
after	O
starting	O
minocycline	B-DRUG
therapy	O
for	O
acne	O
.	O
With	O
the	O
negative	O
viral	O
serologies	O
,	O
the	O
clinical	O
picture	O
was	O
most	O
consistent	O
with	O
an	O
infectious	O
mononucleosis	B-ADVEFFECT
-	I-ADVEFFECT
like	I-ADVEFFECT
syndrome	I-ADVEFFECT
produced	O
by	O
the	O
minocycline	B-DRUG
ingestion	O
.	O
We	O
conclude	O
that	O
the	O
presence	O
of	O
this	O
metabolic	O
defect	O
combined	O
with	O
topical	O
5-FU	B-DRUG
(	O
a	O
drug	O
demonstrating	O
a	O
narrow	O
therapeutic	O
index	O
)	O
results	O
in	O
the	O
unusual	O
presentation	O
of	O
life	B-ADVEFFECT
-	I-ADVEFFECT
threatening	I-ADVEFFECT
toxicity	I-ADVEFFECT
after	O
treatment	O
with	O
a	O
topical	O
drug	O
.	O
We	O
now	O
report	O
the	O
first	O
known	O
cancer	O
patient	O
who	O
developed	O
life	B-ADVEFFECT
-	I-ADVEFFECT
threatening	I-ADVEFFECT
complications	I-ADVEFFECT
after	O
treatment	O
with	O
topical	O
5-FU	B-DRUG
and	O
was	O
shown	O
subsequently	O
to	O
have	O
profound	O
DPD	O
deficiency	O
.	O
An	O
acute	B-ADVEFFECT
ischaemic	I-ADVEFFECT
event	I-ADVEFFECT
associated	O
with	O
the	O
use	O
of	O
venlafaxine	B-DRUG
:	O
a	O
case	O
report	O
and	O
proposed	O
pathophysiological	O
mechanisms	O
.	O
The	O
association	O
of	O
venlafaxine	B-DRUG
treatment	O
with	O
ischaemic	B-ADVEFFECT
events	I-ADVEFFECT
could	O
be	O
explained	O
by	O
its	O
unique	O
pharmacological	O
and	O
haemodynamic	O
properties	O
.	O
This	O
is	O
the	O
first	O
report	O
of	O
a	O
possible	O
association	O
between	O
an	O
acute	B-ADVEFFECT
cardiovascular	I-ADVEFFECT
event	I-ADVEFFECT
and	O
venlafaxine	B-DRUG
.	O
We	O
present	O
a	O
case	O
of	O
an	O
elderly	O
woman	O
with	O
a	O
pre	O
-	O
existing	O
history	O
of	O
ischaemic	O
heart	O
disease	O
,	O
who	O
was	O
treated	O
with	O
venlafaxine	B-DRUG
,	O
and	O
developed	O
acute	B-ADVEFFECT
myocardial	I-ADVEFFECT
ischaemia	I-ADVEFFECT
within	O
the	O
first	O
week	O
of	O
treatment	O
.	O
Apparent	O
cyclophosphamide	B-DRUG
(	O
cytoxan	O
)	O
embryopathy	B-ADVEFFECT
:	O
a	O
distinct	O
phenotype	O
?	O
The	O
purpose	O
of	O
this	O
report	O
is	O
to	O
document	O
a	O
new	O
case	O
of	O
in	O
utero	O
CP	B-DRUG
exposure	O
with	O
multiple	B-ADVEFFECT
congenital	I-ADVEFFECT
anomalies	I-ADVEFFECT
and	O
to	O
establish	O
an	O
apparent	O
CP	B-DRUG
embryopathy	B-ADVEFFECT
phenotype	O
.	O
The	O
purpose	O
of	O
this	O
report	O
is	O
to	O
document	O
a	O
new	O
case	O
of	O
in	O
utero	O
CP	B-DRUG
exposure	O
with	O
multiple	B-ADVEFFECT
congenital	I-ADVEFFECT
anomalies	I-ADVEFFECT
and	O
to	O
establish	O
an	O
apparent	O
CP	B-DRUG
embryopathy	B-ADVEFFECT
phenotype	O
.	O
The	O
reported	O
cases	O
of	O
in	O
utero	O
exposure	O
to	O
cyclosposphamide	B-DRUG
shared	O
the	O
following	O
manifestations	O
with	O
our	O
patient	O
:	O
growth	O
deficiency	O
,	O
developmental	B-ADVEFFECT
delay	I-ADVEFFECT
,	O
craniosynostosis	B-ADVEFFECT
,	O
blepharophimosis	B-ADVEFFECT
,	O
flat	B-ADVEFFECT
nasal	I-ADVEFFECT
bridge	I-ADVEFFECT
,	O
abnormal	O
ears	O
,	O
and	O
distal	B-ADVEFFECT
limb	I-ADVEFFECT
defects	I-ADVEFFECT
including	O
hypoplastic	B-ADVEFFECT
thumbs	I-ADVEFFECT
and	O
oligodactyly	B-ADVEFFECT
.	O
The	O
reported	O
cases	O
of	O
in	O
utero	O
exposure	O
to	O
cyclosposphamide	B-DRUG
shared	O
the	O
following	O
manifestations	O
with	O
our	O
patient	O
:	O
growth	O
deficiency	O
,	O
developmental	B-ADVEFFECT
delay	I-ADVEFFECT
,	O
craniosynostosis	B-ADVEFFECT
,	O
blepharophimosis	B-ADVEFFECT
,	O
flat	B-ADVEFFECT
nasal	I-ADVEFFECT
bridge	I-ADVEFFECT
,	O
abnormal	O
ears	O
,	O
and	O
distal	B-ADVEFFECT
limb	I-ADVEFFECT
defects	I-ADVEFFECT
including	O
hypoplastic	B-ADVEFFECT
thumbs	I-ADVEFFECT
and	O
oligodactyly	B-ADVEFFECT
.	O
The	O
reported	O
cases	O
of	O
in	O
utero	O
exposure	O
to	O
cyclosposphamide	B-DRUG
shared	O
the	O
following	O
manifestations	O
with	O
our	O
patient	O
:	O
growth	O
deficiency	O
,	O
developmental	B-ADVEFFECT
delay	I-ADVEFFECT
,	O
craniosynostosis	B-ADVEFFECT
,	O
blepharophimosis	B-ADVEFFECT
,	O
flat	B-ADVEFFECT
nasal	I-ADVEFFECT
bridge	I-ADVEFFECT
,	O
abnormal	O
ears	O
,	O
and	O
distal	B-ADVEFFECT
limb	I-ADVEFFECT
defects	I-ADVEFFECT
including	O
hypoplastic	B-ADVEFFECT
thumbs	I-ADVEFFECT
and	O
oligodactyly	B-ADVEFFECT
.	O
The	O
reported	O
cases	O
of	O
in	O
utero	O
exposure	O
to	O
cyclosposphamide	B-DRUG
shared	O
the	O
following	O
manifestations	O
with	O
our	O
patient	O
:	O
growth	O
deficiency	O
,	O
developmental	B-ADVEFFECT
delay	I-ADVEFFECT
,	O
craniosynostosis	B-ADVEFFECT
,	O
blepharophimosis	B-ADVEFFECT
,	O
flat	B-ADVEFFECT
nasal	I-ADVEFFECT
bridge	I-ADVEFFECT
,	O
abnormal	O
ears	O
,	O
and	O
distal	B-ADVEFFECT
limb	I-ADVEFFECT
defects	I-ADVEFFECT
including	O
hypoplastic	B-ADVEFFECT
thumbs	I-ADVEFFECT
and	O
oligodactyly	B-ADVEFFECT
.	O
The	O
reported	O
cases	O
of	O
in	O
utero	O
exposure	O
to	O
cyclosposphamide	B-DRUG
shared	O
the	O
following	O
manifestations	O
with	O
our	O
patient	O
:	O
growth	O
deficiency	O
,	O
developmental	B-ADVEFFECT
delay	I-ADVEFFECT
,	O
craniosynostosis	B-ADVEFFECT
,	O
blepharophimosis	B-ADVEFFECT
,	O
flat	B-ADVEFFECT
nasal	I-ADVEFFECT
bridge	I-ADVEFFECT
,	O
abnormal	O
ears	O
,	O
and	O
distal	B-ADVEFFECT
limb	I-ADVEFFECT
defects	I-ADVEFFECT
including	O
hypoplastic	B-ADVEFFECT
thumbs	I-ADVEFFECT
and	O
oligodactyly	B-ADVEFFECT
.	O
The	O
reported	O
cases	O
of	O
in	O
utero	O
exposure	O
to	O
cyclosposphamide	B-DRUG
shared	O
the	O
following	O
manifestations	O
with	O
our	O
patient	O
:	O
growth	O
deficiency	O
,	O
developmental	B-ADVEFFECT
delay	I-ADVEFFECT
,	O
craniosynostosis	B-ADVEFFECT
,	O
blepharophimosis	B-ADVEFFECT
,	O
flat	B-ADVEFFECT
nasal	I-ADVEFFECT
bridge	I-ADVEFFECT
,	O
abnormal	O
ears	O
,	O
and	O
distal	B-ADVEFFECT
limb	I-ADVEFFECT
defects	I-ADVEFFECT
including	O
hypoplastic	B-ADVEFFECT
thumbs	I-ADVEFFECT
and	O
oligodactyly	B-ADVEFFECT
.	O
The	O
reported	O
cases	O
of	O
in	O
utero	O
exposure	O
to	O
cyclosposphamide	B-DRUG
shared	O
the	O
following	O
manifestations	O
with	O
our	O
patient	O
:	O
growth	O
deficiency	O
,	O
developmental	B-ADVEFFECT
delay	I-ADVEFFECT
,	O
craniosynostosis	B-ADVEFFECT
,	O
blepharophimosis	B-ADVEFFECT
,	O
flat	B-ADVEFFECT
nasal	I-ADVEFFECT
bridge	I-ADVEFFECT
,	O
abnormal	O
ears	O
,	O
and	O
distal	B-ADVEFFECT
limb	I-ADVEFFECT
defects	I-ADVEFFECT
including	O
hypoplastic	B-ADVEFFECT
thumbs	I-ADVEFFECT
and	O
oligodactyly	B-ADVEFFECT
.	O
We	O
conclude	O
that	O
(	O
a	O
)	O
cyclophosphamide	B-DRUG
is	O
a	O
human	B-ADVEFFECT
teratogen	I-ADVEFFECT
,	O
(	O
b	O
)	O
a	O
distinct	O
phenotype	O
exists	O
,	O
and	O
(	O
c	O
)	O
the	O
safety	O
of	O
CP	B-DRUG
in	O
pregnancy	O
is	O
in	O
serious	O
question	O
.	O
In	O
all	O
cases	O
,	O
seizures	B-ADVEFFECT
were	O
controlled	O
by	O
withdrawal	O
of	O
phenytoin	B-DRUG
and	O
reduction	O
of	O
drug	O
levels	O
.	O
Paradoxical	O
seizures	B-ADVEFFECT
in	O
phenytoin	B-DRUG
toxicity	O
.	O
We	O
present	O
three	O
patients	O
with	O
paradoxical	O
seizures	B-ADVEFFECT
;	O
their	O
serum	O
phenytoin	B-DRUG
levels	O
were	O
43.5	O
mcg	O
/	O
mL	O
,	O
46.5	O
mcg	O
/	O
mL	O
and	O
38.3	O
mcg	O
/	O
Ml	O
.	O
CONCLUSIONS	O
:	O
This	O
case	O
suggests	O
that	O
losartan	B-DRUG
can	O
induce	O
late	O
-	O
onset	O
angioedema	B-ADVEFFECT
in	O
patients	O
with	O
normal	O
renal	O
function	O
and	O
that	O
the	O
reaction	O
can	O
recur	O
after	O
initial	O
resolution	O
of	O
the	O
symptoms	O
.	O
Losartan	B-DRUG
-	O
induced	O
angioedema	B-ADVEFFECT
.	O
OBJECTIVE	O
:	O
To	O
report	O
a	O
case	O
of	O
angioedema	B-ADVEFFECT
associated	O
with	O
losartan	B-DRUG
administration	O
.	O
The	O
incidence	O
of	O
angioedema	B-ADVEFFECT
secondary	O
to	O
losartan	B-DRUG
,	O
an	O
angiotensin	O
II	O
receptor	O
antagonist	O
,	O
is	O
unknown	O
.	O
We	O
report	O
the	O
case	O
of	O
a	O
female	O
acromegalic	O
patient	O
in	O
whom	O
multiple	O
hepatic	B-ADVEFFECT
adenomas	I-ADVEFFECT
appeared	O
soon	O
after	O
danazol	B-DRUG
treatment	O
for	O
uterine	O
fibromatosis	O
.	O
Heparin	B-DRUG
-	O
induced	O
thrombocytopenia	B-ADVEFFECT
is	O
a	O
rare	O
and	O
serious	O
complication	O
of	O
anticoagulation	O
therapy	O
.	O
Pediatric	O
heparin	B-DRUG
-	O
induced	O
thrombocytopenia	B-ADVEFFECT
:	O
management	O
with	O
Danaparoid	O
(	O
orgaran	O
)	O
.	O
There	O
remains	O
a	O
paucity	O
of	O
information	O
pertaining	O
to	O
alternative	O
anticoagulation	O
strategies	O
for	O
use	O
during	O
cardiopulmonary	O
bypass	O
concomitant	O
with	O
heparin	B-DRUG
-	O
induced	O
thrombocytopenia	B-ADVEFFECT
,	O
especially	O
in	O
children	O
.	O
We	O
report	O
the	O
successful	O
treatment	O
of	O
heparin	B-DRUG
-	O
induced	O
thrombocytopenia	B-ADVEFFECT
and	O
subsequent	O
hemorrhagic	B-ADVEFFECT
complications	I-ADVEFFECT
postoperatively	O
in	O
a	O
2-year	O
-	O
old	O
child	O
with	O
Danaparoid	O
(	O
orgaran	O
)	O
.	O
We	O
report	O
the	O
successful	O
treatment	O
of	O
heparin	B-DRUG
-	O
induced	O
thrombocytopenia	B-ADVEFFECT
and	O
subsequent	O
hemorrhagic	B-ADVEFFECT
complications	I-ADVEFFECT
postoperatively	O
in	O
a	O
2-year	O
-	O
old	O
child	O
with	O
Danaparoid	O
(	O
orgaran	O
)	O
.	O
Taxane	B-DRUG
-	O
induced	O
glaucoma	B-ADVEFFECT
.	O
We	O
report	O
a	O
case	O
of	O
glaucoma	B-ADVEFFECT
induced	O
by	O
doxetaxel	B-DRUG
therapy	O
for	O
metastatic	O
breast	O
cancer	O
.	O
Acute	O
hyperphosphatemia	B-ADVEFFECT
caused	O
by	O
sodium	B-DRUG
phosphate	I-DRUG
enema	O
in	O
a	O
patient	O
with	O
liver	O
dysfunction	O
and	O
chronic	O
renal	O
failure	O
.	O
We	O
report	O
a	O
case	O
of	O
acute	O
hyperphosphatemia	B-ADVEFFECT
secondary	O
to	O
rectal	O
administration	O
of	O
sodium	B-DRUG
phosphate	I-DRUG
and	O
sodium	B-DRUG
biphosphate	I-DRUG
(	O
Fleet	O
enema	O
)	O
.	O
We	O
report	O
a	O
case	O
of	O
acute	O
hyperphosphatemia	B-ADVEFFECT
secondary	O
to	O
rectal	O
administration	O
of	O
sodium	B-DRUG
phosphate	I-DRUG
and	O
sodium	B-DRUG
biphosphate	I-DRUG
(	O
Fleet	O
enema	O
)	O
.	O
Prolongation	B-ADVEFFECT
of	I-ADVEFFECT
the	I-ADVEFFECT
QT	I-ADVEFFECT
interval	I-ADVEFFECT
and	O
ventricular	B-ADVEFFECT
tachyarrhymias	I-ADVEFFECT
have	O
been	O
described	O
in	O
patients	O
on	O
amiodarone	B-DRUG
therapy	O
.	O
Prolongation	B-ADVEFFECT
of	I-ADVEFFECT
the	I-ADVEFFECT
QT	I-ADVEFFECT
interval	I-ADVEFFECT
and	O
ventricular	B-ADVEFFECT
tachyarrhymias	I-ADVEFFECT
have	O
been	O
described	O
in	O
patients	O
on	O
amiodarone	B-DRUG
therapy	O
.	O
We	O
report	O
a	O
case	O
of	O
recurrent	O
torsades	B-ADVEFFECT
de	I-ADVEFFECT
pointes	I-ADVEFFECT
following	O
treatment	O
with	O
pentavalent	O
antimonial	O
drugs	O
and	O
amiodarone	B-DRUG
.	O
Emphasis	O
is	O
given	O
to	O
the	O
differentiation	O
of	O
diphenylhydantoin	B-DRUG
induced	O
gingival	B-ADVEFFECT
hyperplasia	I-ADVEFFECT
from	O
the	O
angiomatous	O
enlargement	O
of	O
the	O
gingiva	O
before	O
any	O
treatment	O
is	O
planned	O
.	O
A	O
66-year	O
-	O
old	O
Japanese	O
woman	O
with	O
severe	O
scleroderma	O
developed	O
anemia	B-ADVEFFECT
and	O
thrombocytopenia	B-ADVEFFECT
due	O
to	O
D	B-DRUG
-	I-DRUG
penicillamine	I-DRUG
(	O
D	B-DRUG
-	I-DRUG
Pen	I-DRUG
)	O
treatment	O
,	O
although	O
the	O
leukopenia	O
was	O
not	O
markedly	O
severe	O
.	O
A	O
66-year	O
-	O
old	O
Japanese	O
woman	O
with	O
severe	O
scleroderma	O
developed	O
anemia	B-ADVEFFECT
and	O
thrombocytopenia	B-ADVEFFECT
due	O
to	O
D	B-DRUG
-	I-DRUG
penicillamine	I-DRUG
(	O
D	B-DRUG
-	I-DRUG
Pen	I-DRUG
)	O
treatment	O
,	O
although	O
the	O
leukopenia	O
was	O
not	O
markedly	O
severe	O
.	O
A	O
66-year	O
-	O
old	O
Japanese	O
woman	O
with	O
severe	O
scleroderma	O
developed	O
anemia	B-ADVEFFECT
and	O
thrombocytopenia	B-ADVEFFECT
due	O
to	O
D	B-DRUG
-	I-DRUG
penicillamine	I-DRUG
(	O
D	B-DRUG
-	I-DRUG
Pen	I-DRUG
)	O
treatment	O
,	O
although	O
the	O
leukopenia	O
was	O
not	O
markedly	O
severe	O
.	O
A	O
66-year	O
-	O
old	O
Japanese	O
woman	O
with	O
severe	O
scleroderma	O
developed	O
anemia	B-ADVEFFECT
and	O
thrombocytopenia	B-ADVEFFECT
due	O
to	O
D	B-DRUG
-	I-DRUG
penicillamine	I-DRUG
(	O
D	B-DRUG
-	I-DRUG
Pen	I-DRUG
)	O
treatment	O
,	O
although	O
the	O
leukopenia	O
was	O
not	O
markedly	O
severe	O
.	O
Cessation	O
of	O
D	B-DRUG
-	I-DRUG
Pen	I-DRUG
and	O
the	O
start	O
of	O
corticosteroid	O
therapy	O
were	O
followed	O
by	O
recovery	O
from	O
bicytopenia	B-ADVEFFECT
.	O
In	O
vitro	O
inhibition	B-ADVEFFECT
of	I-ADVEFFECT
hematopoiesis	I-ADVEFFECT
in	O
a	O
patient	O
with	O
systemic	O
sclerosis	O
treated	O
with	O
D	B-DRUG
-	I-DRUG
penicillamine	I-DRUG
.	O
These	O
findings	O
suggest	O
that	O
bicytopenia	B-ADVEFFECT
in	O
this	O
patient	O
was	O
caused	O
by	O
D	B-DRUG
-	I-DRUG
Pen	I-DRUG
and	O
may	O
be	O
due	O
to	O
different	O
sensitivities	O
in	O
the	O
hematopoietic	O
lineage	O
.	O
A	O
48-year	O
-	O
old	O
woman	O
who	O
was	O
treated	O
for	O
thyrotoxicosis	O
with	O
methimazole	B-DRUG
developed	O
agranulocytosis	B-ADVEFFECT
.	O
Postoperative	O
hypocalcemic	B-ADVEFFECT
tetany	I-ADVEFFECT
caused	O
by	O
fleet	B-DRUG
phospho	I-DRUG
-	I-DRUG
soda	I-DRUG
preparation	O
in	O
a	O
patient	O
taking	O
alendronate	B-DRUG
sodium	I-DRUG
:	O
report	O
of	O
a	O
case	O
.	O
Postoperative	O
hypocalcemic	B-ADVEFFECT
tetany	I-ADVEFFECT
caused	O
by	O
fleet	B-DRUG
phospho	I-DRUG
-	I-DRUG
soda	I-DRUG
preparation	O
in	O
a	O
patient	O
taking	O
alendronate	B-DRUG
sodium	I-DRUG
:	O
report	O
of	O
a	O
case	O
.	O
This	O
case	O
report	O
describes	O
a	O
patient	O
who	O
was	O
previously	O
prescribed	O
alendronate	B-DRUG
(	O
Fosamax	B-DRUG
)	O
and	O
presented	O
with	O
postoperative	O
hypophosphatemia	B-ADVEFFECT
and	O
hypocalcemic	B-ADVEFFECT
tetany	I-ADVEFFECT
after	O
bowel	O
preparation	O
with	O
Fleet	B-DRUG
Phospho	I-DRUG
-	I-DRUG
Soda	I-DRUG
.	O
This	O
case	O
report	O
describes	O
a	O
patient	O
who	O
was	O
previously	O
prescribed	O
alendronate	B-DRUG
(	O
Fosamax	B-DRUG
)	O
and	O
presented	O
with	O
postoperative	O
hypophosphatemia	B-ADVEFFECT
and	O
hypocalcemic	B-ADVEFFECT
tetany	I-ADVEFFECT
after	O
bowel	O
preparation	O
with	O
Fleet	B-DRUG
Phospho	I-DRUG
-	I-DRUG
Soda	I-DRUG
.	O
This	O
case	O
report	O
describes	O
a	O
patient	O
who	O
was	O
previously	O
prescribed	O
alendronate	B-DRUG
(	O
Fosamax	B-DRUG
)	O
and	O
presented	O
with	O
postoperative	O
hypophosphatemia	B-ADVEFFECT
and	O
hypocalcemic	B-ADVEFFECT
tetany	I-ADVEFFECT
after	O
bowel	O
preparation	O
with	O
Fleet	B-DRUG
Phospho	I-DRUG
-	I-DRUG
Soda	I-DRUG
.	O
This	O
case	O
report	O
describes	O
a	O
patient	O
who	O
was	O
previously	O
prescribed	O
alendronate	B-DRUG
(	O
Fosamax	B-DRUG
)	O
and	O
presented	O
with	O
postoperative	O
hypophosphatemia	B-ADVEFFECT
and	O
hypocalcemic	B-ADVEFFECT
tetany	I-ADVEFFECT
after	O
bowel	O
preparation	O
with	O
Fleet	B-DRUG
Phospho	I-DRUG
-	I-DRUG
Soda	I-DRUG
.	O
This	O
case	O
report	O
describes	O
a	O
patient	O
who	O
was	O
previously	O
prescribed	O
alendronate	B-DRUG
(	O
Fosamax	B-DRUG
)	O
and	O
presented	O
with	O
postoperative	O
hypophosphatemia	B-ADVEFFECT
and	O
hypocalcemic	B-ADVEFFECT
tetany	I-ADVEFFECT
after	O
bowel	O
preparation	O
with	O
Fleet	B-DRUG
Phospho	I-DRUG
-	I-DRUG
Soda	I-DRUG
.	O
This	O
case	O
report	O
describes	O
a	O
patient	O
who	O
was	O
previously	O
prescribed	O
alendronate	B-DRUG
(	O
Fosamax	B-DRUG
)	O
and	O
presented	O
with	O
postoperative	O
hypophosphatemia	B-ADVEFFECT
and	O
hypocalcemic	B-ADVEFFECT
tetany	I-ADVEFFECT
after	O
bowel	O
preparation	O
with	O
Fleet	B-DRUG
Phospho	I-DRUG
-	I-DRUG
Soda	I-DRUG
.	O
Described	O
here	O
are	O
2	O
patients	O
who	O
developed	O
thrombotic	B-ADVEFFECT
microangiopathy	I-ADVEFFECT
of	O
the	O
kidneys	O
after	O
receiving	O
high	O
cumulative	O
doses	O
of	O
the	O
new	O
anticancer	O
drug	O
gemcitabine	B-DRUG
.	O
Thrombotic	B-ADVEFFECT
microangiopathy	I-ADVEFFECT
with	O
renal	B-ADVEFFECT
failure	I-ADVEFFECT
in	O
two	O
patients	O
undergoing	O
gemcitabine	B-DRUG
chemotherapy	O
.	O
Thrombotic	B-ADVEFFECT
microangiopathy	I-ADVEFFECT
with	O
renal	B-ADVEFFECT
failure	I-ADVEFFECT
in	O
two	O
patients	O
undergoing	O
gemcitabine	B-DRUG
chemotherapy	O
.	O
The	O
first	O
patient	O
was	O
a	O
61-year	O
-	O
old	O
man	O
with	O
a	O
30-year	O
history	O
of	O
fistulizing	O
CD	O
in	O
whom	O
B	B-ADVEFFECT
-	I-ADVEFFECT
cell	I-ADVEFFECT
non	I-ADVEFFECT
-	I-ADVEFFECT
Hodgkin	I-ADVEFFECT
's	I-ADVEFFECT
lymphoma	I-ADVEFFECT
was	O
diagnosed	O
9	O
months	O
after	O
treatment	O
with	O
infliximab	B-DRUG
.	O
The	O
relationship	O
between	O
infliximab	B-DRUG
treatment	O
and	O
lymphoma	B-ADVEFFECT
in	O
Crohn	O
's	O
disease	O
.	O
The	O
second	O
is	O
a	O
29-year	O
-	O
old	O
man	O
with	O
CD	O
in	O
whom	O
nodular	B-ADVEFFECT
sclerosing	I-ADVEFFECT
Hodgkin	I-ADVEFFECT
's	I-ADVEFFECT
lymphoma	I-ADVEFFECT
was	O
diagnosed	O
3	O
weeks	O
after	O
infusion	O
with	O
infliximab	B-DRUG
.	O
We	O
describe	O
the	O
clinical	O
course	O
of	O
2	O
patients	O
with	O
Crohn	O
's	O
disease	O
(	O
CD	O
)	O
in	O
whom	O
lymphoma	B-ADVEFFECT
was	O
diagnosed	O
after	O
treatment	O
with	O
infliximab	B-DRUG
.	O
Codeine	B-ADVEFFECT
intoxication	I-ADVEFFECT
in	O
the	O
neonate	O
.	O
We	O
report	O
a	O
case	O
of	O
codeine	B-ADVEFFECT
intoxication	I-ADVEFFECT
in	O
the	O
neonate	O
,	O
in	O
which	O
the	O
drug	O
was	O
prescribed	O
for	O
cough	O
control	O
during	O
an	O
emergency	O
department	O
visit	O
.	O
Hydroxyurea	B-DRUG
(	O
HU	B-DRUG
)	O
and	O
sodium	B-DRUG
phenylbutyrate	I-DRUG
(	O
SPB	B-DRUG
)	O
have	O
been	O
shown	O
to	O
increase	B-ADVEFFECT
fetal	I-ADVEFFECT
hemoglobin	I-ADVEFFECT
(	O
Hb	O
F	O
)	O
levels	O
in	O
patients	O
with	O
thalassemia	O
intermedia	O
.	O
Hydroxyurea	B-DRUG
(	O
HU	B-DRUG
)	O
and	O
sodium	B-DRUG
phenylbutyrate	I-DRUG
(	O
SPB	B-DRUG
)	O
have	O
been	O
shown	O
to	O
increase	B-ADVEFFECT
fetal	I-ADVEFFECT
hemoglobin	I-ADVEFFECT
(	O
Hb	O
F	O
)	O
levels	O
in	O
patients	O
with	O
thalassemia	O
intermedia	O
.	O
Of	O
the	O
four	O
patients	O
who	O
responded	O
to	O
HU	B-DRUG
with	O
an	O
increase	B-ADVEFFECT
in	I-ADVEFFECT
total	I-ADVEFFECT
Hb	I-ADVEFFECT
,	O
all	O
reported	O
symptomatic	O
improvement	O
and	O
three	O
have	O
not	O
required	O
further	O
transfusions	O
.	O
Prolonged	O
responses	O
were	O
achieved	O
with	O
low	O
doses	O
of	O
HU	B-DRUG
(	O
3	O
-	O
10	O
mg	O
/	O
kg	O
/	O
day	O
)	O
and	O
higher	O
doses	O
were	O
associated	O
with	O
mild	B-ADVEFFECT
reversible	I-ADVEFFECT
hematologic	I-ADVEFFECT
or	O
hepatic	B-ADVEFFECT
toxicity	I-ADVEFFECT
and	O
no	O
further	O
increases	O
in	O
Hb	O
.	O
Prolonged	O
responses	O
were	O
achieved	O
with	O
low	O
doses	O
of	O
HU	B-DRUG
(	O
3	O
-	O
10	O
mg	O
/	O
kg	O
/	O
day	O
)	O
and	O
higher	O
doses	O
were	O
associated	O
with	O
mild	B-ADVEFFECT
reversible	I-ADVEFFECT
hematologic	I-ADVEFFECT
or	O
hepatic	B-ADVEFFECT
toxicity	I-ADVEFFECT
and	O
no	O
further	O
increases	O
in	O
Hb	O
.	O
Sodium	B-DRUG
phenylbutyrate	I-DRUG
was	O
added	O
to	O
treatment	O
with	O
HU	B-DRUG
in	O
two	O
patients	O
,	O
but	O
failed	O
to	O
produce	O
an	O
increase	B-ADVEFFECT
in	I-ADVEFFECT
total	I-ADVEFFECT
Hb	I-ADVEFFECT
despite	O
increasing	B-ADVEFFECT
Hb	I-ADVEFFECT
F	I-ADVEFFECT
levels	O
.	O
Sodium	B-DRUG
phenylbutyrate	I-DRUG
was	O
added	O
to	O
treatment	O
with	O
HU	B-DRUG
in	O
two	O
patients	O
,	O
but	O
failed	O
to	O
produce	O
an	O
increase	O
in	B-ADVEFFECT
total	I-ADVEFFECT
Hb	I-ADVEFFECT
despite	O
increasing	B-ADVEFFECT
Hb	I-ADVEFFECT
F	I-ADVEFFECT
levels	O
.	O
We	O
conclude	O
that	O
low	O
-	O
dose	O
HU	B-DRUG
therapy	O
in	O
patients	O
with	O
thalassemia	O
intermedia	O
may	O
increase	B-ADVEFFECT
total	I-ADVEFFECT
Hb	I-ADVEFFECT
levels	O
sufficiently	O
to	O
eliminate	O
the	O
need	O
for	O
transfusions	O
.	O
We	O
describe	O
the	O
clinical	O
response	O
,	O
as	O
determined	O
by	O
increases	B-ADVEFFECT
in	I-ADVEFFECT
total	I-ADVEFFECT
Hb	I-ADVEFFECT
and	O
decreased	O
transfusion	O
needs	O
,	O
in	O
five	O
patients	O
with	O
thalassemia	O
intermedia	O
treated	O
with	O
HU	B-DRUG
alone	O
or	O
in	O
combination	O
with	O
SPB	B-DRUG
.	O
We	O
describe	O
the	O
clinical	O
response	O
,	O
as	O
determined	O
by	O
increases	B-ADVEFFECT
in	I-ADVEFFECT
total	I-ADVEFFECT
Hb	I-ADVEFFECT
and	O
decreased	O
transfusion	O
needs	O
,	O
in	O
five	O
patients	O
with	O
thalassemia	O
intermedia	O
treated	O
with	O
HU	B-DRUG
alone	O
or	O
in	O
combination	O
with	O
SPB	B-DRUG
.	O
A	O
36-y	O
-	O
o	O
patient	O
with	O
schizophrenia	O
,	O
who	O
had	O
consumed	O
gradually	O
increasing	O
quantities	O
of	O
oolong	B-DRUG
tea	I-DRUG
that	O
eventually	O
reached	O
15	O
L	O
each	O
day	O
,	O
became	O
delirious	B-ADVEFFECT
and	O
was	O
admitted	O
to	O
a	O
psychiatric	O
hospital	O
.	O
After	O
abstinence	O
from	O
oolong	B-DRUG
tea	I-DRUG
his	O
delirium	B-ADVEFFECT
resolved	O
.	O
Severe	O
rhabdomyolysis	B-ADVEFFECT
following	O
massive	O
ingestion	O
of	O
oolong	B-DRUG
tea	O
:	O
caffeine	B-ADVEFFECT
intoxication	I-ADVEFFECT
with	O
coexisting	O
hyponatremia	B-ADVEFFECT
.	O
Severe	O
rhabdomyolysis	B-ADVEFFECT
following	O
massive	O
ingestion	O
of	O
oolong	B-DRUG
tea	I-DRUG
:	O
caffeine	B-ADVEFFECT
intoxication	I-ADVEFFECT
with	O
coexisting	O
hyponatremia	B-ADVEFFECT
.	O
Severe	O
rhabdomyolysis	B-ADVEFFECT
following	O
massive	O
ingestion	O
of	O
oolong	B-DRUG
tea	I-DRUG
:	O
caffeine	B-ADVEFFECT
intoxication	I-ADVEFFECT
with	O
coexisting	O
hyponatremia	B-ADVEFFECT
.	O
Severe	O
rhabdomyolysis	B-ADVEFFECT
following	O
massive	O
ingestion	O
of	O
oolong	B-DRUG
tea	I-DRUG
:	O
caffeine	B-ADVEFFECT
intoxication	I-ADVEFFECT
with	O
coexisting	O
hyponatremia	B-ADVEFFECT
.	O
The	O
clinical	O
course	O
suggests	O
that	O
caffeine	B-DRUG
,	O
which	O
is	O
present	O
in	O
oolong	B-DRUG
tea	I-DRUG
,	O
was	O
mainly	O
responsible	O
for	O
the	O
rhabdomyolysis	B-ADVEFFECT
as	O
well	O
as	O
the	O
delirium	B-ADVEFFECT
,	O
although	O
severe	O
hyponatremia	B-ADVEFFECT
has	O
been	O
reported	O
to	O
cause	O
rhabdomyolysis	B-ADVEFFECT
on	O
rare	O
occasions	O
.	O
The	O
clinical	O
course	O
suggests	O
that	O
caffeine	B-DRUG
,	O
which	O
is	O
present	O
in	O
oolong	B-DRUG
tea	I-DRUG
,	O
was	O
mainly	O
responsible	O
for	O
the	O
rhabdomyolysis	B-ADVEFFECT
as	O
well	O
as	O
the	O
delirium	B-ADVEFFECT
,	O
although	O
severe	O
hyponatremia	B-ADVEFFECT
has	O
been	O
reported	O
to	O
cause	O
rhabdomyolysis	B-ADVEFFECT
on	O
rare	O
occasions	O
.	O
The	O
clinical	O
course	O
suggests	O
that	O
caffeine	B-DRUG
,	O
which	O
is	O
present	O
in	O
oolong	B-DRUG
tea	I-DRUG
,	O
was	O
mainly	O
responsible	O
for	O
the	O
rhabdomyolysis	B-ADVEFFECT
as	O
well	O
as	O
the	O
delirium	B-ADVEFFECT
,	O
although	O
severe	O
hyponatremia	B-ADVEFFECT
has	O
been	O
reported	O
to	O
cause	O
rhabdomyolysis	B-ADVEFFECT
on	O
rare	O
occasions	O
.	O
The	O
clinical	O
course	O
suggests	O
that	O
caffeine	B-DRUG
,	O
which	O
is	O
present	O
in	O
oolong	B-DRUG
tea	I-DRUG
,	O
was	O
mainly	O
responsible	O
for	O
the	O
rhabdomyolysis	B-ADVEFFECT
as	O
well	O
as	O
the	O
delirium	B-ADVEFFECT
,	O
although	O
severe	O
hyponatremia	B-ADVEFFECT
has	O
been	O
reported	O
to	O
cause	O
rhabdomyolysis	B-ADVEFFECT
on	O
rare	O
occasions	O
.	O
The	O
possibility	O
of	O
severe	O
rhabdomyolysis	B-ADVEFFECT
should	O
be	O
considered	O
in	O
a	O
patient	O
with	O
water	B-ADVEFFECT
intoxication	I-ADVEFFECT
due	O
to	O
massive	O
ingestion	O
of	O
caffeine	B-DRUG
-	O
containing	O
beverages	O
.	O
The	O
possibility	O
of	O
severe	O
rhabdomyolysis	B-ADVEFFECT
should	O
be	O
considered	O
in	O
a	O
patient	O
with	O
water	B-ADVEFFECT
intoxication	I-ADVEFFECT
due	O
to	O
massive	O
ingestion	O
of	O
caffeine	B-DRUG
-	O
containing	O
beverages	O
.	O
We	O
hypothesize	O
that	O
caffeine	B-ADVEFFECT
toxicity	I-ADVEFFECT
injured	O
the	O
muscle	O
cells	O
,	O
which	O
were	O
fragile	O
due	O
to	O
the	O
potassium	B-ADVEFFECT
depletion	I-ADVEFFECT
induced	O
by	O
the	O
coexisting	O
hyponatremia	B-ADVEFFECT
,	O
to	O
result	O
in	O
unusually	O
severe	O
rhabdomyolysis	B-ADVEFFECT
.	O
We	O
hypothesize	O
that	O
caffeine	B-ADVEFFECT
toxicity	I-ADVEFFECT
injured	O
the	O
muscle	O
cells	O
,	O
which	O
were	O
fragile	O
due	O
to	O
the	O
potassium	B-ADVEFFECT
depletion	I-ADVEFFECT
induced	O
by	O
the	O
coexisting	O
hyponatremia	B-ADVEFFECT
,	O
to	O
result	O
in	O
unusually	O
severe	O
rhabdomyolysis	B-ADVEFFECT
.	O
We	O
hypothesize	O
that	O
caffeine	B-ADVEFFECT
toxicity	I-ADVEFFECT
injured	O
the	O
muscle	O
cells	O
,	O
which	O
were	O
fragile	O
due	O
to	O
the	O
potassium	B-ADVEFFECT
depletion	I-ADVEFFECT
induced	O
by	O
the	O
coexisting	O
hyponatremia	B-ADVEFFECT
,	O
to	O
result	O
in	O
unusually	O
severe	O
rhabdomyolysis	B-ADVEFFECT
.	O
We	O
hypothesize	O
that	O
caffeine	B-ADVEFFECT
toxicity	I-ADVEFFECT
injured	O
the	O
muscle	O
cells	O
,	O
which	O
were	O
fragile	O
due	O
to	O
the	O
potassium	B-ADVEFFECT
depletion	I-ADVEFFECT
induced	O
by	O
the	O
coexisting	O
hyponatremia	B-ADVEFFECT
,	O
to	O
result	O
in	O
unusually	O
severe	O
rhabdomyolysis	B-ADVEFFECT
.	O
We	O
hypothesize	O
that	O
caffeine	B-ADVEFFECT
toxicity	I-ADVEFFECT
injured	O
the	O
muscle	O
cells	O
,	O
which	O
were	O
fragile	O
due	O
to	O
the	O
potassium	B-ADVEFFECT
depletion	I-ADVEFFECT
induced	O
by	O
the	O
coexisting	O
hyponatremia	B-ADVEFFECT
,	O
to	O
result	O
in	O
unusually	O
severe	O
rhabdomyolysis	B-ADVEFFECT
.	O
After	O
the	O
addition	O
of	O
citalopram	B-DRUG
,	O
a	O
desmethylclomipramine	B-ADVEFFECT
plasma	I-ADVEFFECT
level	I-ADVEFFECT
increase	I-ADVEFFECT
and	O
an	O
8-hydroacy	B-ADVEFFECT
-	I-ADVEFFECT
desmethylclomipramine	I-ADVEFFECT
plasma	I-ADVEFFECT
level	I-ADVEFFECT
decrease	I-ADVEFFECT
were	O
observed	O
.	O
After	O
the	O
addition	O
of	O
citalopram	B-DRUG
,	O
a	O
desmethylclomipramine	B-ADVEFFECT
plasma	I-ADVEFFECT
level	I-ADVEFFECT
increase	I-ADVEFFECT
and	O
an	O
8-hydroacy	B-ADVEFFECT
-	I-ADVEFFECT
desmethylclomipramine	I-ADVEFFECT
plasma	I-ADVEFFECT
level	I-ADVEFFECT
decrease	I-ADVEFFECT
were	O
observed	O
.	O
We	O
report	O
3	O
cases	O
of	O
HIV-1	O
infected	O
patients	O
who	O
experienced	O
symptomatic	O
angiolipomas	B-ADVEFFECT
shortly	O
after	O
starting	O
antiretroviral	O
therapy	O
including	O
the	O
protease	O
inhibitor	O
indinavir	B-DRUG
.	O
Elevated	B-ADVEFFECT
serum	I-ADVEFFECT
triglycerides	I-ADVEFFECT
with	O
clozapine	B-DRUG
resolved	O
with	O
risperidone	O
in	O
four	O
patients	O
.	O
In	O
two	O
patients	O
clozapine	B-DRUG
was	O
reinstated	O
after	O
risperidone	O
was	O
discontinued	O
;	O
serum	B-ADVEFFECT
triglyceride	I-ADVEFFECT
levels	I-ADVEFFECT
increased	I-ADVEFFECT
.	O
This	O
increase	O
when	O
clozapine	B-DRUG
was	O
switched	O
to	O
risperidone	O
and	O
vice	O
versa	O
is	O
consistent	O
with	O
our	O
previous	O
report	O
of	O
elevated	B-ADVEFFECT
serum	I-ADVEFFECT
triglyceride	I-ADVEFFECT
levels	I-ADVEFFECT
in	O
clozapine	B-DRUG
-	O
treated	O
patients	O
.	O
Intravenous	O
valproate	B-DRUG
associated	O
with	O
significant	O
hypotension	B-ADVEFFECT
in	O
the	O
treatment	O
of	O
status	O
epilepticus	O
.	O
To	O
our	O
knowledge	O
,	O
this	O
is	O
the	O
first	O
report	O
of	O
significant	O
hypotension	B-ADVEFFECT
associated	O
with	O
intravenous	O
valproate	B-DRUG
in	O
the	O
treatment	O
of	O
status	O
epilepticus	O
in	O
the	O
pediatric	O
population	O
.	O
We	O
report	O
a	O
case	O
of	O
severe	O
hypotension	B-ADVEFFECT
associated	O
with	O
intravenous	O
valproate	B-DRUG
used	O
to	O
treat	O
status	O
epilepticus	O
in	O
an	O
11-year	O
-	O
old	O
girl	O
.	O
In	O
both	O
patients	O
the	O
rippling	B-ADVEFFECT
phenomena	I-ADVEFFECT
worsened	I-ADVEFFECT
with	O
pyridostigmine	B-DRUG
treatment	O
but	O
markedly	O
improved	O
after	O
immunosuppression	O
with	O
azathioprine	O
.	O
A	O
diagnosis	O
of	O
masked	O
theophylline	B-ADVEFFECT
poisoning	I-ADVEFFECT
should	O
be	O
considered	O
in	O
similar	O
situations	O
involving	O
a	O
rapid	O
decrease	O
of	O
insulin	O
requirements	O
.	O
Salicylate	O
intoxication	B-ADVEFFECT
was	O
excluded	O
,	O
and	O
theophylline	B-DRUG
was	O
finally	O
incriminated	O
.	O
Theophylline	B-ADVEFFECT
intoxication	I-ADVEFFECT
mimicking	O
diabetic	O
ketoacidosis	O
in	O
a	O
child	O
.	O
This	O
compound	O
,	O
used	O
by	O
adults	O
in	O
the	O
child	O
's	O
home	O
,	O
had	O
caused	O
accidental	O
theophylline	B-ADVEFFECT
poisoning	I-ADVEFFECT
,	O
mimicking	O
diabetic	O
ketoacidosis	O
.	O
Methylene	O
blue	O
in	O
the	O
treatment	O
and	O
prevention	O
of	O
ifosfamide	B-ADVEFFECT
-	I-ADVEFFECT
induced	I-ADVEFFECT
encephalopathy	I-ADVEFFECT
:	O
report	O
of	O
12	O
cases	O
and	O
a	O
review	O
of	O
the	O
literature	O
.	O
Ten	O
to	O
15	O
%	O
of	O
patients	O
treated	O
with	O
ifosfamide	B-DRUG
develop	O
an	O
encephalopathy	B-ADVEFFECT
.	O
We	O
conclude	O
that	O
MB	O
is	O
an	O
effective	O
treatment	O
for	O
ifosfamide	B-ADVEFFECT
-	I-ADVEFFECT
induced	I-ADVEFFECT
encephalopathy	I-ADVEFFECT
.	O
Portal	B-ADVEFFECT
vein	I-ADVEFFECT
thrombosis	I-ADVEFFECT
in	O
a	O
patient	O
with	O
severe	O
haemophilia	O
A	O
and	O
F	O
V	O
G1691A	O
mutation	O
during	O
continuous	O
infusion	O
of	O
F	B-DRUG
VIII	I-DRUG
after	O
intramural	O
jejunal	O
bleeding	O
--	O
successful	O
thrombolysis	O
under	O
heparin	O
therapy	O
.	O
We	O
report	O
on	O
a	O
14-year	O
-	O
old	O
boy	O
with	O
severe	O
haemophilia	O
A	O
who	O
developed	O
a	O
portal	B-ADVEFFECT
vein	I-ADVEFFECT
thrombosis	I-ADVEFFECT
during	O
continuous	O
infusion	O
of	O
F	B-DRUG
VIII	I-DRUG
.	O
A	O
60-year	O
-	O
old	O
woman	O
with	O
diabetes	O
mellitus	O
(	O
type	O
2	O
)	O
developed	O
an	O
acute	B-ADVEFFECT
icteric	I-ADVEFFECT
hepatitis	I-ADVEFFECT
-	I-ADVEFFECT
like	I-ADVEFFECT
illness	I-ADVEFFECT
6	O
weeks	O
after	O
the	O
initiation	O
of	O
gliclazide	B-DRUG
therapy	O
.	O
Gliclazide	B-DRUG
-	O
induced	O
acute	B-ADVEFFECT
hepatitis	I-ADVEFFECT
.	O
In	O
conclusion	O
,	O
this	O
case	O
strongly	O
suggests	O
that	O
gliclazide	B-DRUG
can	O
induce	O
acute	B-ADVEFFECT
icteric	I-ADVEFFECT
liver	I-ADVEFFECT
necro	I-ADVEFFECT
-	I-ADVEFFECT
inflammation	I-ADVEFFECT
which	O
may	O
be	O
misdiagnosed	O
clinically	O
as	O
acute	O
viral	O
hepatitis	O
.	O
We	O
believe	O
that	O
this	O
is	O
the	O
first	O
description	O
of	O
acute	B-ADVEFFECT
hepatitis	I-ADVEFFECT
caused	O
by	O
an	O
idiosyncratic	O
adverse	O
reaction	O
to	O
gliclazide	B-DRUG
or	O
to	O
one	O
of	O
its	O
metabolites	O
.	O
We	O
describe	O
the	O
case	O
of	O
acute	B-ADVEFFECT
hepatitis	I-ADVEFFECT
induced	O
by	O
gliclazide	B-DRUG
,	O
a	O
second	O
generation	O
sulfonylurea	O
.	O
Caution	O
is	O
,	O
therefore	O
,	O
needed	O
to	O
prevent	O
undesired	O
accumulation	O
of	O
TCA	B-DRUG
that	O
may	O
lead	O
to	O
protracted	O
Cushing	B-ADVEFFECT
's	I-ADVEFFECT
syndrome	I-ADVEFFECT
.	O
Cushing	B-ADVEFFECT
's	I-ADVEFFECT
syndrome	I-ADVEFFECT
persisted	O
more	O
than	O
6	O
months	O
while	O
TCA	B-DRUG
concentrations	O
remained	O
detectable	O
for	O
at	O
least	O
80	O
days	O
.	O
The	O
presented	O
patient	O
was	O
treated	O
with	O
200	O
mg	O
TCA	B-DRUG
and	O
developed	O
Cushing	B-ADVEFFECT
's	I-ADVEFFECT
syndrome	I-ADVEFFECT
6	O
weeks	O
later	O
(	O
cortisol	O
and	O
ACTH	O
concentrations	O
were	O
below	O
limits	O
of	O
detection	O
,	O
TCA	B-DRUG
concentrations	O
were	O
>	O
3	O
micrograms	O
/	O
l	O
)	O
.	O
Both	O
had	O
impaired	O
lung	O
function	O
and	O
abnormal	B-ADVEFFECT
computed	I-ADVEFFECT
tomographic	I-ADVEFFECT
scans	I-ADVEFFECT
,	O
and	O
their	O
condition	O
improved	O
when	O
nitrofurantoin	B-DRUG
was	O
withdrawn	O
and	O
corticosteroid	O
treatment	O
commenced	O
.	O
Both	O
had	O
impaired	B-ADVEFFECT
lung	I-ADVEFFECT
function	I-ADVEFFECT
and	O
abnormal	B-ADVEFFECT
computed	I-ADVEFFECT
tomographic	I-ADVEFFECT
scans	I-ADVEFFECT
,	O
and	O
their	O
condition	O
improved	O
when	O
nitrofurantoin	B-DRUG
was	O
withdrawn	O
and	O
corticosteroid	O
treatment	O
commenced	O
.	O
Bronchiolitis	B-ADVEFFECT
obliterans	I-ADVEFFECT
organising	I-ADVEFFECT
pneumonia	I-ADVEFFECT
associated	O
with	O
the	O
use	O
of	O
nitrofurantoin	B-DRUG
.	O
The	O
case	O
histories	O
are	O
presented	O
of	O
two	O
patients	O
who	O
developed	O
lung	B-ADVEFFECT
disease	I-ADVEFFECT
associated	O
with	O
the	O
use	O
of	O
nitrofurantoin	B-DRUG
with	O
histological	O
features	O
of	O
bronchiolitis	B-ADVEFFECT
obliterans	I-ADVEFFECT
organising	I-ADVEFFECT
pneumonia	I-ADVEFFECT
(	O
BOOP	B-ADVEFFECT
)	O
,	O
a	O
rare	O
but	O
recognised	O
form	O
of	O
drug	O
induced	O
injury	O
.	O
The	O
case	O
histories	O
are	O
presented	O
of	O
two	O
patients	O
who	O
developed	O
lung	B-ADVEFFECT
disease	I-ADVEFFECT
associated	O
with	O
the	O
use	O
of	O
nitrofurantoin	B-DRUG
with	O
histological	O
features	O
of	O
bronchiolitis	B-ADVEFFECT
obliterans	I-ADVEFFECT
organising	I-ADVEFFECT
pneumonia	I-ADVEFFECT
(	O
BOOP	B-ADVEFFECT
)	O
,	O
a	O
rare	O
but	O
recognised	O
form	O
of	O
drug	O
induced	O
injury	O
.	O
The	O
case	O
histories	O
are	O
presented	O
of	O
two	O
patients	O
who	O
developed	O
lung	B-ADVEFFECT
disease	I-ADVEFFECT
associated	O
with	O
the	O
use	O
of	O
nitrofurantoin	B-DRUG
with	O
histological	O
features	O
of	O
bronchiolitis	B-ADVEFFECT
obliterans	I-ADVEFFECT
organising	I-ADVEFFECT
pneumonia	I-ADVEFFECT
(	O
BOOP	B-ADVEFFECT
)	O
,	O
a	O
rare	O
but	O
recognised	O
form	O
of	O
drug	O
induced	O
injury	O
.	O
The	O
favourable	O
outcome	O
in	O
these	O
two	O
patients	O
contrasts	O
with	O
the	O
fatal	B-ADVEFFECT
outcome	I-ADVEFFECT
of	O
the	O
two	O
other	O
reported	O
cases	O
of	O
nitrofurantoin	B-ADVEFFECT
induced	I-ADVEFFECT
BOOP	I-ADVEFFECT
.	O
The	O
favourable	O
outcome	O
in	O
these	O
two	O
patients	O
contrasts	O
with	O
the	O
fatal	B-ADVEFFECT
outcome	I-ADVEFFECT
of	O
the	O
two	O
other	O
reported	O
cases	O
of	O
nitrofurantoin	B-ADVEFFECT
induced	I-ADVEFFECT
BOOP	I-ADVEFFECT
.	O
The	O
spectrum	O
of	O
nitrofurantoin	B-DRUG
lung	B-ADVEFFECT
injury	I-ADVEFFECT
continues	O
to	O
widen	O
.	O
The	O
two	O
middle	O
aged	O
women	O
presented	O
with	O
respiratory	B-ADVEFFECT
symptoms	I-ADVEFFECT
after	O
prolonged	O
treatment	O
with	O
nitrofurantoin	B-DRUG
.	O
We	O
suggest	O
that	O
the	O
previous	O
classification	O
of	O
nitrofurantoin	B-ADVEFFECT
induced	I-ADVEFFECT
lung	I-ADVEFFECT
injury	I-ADVEFFECT
into	O
""""	O
acute	O
""""	O
and	O
""""	O
chronic	O
""""	O
injury	O
is	O
an	O
oversimplification	O
in	O
view	O
of	O
the	O
wide	O
variety	O
of	O
pathological	O
entities	O
that	O
have	O
subsequently	O
emerged	O
.	O
Intravenous	O
administration	O
of	O
levodopa	O
ameliorated	O
a	O
refractory	O
akathisia	B-ADVEFFECT
case	O
induced	O
by	O
interferon	B-DRUG
-	I-DRUG
alpha	I-DRUG
.	O
The	O
present	O
report	O
illustrates	O
a	O
rare	O
case	O
of	O
refractory	O
akathisia	B-ADVEFFECT
after	O
interferon	B-DRUG
-	I-DRUG
alpha	I-DRUG
treatment	O
and	O
also	O
that	O
levodopa	O
treatment	O
would	O
be	O
theoretically	O
and	O
practically	O
useful	O
in	O
reducing	O
the	O
neurotoxicity	B-ADVEFFECT
associated	O
with	O
interferon	B-DRUG
-	I-DRUG
alpha	I-DRUG
.	O
The	O
present	O
report	O
illustrates	O
a	O
rare	O
case	O
of	O
refractory	O
akathisia	B-ADVEFFECT
after	O
interferon	B-DRUG
-	I-DRUG
alpha	I-DRUG
treatment	O
and	O
also	O
that	O
levodopa	O
treatment	O
would	O
be	O
theoretically	O
and	O
practically	O
useful	O
in	O
reducing	O
the	O
neurotoxicity	B-ADVEFFECT
associated	O
with	O
interferon	B-DRUG
-	I-DRUG
alpha	I-DRUG
.	O
Acute	B-ADVEFFECT
erythroid	I-ADVEFFECT
leukemia	I-ADVEFFECT
after	O
cyclophosphamide	B-DRUG
therapy	O
for	O
multiple	O
myeloma	O
:	O
report	O
of	O
two	O
cases	O
.	O
The	O
development	O
of	O
erythroid	O
leukemia	O
plus	O
carcinoma	B-ADVEFFECT
in	O
these	O
two	O
men	O
suggests	O
mutagenic	O
change	O
secondary	O
to	O
cyclophosphamide	B-DRUG
therapy	O
.	O
Scleroderma	B-ADVEFFECT
-	I-ADVEFFECT
like	I-ADVEFFECT
reaction	I-ADVEFFECT
induced	O
by	O
uracil	B-DRUG
-	I-DRUG
tegafur	I-DRUG
(	O
UFT	B-DRUG
)	O
,	O
a	O
second	O
-	O
generation	O
anticancer	O
agent	O
.	O
Scleroderma	B-ADVEFFECT
-	I-ADVEFFECT
like	I-ADVEFFECT
reaction	I-ADVEFFECT
induced	O
by	O
uracil	B-DRUG
-	I-DRUG
tegafur	I-DRUG
(	O
UFT	B-DRUG
)	O
,	O
a	O
second	O
-	O
generation	O
anticancer	O
agent	O
.	O
This	O
is	O
the	O
first	O
report	O
of	O
UFT	B-ADVEFFECT
-	I-ADVEFFECT
induced	I-ADVEFFECT
scleroderma	I-ADVEFFECT
-	I-ADVEFFECT
like	I-ADVEFFECT
reaction	I-ADVEFFECT
.	O
We	O
report	O
a	O
case	O
of	O
a	O
scleroderma	B-ADVEFFECT
-	I-ADVEFFECT
like	I-ADVEFFECT
reaction	I-ADVEFFECT
induced	O
by	O
long	O
-	O
term	O
administration	O
of	O
UFT	B-DRUG
.	O
Central	B-ADVEFFECT
nervous	I-ADVEFFECT
system	I-ADVEFFECT
manifestations	I-ADVEFFECT
of	O
an	O
ibuprofen	B-DRUG
overdose	O
reversed	O
by	O
naloxone	O
.	O
Ibuprofen	B-DRUG
overdose	O
is	O
usually	O
characterized	O
by	O
GI	B-ADVEFFECT
upset	I-ADVEFFECT
,	O
dizziness	B-ADVEFFECT
,	O
and	O
mild	B-ADVEFFECT
sedation	I-ADVEFFECT
.	O
Ibuprofen	B-DRUG
overdose	O
is	O
usually	O
characterized	O
by	O
GI	B-ADVEFFECT
upset	I-ADVEFFECT
,	O
dizziness	B-ADVEFFECT
,	O
and	O
mild	B-ADVEFFECT
sedation	I-ADVEFFECT
.	O
Ibuprofen	B-DRUG
overdose	O
is	O
usually	O
characterized	O
by	O
GI	B-ADVEFFECT
upset	I-ADVEFFECT
,	O
dizziness	B-ADVEFFECT
,	O
and	O
mild	B-ADVEFFECT
sedation	I-ADVEFFECT
.	O
Presently	O
,	O
treatment	O
of	O
acute	O
ibuprofen	B-ADVEFFECT
intoxication	I-ADVEFFECT
with	O
complications	O
requires	O
supportive	O
therapy	O
until	O
the	O
symptoms	O
resolve	O
over	O
24	O
to	O
48	O
hours	O
.	O
We	O
report	O
the	O
case	O
of	O
an	O
11-month	O
-	O
old	O
female	O
infant	O
with	O
a	O
depressed	B-ADVEFFECT
level	I-ADVEFFECT
of	I-ADVEFFECT
consciousness	I-ADVEFFECT
after	O
ingestion	O
of	O
ibuprofen	B-DRUG
whose	O
mental	O
status	O
markedly	O
improved	O
with	O
administration	O
of	O
naloxone	O
.	O
Flecainide	B-DRUG
-	O
associated	O
pneumonitis	B-ADVEFFECT
with	O
acute	B-ADVEFFECT
respiratory	I-ADVEFFECT
failure	I-ADVEFFECT
in	O
a	O
patient	O
with	O
the	O
LEOPARD	O
syndrome	O
.	O
Flecainide	B-DRUG
-	O
associated	O
pneumonitis	B-ADVEFFECT
with	O
acute	B-ADVEFFECT
respiratory	I-ADVEFFECT
failure	I-ADVEFFECT
in	O
a	O
patient	O
with	O
the	O
LEOPARD	O
syndrome	O
.	O
Flecainide	B-DRUG
is	O
a	O
rare	O
cause	O
of	O
hypersensitivity	B-ADVEFFECT
pneumonitis	I-ADVEFFECT
,	O
and	O
few	O
cases	O
have	O
been	O
reported	O
.	O
We	O
describe	O
a	O
case	O
of	O
interstitial	B-ADVEFFECT
hypoxaemiant	I-ADVEFFECT
pneumonitis	I-ADVEFFECT
probably	O
related	O
to	O
flecainide	B-DRUG
in	O
a	O
patient	O
with	O
the	O
LEOPARD	O
syndrome	O
,	O
a	O
rare	O
congenital	O
disorder	O
.	O
Sagittal	B-ADVEFFECT
sinus	I-ADVEFFECT
thrombosis	I-ADVEFFECT
associated	O
with	O
transient	B-ADVEFFECT
free	I-ADVEFFECT
protein	I-ADVEFFECT
S	I-ADVEFFECT
deficiency	I-ADVEFFECT
after	O
L	B-DRUG
-	I-DRUG
asparaginase	I-DRUG
treatment	O
:	O
case	O
report	O
and	O
review	O
of	O
the	O
literature	O
.	O
Sagittal	B-ADVEFFECT
sinus	I-ADVEFFECT
thrombosis	I-ADVEFFECT
associated	O
with	O
transient	B-ADVEFFECT
free	I-ADVEFFECT
protein	I-ADVEFFECT
S	I-ADVEFFECT
deficiency	I-ADVEFFECT
after	O
L	B-DRUG
-	I-DRUG
asparaginase	I-DRUG
treatment	O
:	O
case	O
report	O
and	O
review	O
of	O
the	O
literature	O
.	O
We	O
report	O
the	O
case	O
of	O
an	O
adult	O
patient	O
with	O
acute	O
lymphoblastic	O
leukemia	O
who	O
presented	O
with	O
repeated	O
transient	B-ADVEFFECT
ischemic	I-ADVEFFECT
attacks	I-ADVEFFECT
followed	O
by	O
a	O
seizure	B-ADVEFFECT
during	O
consolidation	O
treatment	O
with	O
L	B-DRUG
-	I-DRUG
asparaginase	I-DRUG
.	O
We	O
report	O
the	O
case	O
of	O
an	O
adult	O
patient	O
with	O
acute	O
lymphoblastic	O
leukemia	O
who	O
presented	O
with	O
repeated	O
transient	B-ADVEFFECT
ischemic	I-ADVEFFECT
attacks	I-ADVEFFECT
followed	O
by	O
a	O
seizure	B-ADVEFFECT
during	O
consolidation	O
treatment	O
with	O
L	B-DRUG
-	I-DRUG
asparaginase	I-DRUG
.	O
We	O
report	O
on	O
a	O
young	O
adolescent	O
with	O
benign	B-ADVEFFECT
intracranial	I-ADVEFFECT
hypertension	I-ADVEFFECT
which	O
we	O
attribute	O
to	O
the	O
use	O
of	O
minocycline	B-DRUG
for	O
acne	O
.	O
We	O
report	O
2	O
patients	O
who	O
developed	O
polyarteritis	B-ADVEFFECT
nodosa	I-ADVEFFECT
following	O
vaccination	B-DRUG
against	I-DRUG
hepatitis	I-DRUG
B	I-DRUG
.	O
In	O
this	O
case	O
,	O
it	O
was	O
suspected	O
that	O
a	O
combination	O
of	O
cigarette	O
smoking	O
,	O
pulmonary	O
fibrosis	O
,	O
and	O
low	O
-	O
dose	O
methotrexate	B-DRUG
therapy	O
might	O
have	O
promoted	O
the	O
development	O
of	O
lung	B-ADVEFFECT
cancer	I-ADVEFFECT
.	O
This	O
case	O
report	O
illustrates	O
the	O
use	O
of	O
continuous	O
high	O
-	O
dose	O
intracoronary	O
nitroglycerin	O
infusion	O
through	O
a	O
6	O
French	O
coronary	O
guiding	O
catheter	O
in	O
the	O
treatment	O
of	O
a	O
patient	O
with	O
cocaine	B-DRUG
-	O
induced	O
refractory	B-ADVEFFECT
coronary	I-ADVEFFECT
vasospasm	I-ADVEFFECT
.	O
However	O
,	O
as	O
illustrated	O
by	O
these	O
and	O
other	O
cases	O
reported	O
to	O
date	O
,	O
the	O
onset	O
of	O
troglitazone	B-DRUG
-	O
induced	O
liver	B-ADVEFFECT
injury	I-ADVEFFECT
is	O
insidious	O
and	O
temporally	O
variable	O
.	O
It	O
remains	O
to	O
be	O
seen	O
whether	O
the	O
hepatotoxicity	B-ADVEFFECT
associated	O
with	O
troglitazone	B-DRUG
is	O
a	O
drug	O
-	O
class	O
effect	O
or	O
specific	O
to	O
troglitazone	B-DRUG
.	O
It	O
remains	O
to	O
be	O
seen	O
whether	O
the	O
hepatotoxicity	B-ADVEFFECT
associated	O
with	O
troglitazone	B-DRUG
is	O
a	O
drug	O
-	O
class	O
effect	O
or	O
specific	O
to	O
troglitazone	B-DRUG
.	O
Other	O
thiazolidinediones	O
currently	O
in	O
clinical	O
trials	O
may	O
be	O
able	O
to	O
provide	O
the	O
therapeutic	O
benefits	O
of	O
troglitazone	B-DRUG
without	O
significant	O
hepatotoxicity	B-ADVEFFECT
.	O
The	O
three	O
reported	O
cases	O
demonstrate	O
that	O
troglitazone	B-DRUG
is	O
an	O
idiosyncratic	O
hepatotoxin	O
that	O
can	O
lead	O
to	O
irreversible	B-ADVEFFECT
liver	I-ADVEFFECT
injury	I-ADVEFFECT
.	O
Troglitazone	B-DRUG
-	O
induced	O
fulminant	B-ADVEFFECT
hepatic	I-ADVEFFECT
failure	I-ADVEFFECT
.	O
Nitrofurantoin	B-DRUG
-	O
induced	O
lung	B-ADVEFFECT
disease	I-ADVEFFECT
:	O
two	O
cases	O
demonstrating	O
resolution	O
of	O
apparently	O
irreversible	O
CT	O
abnormalities	O
.	O
We	O
present	O
two	O
cases	O
of	O
nitrofurantoin	B-DRUG
-	O
induced	O
pulmonary	B-ADVEFFECT
toxicity	I-ADVEFFECT
in	O
which	O
the	O
initial	O
HRCT	O
showed	O
a	O
widespread	B-ADVEFFECT
reticular	I-ADVEFFECT
pattern	I-ADVEFFECT
and	O
associated	O
distortion	B-ADVEFFECT
of	I-ADVEFFECT
the	I-ADVEFFECT
lung	I-ADVEFFECT
parenchyma	I-ADVEFFECT
,	O
thought	O
to	O
represent	O
established	O
fibrosis	B-ADVEFFECT
.	O
We	O
present	O
two	O
cases	O
of	O
nitrofurantoin	B-DRUG
-	O
induced	O
pulmonary	B-ADVEFFECT
toxicity	I-ADVEFFECT
in	O
which	O
the	O
initial	O
HRCT	O
showed	O
a	O
widespread	B-ADVEFFECT
reticular	I-ADVEFFECT
pattern	I-ADVEFFECT
and	O
associated	O
distortion	B-ADVEFFECT
of	I-ADVEFFECT
the	I-ADVEFFECT
lung	I-ADVEFFECT
parenchyma	I-ADVEFFECT
,	O
thought	O
to	O
represent	O
established	O
fibrosis	B-ADVEFFECT
.	O
We	O
present	O
two	O
cases	O
of	O
nitrofurantoin	B-DRUG
-	O
induced	O
pulmonary	B-ADVEFFECT
toxicity	I-ADVEFFECT
in	O
which	O
the	O
initial	O
HRCT	O
showed	O
a	O
widespread	B-ADVEFFECT
reticular	I-ADVEFFECT
pattern	I-ADVEFFECT
and	O
associated	O
distortion	B-ADVEFFECT
of	I-ADVEFFECT
the	I-ADVEFFECT
lung	I-ADVEFFECT
parenchyma	I-ADVEFFECT
,	O
thought	O
to	O
represent	O
established	O
fibrosis	B-ADVEFFECT
.	O
We	O
present	O
two	O
cases	O
of	O
nitrofurantoin	B-DRUG
-	O
induced	O
pulmonary	B-ADVEFFECT
toxicity	I-ADVEFFECT
in	O
which	O
the	O
initial	O
HRCT	O
showed	O
a	O
widespread	B-ADVEFFECT
reticular	I-ADVEFFECT
pattern	I-ADVEFFECT
and	O
associated	O
distortion	B-ADVEFFECT
of	I-ADVEFFECT
the	I-ADVEFFECT
lung	I-ADVEFFECT
parenchyma	I-ADVEFFECT
,	O
thought	O
to	O
represent	O
established	O
fibrosis	B-ADVEFFECT
.	O
Fluoxetine	B-DRUG
-	O
related	O
death	B-ADVEFFECT
in	O
a	O
child	O
with	O
cytochrome	O
P-450	O
2D6	O
genetic	O
deficiency	O
.	O
The	O
medical	O
examiner	O
's	O
report	O
indicated	O
death	B-ADVEFFECT
caused	O
by	O
fluoxetine	B-ADVEFFECT
toxicity	O
.	O
The	O
medical	O
examiner	O
's	O
report	O
indicated	O
death	B-ADVEFFECT
caused	O
by	O
fluoxetine	B-ADVEFFECT
toxicity	I-ADVEFFECT
.	O
This	O
is	O
the	O
first	O
report	O
of	O
a	O
fluoxetine	B-DRUG
-	O
related	O
death	B-ADVEFFECT
in	O
a	O
child	O
with	O
a	O
confirmed	O
genetic	O
polymorphism	O
of	O
the	O
CYP2D6	O
gene	O
that	O
results	O
in	O
impaired	O
drug	O
metabolism	O
.	O
A	O
50-year	O
-	O
old	O
woman	O
with	O
a	O
history	O
of	O
migraine	O
without	O
aura	O
,	O
predominantly	O
occurring	O
around	O
her	O
menstrual	O
periods	O
,	O
developed	O
a	O
spinal	B-ADVEFFECT
cord	I-ADVEFFECT
lesion	I-ADVEFFECT
following	O
the	O
use	O
of	O
zolmitriptan	B-DRUG
.	O
Spinal	B-ADVEFFECT
cord	I-ADVEFFECT
infarction	I-ADVEFFECT
during	O
use	O
of	O
zolmitriptan	B-DRUG
:	O
a	O
case	O
report	O
.	O
The	O
temporal	O
relationship	O
suggests	O
that	O
the	O
spinal	B-ADVEFFECT
cord	I-ADVEFFECT
infarction	I-ADVEFFECT
may	O
be	O
related	O
to	O
the	O
use	O
of	O
zolmitriptan	B-DRUG
.	O
CASE	O
SUMMARY	O
:	O
A	O
10-year	O
-	O
old	O
white	O
girl	O
with	O
bilateral	O
optic	O
glioma	O
developed	O
a	O
hypersensitivity	B-ADVEFFECT
reaction	O
to	O
carboplatin	B-DRUG
after	O
nine	O
courses	O
.	O
This	O
regimen	O
could	O
prove	O
useful	O
for	O
other	O
patients	O
who	O
develop	O
hypersensitivity	B-ADVEFFECT
reactions	O
to	O
carboplatin	B-DRUG
and	O
allow	O
therapy	O
to	O
continue	O
.	O
Perinatal	O
vasoconstrictive	O
renal	B-ADVEFFECT
insufficiency	I-ADVEFFECT
associated	O
with	O
maternal	O
nimesulide	B-DRUG
use	O
.	O
This	O
is	O
the	O
first	O
report	O
of	O
an	O
adverse	B-ADVEFFECT
effect	I-ADVEFFECT
of	I-ADVEFFECT
fetal	I-ADVEFFECT
renal	I-ADVEFFECT
circulation	I-ADVEFFECT
by	O
maternal	O
ingestion	O
of	O
nimesulide	B-DRUG
.	O
Although	O
the	O
t	B-ADVEFFECT
-	I-ADVEFFECT
AML	I-ADVEFFECT
developed	O
following	O
oral	O
etoposide	B-DRUG
therapy	O
,	O
the	O
child	O
had	O
previously	O
received	O
high	O
-	O
dose	O
,	O
multiagent	O
chemotherapy	O
,	O
and	O
rearrangement	O
of	O
the	O
MLL	O
gene	O
was	O
not	O
demonstrated	O
.	O
Secondary	B-ADVEFFECT
leukemia	I-ADVEFFECT
in	O
a	O
child	O
with	O
neuroblastoma	O
while	O
on	O
oral	O
etoposide	B-DRUG
:	O
what	O
is	O
the	O
cause	O
?	O
.	O
The	O
authors	O
present	O
a	O
case	O
of	B-ADVEFFECT
t	I-ADVEFFECT
-	I-ADVEFFECT
AML	O
that	O
developed	O
in	O
a	O
child	O
with	O
metastatic	O
neuroblastoma	O
18	O
months	O
after	O
he	O
received	O
oral	B-DRUG
etoposide	O
,	O
given	O
for	O
palliation	O
purpose	O
.	O
BACKGROUND	O
:	O
Cyanamide	B-DRUG
,	O
an	O
aversive	O
agent	O
widely	O
used	O
in	O
Japan	O
,	O
is	O
known	O
to	O
induce	O
various	O
degrees	O
of	O
hepatic	B-ADVEFFECT
lesion	I-ADVEFFECT
with	I-ADVEFFECT
ground	I-ADVEFFECT
-	I-ADVEFFECT
glass	I-ADVEFFECT
inclusion	I-ADVEFFECT
bodies	I-ADVEFFECT
.	O
Case	O
2	O
:	O
A	O
43-year	O
-	O
old	O
male	O
alcoholic	O
remained	O
completely	O
abstinent	O
with	O
cyanamide	B-DRUG
treatment	O
for	O
5	O
years	O
and	O
complained	O
of	O
general	B-ADVEFFECT
fatigue	I-ADVEFFECT
.	O
Case	O
3	O
:	O
A	O
29-year	O
-	O
old	O
female	O
alcoholic	O
complained	O
of	O
general	O
fatigue	B-ADVEFFECT
and	O
a	O
slight	O
fever	B-ADVEFFECT
after	O
1.5	O
years	O
of	O
abstinence	O
with	O
cyanamide	B-DRUG
treatment	O
.	O
Case	O
3	O
:	O
A	O
29-year	O
-	O
old	O
female	O
alcoholic	O
complained	O
of	O
general	B-ADVEFFECT
fatigue	I-ADVEFFECT
and	O
a	O
slight	O
fever	B-ADVEFFECT
after	O
1.5	O
years	O
of	O
abstinence	O
with	O
cyanamide	B-DRUG
treatment	O
.	O
Case	O
4	O
:	O
A	O
61-year	O
-	O
old	O
male	O
alcoholic	O
who	O
remained	O
completely	O
abstinent	O
while	O
taking	O
cyanamide	B-DRUG
for	O
3	O
years	O
showed	O
slight	O
elevation	B-ADVEFFECT
of	I-ADVEFFECT
serum	I-ADVEFFECT
transaminases	I-ADVEFFECT
.	O
CONCLUSION	O
:	O
In	O
some	O
abstainers	O
who	O
take	O
cyanamide	B-DRUG
for	O
several	O
years	O
,	O
thin	O
septum	B-ADVEFFECT
-	I-ADVEFFECT
like	I-ADVEFFECT
liver	I-ADVEFFECT
fibrosis	I-ADVEFFECT
progresses	O
along	O
with	O
the	O
emergence	O
of	O
ground	B-ADVEFFECT
-	I-ADVEFFECT
glass	I-ADVEFFECT
hepatocytes	I-ADVEFFECT
.	O
CONCLUSION	O
:	O
In	O
some	O
abstainers	O
who	O
take	O
cyanamide	B-DRUG
for	O
several	O
years	O
,	O
thin	O
septum	B-ADVEFFECT
-	I-ADVEFFECT
like	I-ADVEFFECT
liver	I-ADVEFFECT
fibrosis	I-ADVEFFECT
progresses	O
along	O
with	O
the	O
emergence	O
of	O
ground	B-ADVEFFECT
-	I-ADVEFFECT
glass	I-ADVEFFECT
hepatocytes	I-ADVEFFECT
.	O
Cyanamide	B-DRUG
-	O
induced	O
liver	B-ADVEFFECT
dysfunction	I-ADVEFFECT
after	O
abstinence	O
in	O
alcoholics	O
:	O
a	O
long	O
-	O
term	O
follow	O
-	O
up	O
study	O
on	O
four	O
cases	O
.	O
When	O
cyanamide	B-DRUG
-	O
treated	O
alcoholics	O
relapse	O
into	O
drinking	O
,	O
more	O
severe	O
inflammation	B-ADVEFFECT
develops	O
in	O
the	O
liver	O
.	O
A	O
patient	O
with	O
an	O
allergy	O
to	O
a	O
macrolide	O
antibiotic	O
was	O
given	O
tacrolimus	B-DRUG
and	O
developed	O
a	O
sudden	B-ADVEFFECT
cutaneous	I-ADVEFFECT
reaction	I-ADVEFFECT
.	O
A	O
77-year	O
-	O
old	O
woman	O
with	O
no	O
history	O
of	O
epilepsy	O
presented	O
a	O
probable	O
nonconvulsive	B-ADVEFFECT
status	I-ADVEFFECT
epilepticus	I-ADVEFFECT
while	O
receiving	O
continuous	O
intravenous	O
morphine	B-DRUG
for	O
back	O
pain	O
relating	O
to	O
vertebral	O
metastasis	O
of	O
a	O
malignant	O
lymphoma	O
.	O
A	O
generalized	B-ADVEFFECT
tonic	I-ADVEFFECT
-	I-ADVEFFECT
clonic	I-ADVEFFECT
seizure	I-ADVEFFECT
occurred	O
a	O
few	O
minutes	O
after	O
injection	O
of	O
the	O
morphine	B-DRUG
antagonist	O
naloxone	B-DRUG
.	O
Nonconvulsive	B-ADVEFFECT
status	I-ADVEFFECT
epilepticus	I-ADVEFFECT
:	O
the	O
role	O
of	O
morphine	B-DRUG
and	O
its	O
antagonist	O
.	O
Spontaneous	O
bacterial	B-ADVEFFECT
peritonitis	I-ADVEFFECT
induced	O
by	O
intraarterial	O
vasopressin	B-DRUG
therapy	O
.	O
Although	O
the	O
literature	O
on	O
the	O
use	O
of	O
risperidone	B-DRUG
in	O
elderly	O
patients	O
with	O
dementia	O
consists	O
largely	O
of	O
uncontrolled	O
trials	O
,	O
case	O
reports	O
,	O
and	O
chart	O
reviews	O
,	O
it	O
appears	O
that	O
this	O
agent	O
is	O
effective	O
for	O
managing	O
agitation	O
in	O
this	O
population	O
and	O
does	O
so	O
with	O
a	O
low	O
frequency	O
of	O
extrapyramidal	B-ADVEFFECT
symptoms	I-ADVEFFECT
(	O
EPS	B-ADVEFFECT
)	O
.	O
Although	O
the	O
literature	O
on	O
the	O
use	O
of	O
risperidone	B-DRUG
in	O
elderly	O
patients	O
with	O
dementia	O
consists	O
largely	O
of	O
uncontrolled	O
trials	O
,	O
case	O
reports	O
,	O
and	O
chart	O
reviews	O
,	O
it	O
appears	O
that	O
this	O
agent	O
is	O
effective	O
for	O
managing	O
agitation	O
in	O
this	O
population	O
and	O
does	O
so	O
with	O
a	O
low	O
frequency	O
of	O
extrapyramidal	B-ADVEFFECT
symptoms	I-ADVEFFECT
(	O
EPS	B-ADVEFFECT
)	O
.	O
Three	O
months	O
following	O
splenectomy	O
,	O
multiple	B-ADVEFFECT
abscesses	I-ADVEFFECT
occurred	O
in	O
the	O
muscles	O
of	O
both	O
thighs	O
while	O
the	O
patient	O
was	O
receiving	O
the	O
third	O
course	O
of	O
the	O
CHOP	B-DRUG
regimen	O
.	O
After	O
seven	O
months	O
'	O
continuous	O
treatment	O
for	O
suspected	O
tuberculosis	O
with	O
rifampicin	B-DRUG
and	O
ethambutol	B-DRUG
a	O
nine	O
-	O
year	O
-	O
old	O
boy	O
developed	O
polyarthritis	B-ADVEFFECT
,	O
rash	B-ADVEFFECT
and	O
hepatitis	B-ADVEFFECT
in	O
association	O
with	O
anti	B-ADVEFFECT
-	I-ADVEFFECT
native	I-ADVEFFECT
DNA	I-ADVEFFECT
antibodies	I-ADVEFFECT
and	O
positive	O
antinuclear	O
factor	O
.	O
After	O
seven	O
months	O
'	O
continuous	O
treatment	O
for	O
suspected	O
tuberculosis	O
with	O
rifampicin	B-DRUG
and	O
ethambutol	B-DRUG
a	O
nine	O
-	O
year	O
-	O
old	O
boy	O
developed	O
polyarthritis	B-ADVEFFECT
,	O
rash	B-ADVEFFECT
and	O
hepatitis	B-ADVEFFECT
in	O
association	O
with	O
anti	B-ADVEFFECT
-	I-ADVEFFECT
native	I-ADVEFFECT
DNA	I-ADVEFFECT
antibodies	I-ADVEFFECT
and	O
positive	O
antinuclear	O
factor	O
.	O
After	O
seven	O
months	O
'	O
continuous	O
treatment	O
for	O
suspected	O
tuberculosis	O
with	O
rifampicin	B-DRUG
and	O
ethambutol	B-DRUG
a	O
nine	O
-	O
year	O
-	O
old	O
boy	O
developed	O
polyarthritis	B-ADVEFFECT
,	O
rash	B-ADVEFFECT
and	O
hepatitis	B-ADVEFFECT
in	O
association	O
with	O
anti	B-ADVEFFECT
-	I-ADVEFFECT
native	I-ADVEFFECT
DNA	I-ADVEFFECT
antibodies	I-ADVEFFECT
and	O
positive	O
antinuclear	O
factor	O
.	O
After	O
seven	O
months	O
'	O
continuous	O
treatment	O
for	O
suspected	O
tuberculosis	O
with	O
rifampicin	B-DRUG
and	O
ethambutol	B-DRUG
a	O
nine	O
-	O
year	O
-	O
old	O
boy	O
developed	O
polyarthritis	B-ADVEFFECT
,	O
rash	B-ADVEFFECT
and	O
hepatitis	B-ADVEFFECT
in	O
association	O
with	O
anti	B-ADVEFFECT
-	I-ADVEFFECT
native	I-ADVEFFECT
DNA	I-ADVEFFECT
antibodies	I-ADVEFFECT
and	O
positive	O
antinuclear	O
factor	O
.	O
Polyarthritis	B-ADVEFFECT
,	O
hepatitis	B-ADVEFFECT
and	O
anti	B-ADVEFFECT
-	I-ADVEFFECT
native	I-ADVEFFECT
DNA	I-ADVEFFECT
antibodies	I-ADVEFFECT
after	O
treatment	O
with	O
ethambutol	B-DRUG
and	O
rifampicin	B-DRUG
.	O
Polyarthritis	B-ADVEFFECT
,	O
hepatitis	B-ADVEFFECT
and	O
anti	B-ADVEFFECT
-	I-ADVEFFECT
native	I-ADVEFFECT
DNA	I-ADVEFFECT
antibodies	I-ADVEFFECT
after	O
treatment	O
with	O
ethambutol	B-DRUG
and	O
rifampicin	B-DRUG
.	O
Polyarthritis	B-ADVEFFECT
,	O
hepatitis	B-ADVEFFECT
and	O
anti	B-ADVEFFECT
-	I-ADVEFFECT
native	I-ADVEFFECT
DNA	I-ADVEFFECT
antibodies	I-ADVEFFECT
after	O
treatment	O
with	O
ethambutol	B-DRUG
and	O
rifampicin	B-DRUG
.	O
Polyarthritis	B-ADVEFFECT
,	O
hepatitis	B-ADVEFFECT
and	O
anti	B-ADVEFFECT
-	I-ADVEFFECT
native	I-ADVEFFECT
DNA	I-ADVEFFECT
antibodies	I-ADVEFFECT
after	O
treatment	O
with	O
ethambutol	B-DRUG
and	O
rifampicin	B-DRUG
.	O
Polyarthritis	B-ADVEFFECT
,	O
hepatitis	B-ADVEFFECT
and	O
anti	B-ADVEFFECT
-	I-ADVEFFECT
native	I-ADVEFFECT
DNA	I-ADVEFFECT
antibodies	I-ADVEFFECT
after	O
treatment	O
with	O
ethambutol	B-DRUG
and	O
rifampicin	B-DRUG
.	O
Polyarthritis	B-ADVEFFECT
,	O
hepatitis	B-ADVEFFECT
and	O
anti	B-ADVEFFECT
-	I-ADVEFFECT
native	I-ADVEFFECT
DNA	I-ADVEFFECT
antibodies	I-ADVEFFECT
after	O
treatment	O
with	O
ethambutol	B-DRUG
and	O
rifampicin	B-DRUG
.	O
A	O
case	O
of	O
normotensive	B-ADVEFFECT
scleroderma	I-ADVEFFECT
renal	I-ADVEFFECT
crisis	I-ADVEFFECT
after	O
high	O
-	O
dose	O
methylprednisolone	B-DRUG
treatment	O
.	O
HUS	B-ADVEFFECT
has	O
been	O
reported	O
after	O
several	O
anticancer	O
chemotherapies	O
and	O
most	O
often	O
after	O
mitomycin	B-DRUG
C	I-DRUG
-	O
based	O
chemotherapy	O
regimens	O
.	O
Severe	B-ADVEFFECT
hemolytic	I-ADVEFFECT
uremic	I-ADVEFFECT
syndrome	I-ADVEFFECT
in	O
an	O
advanced	O
ovarian	O
cancer	O
patient	O
treated	O
with	O
carboplatin	B-DRUG
and	O
gemcitabine	B-DRUG
.	O
Severe	B-ADVEFFECT
hemolytic	I-ADVEFFECT
uremic	I-ADVEFFECT
syndrome	I-ADVEFFECT
in	O
an	O
advanced	O
ovarian	O
cancer	O
patient	O
treated	O
with	O
carboplatin	B-DRUG
and	O
gemcitabine	B-DRUG
.	O
We	O
present	O
a	O
case	O
of	O
HUS	B-ADVEFFECT
in	O
an	O
advanced	O
ovarian	O
cancer	O
patient	O
treated	O
with	O
carboplatin	B-DRUG
and	O
gemcitabine	B-DRUG
,	O
and	O
described	O
its	O
favorable	O
outcome	O
after	O
chemotherapy	O
interruption	O
and	O
supportive	O
care	O
with	O
a	O
1	O
year	O
follow	O
-	O
up	O
.	O
We	O
present	O
a	O
case	O
of	O
HUS	B-ADVEFFECT
in	O
an	O
advanced	O
ovarian	O
cancer	O
patient	O
treated	O
with	O
carboplatin	B-DRUG
and	O
gemcitabine	B-DRUG
,	O
and	O
described	O
its	O
favorable	O
outcome	O
after	O
chemotherapy	O
interruption	O
and	O
supportive	O
care	O
with	O
a	O
1	O
year	O
follow	O
-	O
up	O
.	O
An	O
evaluation	O
of	O
ovarian	O
structure	O
and	O
function	O
should	O
be	O
considered	O
in	O
women	O
of	O
reproductive	O
age	O
being	O
treated	O
with	O
valproate	B-DRUG
for	O
epilepsy	O
,	O
especially	O
if	O
they	O
develop	O
menstrual	B-ADVEFFECT
cycle	I-ADVEFFECT
disturbances	I-ADVEFFECT
during	O
treatment	O
.	O
BACKGROUND	O
:	O
Reproductive	B-ADVEFFECT
endocrine	I-ADVEFFECT
disorders	I-ADVEFFECT
characterized	O
by	O
menstrual	B-ADVEFFECT
disorders	I-ADVEFFECT
,	O
polycystic	B-ADVEFFECT
ovaries	I-ADVEFFECT
,	O
and	O
hyperandrogenism	B-ADVEFFECT
seem	O
to	O
be	O
common	O
among	O
women	O
treated	O
with	O
sodium	B-DRUG
valproate	I-DRUG
for	O
epilepsy	O
.	O
BACKGROUND	O
:	O
Reproductive	B-ADVEFFECT
endocrine	I-ADVEFFECT
disorders	I-ADVEFFECT
characterized	O
by	O
menstrual	B-ADVEFFECT
disorders	I-ADVEFFECT
,	O
polycystic	B-ADVEFFECT
ovaries	I-ADVEFFECT
,	O
and	O
hyperandrogenism	B-ADVEFFECT
seem	O
to	O
be	O
common	O
among	O
women	O
treated	O
with	O
sodium	B-DRUG
valproate	I-DRUG
for	O
epilepsy	O
.	O
BACKGROUND	O
:	O
Reproductive	B-ADVEFFECT
endocrine	I-ADVEFFECT
disorders	I-ADVEFFECT
characterized	O
by	O
menstrual	B-ADVEFFECT
disorders	I-ADVEFFECT
,	O
polycystic	B-ADVEFFECT
ovaries	I-ADVEFFECT
,	O
and	O
hyperandrogenism	B-ADVEFFECT
seem	O
to	O
be	O
common	O
among	O
women	O
treated	O
with	O
sodium	B-DRUG
valproate	I-DRUG
for	O
epilepsy	O
.	O
BACKGROUND	O
:	O
Reproductive	B-ADVEFFECT
endocrine	I-ADVEFFECT
disorders	I-ADVEFFECT
characterized	O
by	O
menstrual	B-ADVEFFECT
disorders	I-ADVEFFECT
,	O
polycystic	B-ADVEFFECT
ovaries	I-ADVEFFECT
,	O
and	O
hyperandrogenism	B-ADVEFFECT
seem	O
to	O
be	O
common	O
among	O
women	O
treated	O
with	O
sodium	B-DRUG
valproate	I-DRUG
for	O
epilepsy	O
.	O
CONCLUSIONS	O
:	O
The	O
3	O
cases	O
presented	O
here	O
illustrate	O
the	O
development	O
of	O
reproductive	B-ADVEFFECT
endocrine	I-ADVEFFECT
disorders	I-ADVEFFECT
after	O
the	O
initiation	O
of	O
valproate	B-DRUG
therapy	O
in	O
women	O
with	O
epilepsy	O
.	O
OBJECTIVE	O
:	O
To	O
describe	O
the	O
development	O
of	O
valproate	B-DRUG
-	O
related	O
reproductive	B-ADVEFFECT
endocrine	I-ADVEFFECT
disorders	I-ADVEFFECT
in	O
women	O
with	O
epilepsy	O
.	O
PATIENTS	O
:	O
Three	O
patients	O
developed	O
a	O
reproductive	B-ADVEFFECT
endocrine	I-ADVEFFECT
disorder	I-ADVEFFECT
during	O
treatment	O
with	O
valproate	B-DRUG
.	O
RESULTS	O
:	O
Replacing	O
valproate	B-DRUG
with	O
lamotrigine	O
resulted	O
in	O
a	O
decrease	O
in	O
serum	B-ADVEFFECT
testosterone	B-ADVEFFECT
concentrations	O
in	O
all	O
3	O
women	O
.	O
The	O
polycystic	B-ADVEFFECT
changes	I-ADVEFFECT
disappeared	O
from	O
the	O
ovaries	O
in	O
2	O
of	O
the	O
women	O
after	O
valproate	B-DRUG
therapy	O
was	O
discontinued	O
,	O
and	O
the	O
2	O
women	O
who	O
had	O
gained	B-ADVEFFECT
weight	I-ADVEFFECT
and	O
developed	O
amenorrhea	B-ADVEFFECT
while	O
being	O
treated	O
with	O
valproate	B-DRUG
lost	O
weight	O
and	O
resumed	O
menstruating	O
after	O
the	O
change	O
in	O
medication	O
.	O
The	O
polycystic	B-ADVEFFECT
changes	I-ADVEFFECT
disappeared	O
from	O
the	O
ovaries	O
in	O
2	O
of	O
the	O
women	O
after	O
valproate	B-DRUG
therapy	O
was	O
discontinued	O
,	O
and	O
the	O
2	O
women	O
who	O
had	O
gained	B-ADVEFFECT
weight	I-ADVEFFECT
and	O
developed	O
amenorrhea	B-ADVEFFECT
while	O
being	O
treated	O
with	O
valproate	B-DRUG
lost	O
weight	O
and	O
resumed	O
menstruating	O
after	O
the	O
change	O
in	O
medication	O
.	O
The	O
polycystic	B-ADVEFFECT
changes	I-ADVEFFECT
disappeared	O
from	O
the	O
ovaries	O
in	O
2	O
of	O
the	O
women	O
after	O
valproate	B-DRUG
therapy	O
was	O
discontinued	O
,	O
and	O
the	O
2	O
women	O
who	O
had	O
gained	B-ADVEFFECT
weight	I-ADVEFFECT
and	O
developed	O
amenorrhea	B-ADVEFFECT
while	O
being	O
treated	O
with	O
valproate	B-DRUG
lost	O
weight	O
and	O
resumed	O
menstruating	O
after	O
the	O
change	O
in	O
medication	O
.	O
However	O
,	O
recurrent	O
staphylococcus	B-ADVEFFECT
aureus	I-ADVEFFECT
sepsis	I-ADVEFFECT
developed	O
during	O
CyA	B-DRUG
therapy	O
.	O
Recurrent	O
septicemia	B-ADVEFFECT
with	O
lethal	B-ADVEFFECT
outcome	O
during	O
and	O
after	O
cyclosporine	B-DRUG
therapy	O
in	O
severe	O
ulcerative	O
colitis	O
.	O
Recurrent	O
septicemia	B-ADVEFFECT
with	O
lethal	B-ADVEFFECT
outcome	O
during	O
and	O
after	O
cyclosporine	B-DRUG
therapy	O
in	O
severe	O
ulcerative	O
colitis	O
.	O
A	O
60	O
year	O
-	O
old	O
woman	O
with	O
chronic	O
renal	O
failure	O
developed	O
acute	O
proximal	B-ADVEFFECT
muscle	I-ADVEFFECT
weakness	I-ADVEFFECT
after	O
receiving	O
a	O
regular	O
dosage	O
of	O
colchicine	B-DRUG
.	O
Colchicine	B-DRUG
-	O
induced	O
myopathy	B-ADVEFFECT
in	O
renal	O
failure	O
.	O
Muscle	O
biopsy	O
revealed	O
variation	B-ADVEFFECT
in	I-ADVEFFECT
muscle	I-ADVEFFECT
fiber	I-ADVEFFECT
size	I-ADVEFFECT
and	O
few	O
vacuolated	B-ADVEFFECT
fibers	I-ADVEFFECT
which	O
were	O
features	O
of	O
colchicine	B-DRUG
-	O
induced	O
myopathy	B-ADVEFFECT
.	O
Muscle	O
biopsy	O
revealed	O
variation	B-ADVEFFECT
in	I-ADVEFFECT
muscle	I-ADVEFFECT
fiber	I-ADVEFFECT
size	I-ADVEFFECT
and	O
few	O
vacuolated	B-ADVEFFECT
fibers	I-ADVEFFECT
which	O
were	O
features	O
of	O
colchicine	B-DRUG
-	O
induced	O
myopathy	B-ADVEFFECT
.	O
Muscle	O
biopsy	O
revealed	O
variation	B-ADVEFFECT
in	I-ADVEFFECT
muscle	I-ADVEFFECT
fiber	I-ADVEFFECT
size	I-ADVEFFECT
and	O
few	O
vacuolated	B-ADVEFFECT
fibers	I-ADVEFFECT
which	O
were	O
features	O
of	O
colchicine	B-DRUG
-	O
induced	O
myopathy	B-ADVEFFECT
.	O
A	O
third	O
patient	O
experienced	O
disabling	B-ADVEFFECT
neurotoxicity	I-ADVEFFECT
in	O
the	O
extremity	O
of	O
a	O
prior	O
ulnar	O
nerve	O
and	O
tendon	O
transposition	O
after	O
receiving	O
paclitaxel	B-DRUG
.	O
Phantom	B-ADVEFFECT
limb	I-ADVEFFECT
pain	I-ADVEFFECT
as	O
a	O
manifestation	O
of	O
paclitaxel	B-DRUG
neurotoxicity	B-ADVEFFECT
.	O
Phantom	B-ADVEFFECT
limb	I-ADVEFFECT
pain	I-ADVEFFECT
as	O
a	O
manifestation	O
of	O
paclitaxel	B-DRUG
neurotoxicity	B-ADVEFFECT
.	O
Physicians	O
should	O
be	O
aware	O
that	O
PLP	B-ADVEFFECT
can	O
occur	O
after	O
initiation	O
of	O
paclitaxel	B-DRUG
.	O
We	O
describe	O
2	O
patients	O
with	O
prior	O
amputation	O
who	O
experienced	O
phantom	B-ADVEFFECT
limb	I-ADVEFFECT
pain	I-ADVEFFECT
(	O
PLP	B-ADVEFFECT
)	O
after	O
receiving	O
paclitaxel	B-DRUG
therapy	O
.	O
We	O
describe	O
2	O
patients	O
with	O
prior	O
amputation	O
who	O
experienced	O
phantom	B-ADVEFFECT
limb	I-ADVEFFECT
pain	I-ADVEFFECT
(	O
PLP	B-ADVEFFECT
)	O
after	O
receiving	O
paclitaxel	B-DRUG
therapy	O
.	O
Skin	B-ADVEFFECT
manifestations	I-ADVEFFECT
of	O
a	O
case	O
of	O
phenylbutazone	B-DRUG
-	O
induced	O
serum	O
sickness	B-ADVEFFECT
-	I-ADVEFFECT
like	I-ADVEFFECT
reactions	I-ADVEFFECT
.	O
Skin	B-ADVEFFECT
manifestations	I-ADVEFFECT
of	O
a	O
case	O
of	O
phenylbutazone	B-DRUG
-	O
induced	O
serum	O
sickness	B-ADVEFFECT
-	I-ADVEFFECT
like	I-ADVEFFECT
reactions	I-ADVEFFECT
.	O
Our	O
experience	O
supports	O
hemodialysis	O
for	O
ESRF	O
patients	O
with	O
atenolol	B-ADVEFFECT
toxicity	I-ADVEFFECT
.	O
Allergic	O
reaction	O
to	O
gemfibrozil	B-DRUG
manifesting	O
as	O
eosinophilic	B-ADVEFFECT
gastroenteritis	I-ADVEFFECT
.	O
We	O
describe	O
a	O
case	O
of	O
EGE	B-ADVEFFECT
manifested	O
as	O
an	O
allergy	O
to	O
gemfibrozil	B-DRUG
.	O
This	O
is	O
the	O
second	O
report	O
of	O
lactic	B-ADVEFFECT
acidosis	I-ADVEFFECT
in	O
a	O
patient	O
on	O
stavudine	B-DRUG
and	O
lamivudine	B-DRUG
.	O
This	O
is	O
the	O
second	O
report	O
of	O
lactic	B-ADVEFFECT
acidosis	I-ADVEFFECT
in	O
a	O
patient	O
on	O
stavudine	B-DRUG
and	O
lamivudine	B-DRUG
.	O
We	O
present	O
an	O
AIDS	O
patient	O
with	O
severe	O
and	O
prolonged	O
lactic	B-ADVEFFECT
acidosis	I-ADVEFFECT
on	O
stavudine	B-DRUG
and	O
lamivudine	B-DRUG
.	O
We	O
present	O
an	O
AIDS	O
patient	O
with	O
severe	O
and	O
prolonged	O
lactic	B-ADVEFFECT
acidosis	I-ADVEFFECT
on	O
stavudine	B-DRUG
and	O
lamivudine	B-DRUG
.	O
Ataxia	B-ADVEFFECT
caused	O
by	O
propafenone	B-DRUG
has	O
been	O
reported	O
to	O
the	O
pharmaceutical	O
companies	O
and	O
drug	O
monitoring	O
agencies	O
,	O
but	O
has	O
not	O
been	O
well	O
described	O
or	O
emphasized	O
in	O
the	O
medical	O
literature	O
.	O
A	O
wide	O
variety	O
of	O
adverse	B-ADVEFFECT
central	I-ADVEFFECT
nervous	I-ADVEFFECT
system	I-ADVEFFECT
effects	I-ADVEFFECT
have	O
been	O
reported	O
in	O
association	O
with	O
propafenone	B-DRUG
;	O
dizziness	B-ADVEFFECT
is	O
the	O
most	O
common	O
.	O
A	O
wide	O
variety	O
of	O
adverse	B-ADVEFFECT
central	I-ADVEFFECT
nervous	I-ADVEFFECT
system	I-ADVEFFECT
effects	I-ADVEFFECT
have	O
been	O
reported	O
in	O
association	O
with	O
propafenone	B-DRUG
;	O
dizziness	B-ADVEFFECT
is	O
the	O
most	O
common	O
.	O
Propafenone	B-DRUG
-	O
induced	O
ataxia	B-ADVEFFECT
:	O
report	O
of	O
three	O
cases	O
.	O
We	O
describe	O
3	O
elderly	O
patients	O
with	O
moderate	O
to	O
severe	O
ataxia	B-ADVEFFECT
that	O
occurred	O
while	O
they	O
were	O
taking	O
propafenone	B-DRUG
.	O
A	O
74-year	O
-	O
old	O
man	O
received	O
oral	O
administration	O
of	O
pilsicainide	B-DRUG
,	O
a	O
pure	O
sodium	O
channel	O
blocker	O
with	O
slow	O
recovery	O
kinetics	O
,	O
to	O
convert	O
paroxysmal	O
atrial	O
fibrillation	O
to	O
sinus	O
rhythm	O
and	O
developed	O
loss	B-ADVEFFECT
of	I-ADVEFFECT
consciousness	I-ADVEFFECT
two	O
days	O
later	O
.	O
When	O
pilsicainide	B-DRUG
is	O
prescribed	O
in	O
patients	O
with	O
coronary	O
artery	O
disease	O
or	O
renal	O
dysfunction	O
,	O
close	O
attention	O
must	O
be	O
paid	O
to	O
avoid	O
life	B-ADVEFFECT
-	I-ADVEFFECT
threatening	I-ADVEFFECT
arrhythmias	I-ADVEFFECT
due	O
to	O
high	O
plasma	O
concentrations	O
of	O
the	O
drug	O
.	O
The	O
cases	O
are	O
important	O
in	O
documenting	O
that	O
drug	O
-	O
induced	O
dystonias	B-ADVEFFECT
do	O
occur	O
in	O
patients	O
with	O
dementia	O
,	O
that	O
risperidone	B-DRUG
appears	O
to	O
have	O
contributed	O
to	O
dystonia	O
among	O
elderly	O
patients	O
,	O
and	O
that	O
the	O
categorization	O
of	O
dystonic	O
reactions	O
needs	O
further	O
clarification	O
.	O
Provocation	O
of	O
non	B-ADVEFFECT
-	I-ADVEFFECT
convulsive	I-ADVEFFECT
status	I-ADVEFFECT
epilepticus	I-ADVEFFECT
by	O
tiagabine	B-DRUG
in	O
three	O
adolescent	O
patients	O
.	O
The	O
events	O
of	O
non	B-ADVEFFECT
-	I-ADVEFFECT
convulsive	I-ADVEFFECT
status	I-ADVEFFECT
epilepticus	I-ADVEFFECT
subsided	O
following	O
reduction	O
in	O
tiagabine	B-DRUG
dosages	O
.	O
This	O
is	O
the	O
first	O
report	O
of	O
non	B-ADVEFFECT
-	I-ADVEFFECT
convulsive	I-ADVEFFECT
status	I-ADVEFFECT
epilepticus	I-ADVEFFECT
provoked	O
by	O
tiagabine	B-DRUG
in	O
adolescent	O
patients	O
.	O
There	O
have	O
been	O
many	O
reports	O
of	O
probable	O
lithium	B-DRUG
-	O
induced	O
organic	B-ADVEFFECT
brain	I-ADVEFFECT
syndromes	I-ADVEFFECT
occurring	O
when	O
serum	O
lithium	O
levels	O
are	O
within	O
or	O
close	O
to	O
the	O
therapeutic	O
range	O
.	O
When	O
the	O
acute	O
manic	O
state	O
is	O
characterized	O
by	O
marked	O
psychotic	B-ADVEFFECT
symptoms	I-ADVEFFECT
and	O
intense	B-ADVEFFECT
anxiety	I-ADVEFFECT
,	O
it	O
may	O
be	O
associated	O
with	O
increased	O
vulnerability	O
to	O
the	O
development	O
of	O
severe	O
lithium	B-DRUG
neurotoxicity	B-ADVEFFECT
.	O
When	O
the	O
acute	O
manic	O
state	O
is	O
characterized	O
by	O
marked	O
psychotic	B-ADVEFFECT
symptoms	I-ADVEFFECT
and	O
intense	B-ADVEFFECT
anxiety	I-ADVEFFECT
,	O
it	O
may	O
be	O
associated	O
with	O
increased	O
vulnerability	O
to	O
the	O
development	O
of	O
severe	O
lithium	B-DRUG
neurotoxicity	B-ADVEFFECT
.	O
When	O
the	O
acute	O
manic	O
state	O
is	O
characterized	O
by	O
marked	O
psychotic	B-ADVEFFECT
symptoms	I-ADVEFFECT
and	O
intense	B-ADVEFFECT
anxiety	I-ADVEFFECT
,	O
it	O
may	O
be	O
associated	O
with	O
increased	O
vulnerability	O
to	O
the	O
development	O
of	O
severe	O
lithium	B-DRUG
neurotoxicity	B-ADVEFFECT
.	O
Protease	O
inhibitor	O
-	O
induced	O
carbamazepine	B-ADVEFFECT
toxicity	I-ADVEFFECT
.	O
Protease	O
inhibitors	O
(	O
ritonavir	B-DRUG
and	O
saquinavir	B-DRUG
)	O
were	O
added	O
to	O
the	O
treatment	O
and	O
the	O
patient	O
developed	O
progressive	O
ataxia	O
related	O
to	O
carbamazepine	B-ADVEFFECT
toxicity	I-ADVEFFECT
.	O
Protease	O
inhibitors	O
(	O
ritonavir	B-DRUG
and	O
saquinavir	B-DRUG
)	O
were	O
added	O
to	O
the	O
treatment	O
and	O
the	O
patient	O
developed	O
progressive	O
ataxia	O
related	O
to	O
carbamazepine	B-ADVEFFECT
toxicity	I-ADVEFFECT
.	O
Protease	O
inhibitors	O
(	O
ritonavir	B-DRUG
and	O
saquinavir	B-DRUG
)	O
were	O
added	O
to	O
the	O
treatment	O
and	O
the	O
patient	O
developed	O
progressive	O
ataxia	O
related	O
to	O
carbamazepine	B-ADVEFFECT
toxicity	I-ADVEFFECT
.	O
Protease	O
inhibitors	O
(	O
ritonavir	B-DRUG
and	O
saquinavir	B-DRUG
)	O
were	O
added	O
to	O
the	O
treatment	O
and	O
the	O
patient	O
developed	O
progressive	B-ADVEFFECT
ataxia	I-ADVEFFECT
related	O
to	O
carbamazepine	B-DRUG
toxicity	O
.	O
Protease	O
inhibitors	O
(	O
ritonavir	B-DRUG
and	O
saquinavir	B-DRUG
)	O
were	O
added	O
to	O
the	O
treatment	O
and	O
the	O
patient	O
developed	O
progressive	B-ADVEFFECT
ataxia	I-ADVEFFECT
related	O
to	O
carbamazepine	B-ADVEFFECT
toxicity	I-ADVEFFECT
.	O
Protease	O
inhibitors	O
(	O
ritonavir	B-DRUG
and	O
saquinavir	B-DRUG
)	O
were	O
added	O
to	O
the	O
treatment	O
and	O
the	O
patient	O
developed	O
progressive	B-ADVEFFECT
ataxia	I-ADVEFFECT
related	O
to	O
carbamazepine	B-ADVEFFECT
toxicity	I-ADVEFFECT
.	O
Ritonavir	B-DRUG
acted	O
as	O
a	O
CYP3A4	O
inhibitor	O
,	O
diminishing	B-ADVEFFECT
carbamazepine	I-ADVEFFECT
metabolism	I-ADVEFFECT
and	O
provoking	O
an	O
increase	B-ADVEFFECT
in	I-ADVEFFECT
serum	I-ADVEFFECT
levels	I-ADVEFFECT
and	O
clinical	B-ADVEFFECT
toxicity	I-ADVEFFECT
.	O
Ritonavir	B-DRUG
acted	O
as	O
a	O
CYP3A4	O
inhibitor	O
,	O
diminishing	B-ADVEFFECT
carbamazepine	I-ADVEFFECT
metabolism	I-ADVEFFECT
and	O
provoking	O
an	O
increase	B-ADVEFFECT
in	I-ADVEFFECT
serum	I-ADVEFFECT
levels	I-ADVEFFECT
and	O
clinical	B-ADVEFFECT
toxicity	I-ADVEFFECT
.	O
Ritonavir	B-DRUG
acted	O
as	O
a	O
CYP3A4	O
inhibitor	O
,	O
diminishing	B-ADVEFFECT
carbamazepine	I-ADVEFFECT
metabolism	I-ADVEFFECT
and	O
provoking	O
an	O
increase	B-ADVEFFECT
in	I-ADVEFFECT
serum	I-ADVEFFECT
levels	I-ADVEFFECT
and	O
clinical	B-ADVEFFECT
toxicity	I-ADVEFFECT
.	O
The	O
patient	O
was	O
diagnosed	O
with	O
carbamazepine	B-ADVEFFECT
toxicity	I-ADVEFFECT
related	O
to	O
the	O
introduction	O
of	O
ritonavir	B-DRUG
.	O
The	O
patient	O
was	O
diagnosed	O
with	O
carbamazepine	B-ADVEFFECT
toxicity	I-ADVEFFECT
related	O
to	O
the	O
introduction	O
of	O
ritonavir	B-DRUG
.	O
Anaphylaxis	B-ADVEFFECT
to	O
calcitonin	B-DRUG
.	O
CONCLUSION	O
:	O
We	O
have	O
introduced	O
a	O
case	O
of	O
anaphylaxis	B-ADVEFFECT
by	O
calcitonin	B-DRUG
that	O
suggest	O
an	O
IgE	O
mediated	O
hypersensitivity	O
reaction	O
.	O
The	O
intramuscular	O
challenge	O
test	O
with	O
25	O
UI	O
of	O
Miacalcic	B-DRUG
was	O
positive	O
with	O
an	O
immediate	O
anaphylactic	B-ADVEFFECT
reaction	I-ADVEFFECT
.	O
We	O
introduce	O
a	O
case	O
of	O
a	O
sixty	O
years	O
old	O
woman	O
with	O
several	O
previous	O
episodes	O
of	O
rhinitis	B-ADVEFFECT
,	O
conjunctivitis	B-ADVEFFECT
and	O
perspiration	B-ADVEFFECT
immediately	O
after	O
the	O
administration	O
of	O
salmon	O
calcitonin	B-DRUG
with	O
nasal	O
spray	O
or	O
intramuscular	O
administration	O
(	O
Calsynar	B-DRUG
)	O
.	O
We	O
introduce	O
a	O
case	O
of	O
a	O
sixty	O
years	O
old	O
woman	O
with	O
several	O
previous	O
episodes	O
of	O
rhinitis	B-ADVEFFECT
,	O
conjunctivitis	B-ADVEFFECT
and	O
perspiration	B-ADVEFFECT
immediately	O
after	O
the	O
administration	O
of	O
salmon	O
calcitonin	B-DRUG
with	O
nasal	O
spray	O
or	O
intramuscular	O
administration	O
(	O
Calsynar	B-DRUG
)	O
.	O
We	O
introduce	O
a	O
case	O
of	O
a	O
sixty	O
years	O
old	O
woman	O
with	O
several	O
previous	O
episodes	O
of	O
rhinitis	B-ADVEFFECT
,	O
conjunctivitis	B-ADVEFFECT
and	O
perspiration	B-ADVEFFECT
immediately	O
after	O
the	O
administration	O
of	O
salmon	O
calcitonin	B-DRUG
with	O
nasal	O
spray	O
or	O
intramuscular	O
administration	O
(	O
Calsynar	B-DRUG
)	O
.	O
We	O
introduce	O
a	O
case	O
of	O
a	O
sixty	O
years	O
old	O
woman	O
with	O
several	O
previous	O
episodes	O
of	O
rhinitis	B-ADVEFFECT
,	O
conjunctivitis	B-ADVEFFECT
and	O
perspiration	B-ADVEFFECT
immediately	O
after	O
the	O
administration	O
of	O
salmon	O
calcitonin	B-DRUG
with	O
nasal	O
spray	O
or	O
intramuscular	O
administration	O
(	O
Calsynar	B-DRUG
)	O
.	O
We	O
introduce	O
a	O
case	O
of	O
a	O
sixty	O
years	O
old	O
woman	O
with	O
several	O
previous	O
episodes	O
of	O
rhinitis	B-ADVEFFECT
,	O
conjunctivitis	B-ADVEFFECT
and	O
perspiration	B-ADVEFFECT
immediately	O
after	O
the	O
administration	O
of	O
salmon	O
calcitonin	B-DRUG
with	O
nasal	O
spray	O
or	O
intramuscular	O
administration	O
(	O
Calsynar	B-DRUG
)	O
.	O
We	O
introduce	O
a	O
case	O
of	O
a	O
sixty	O
years	O
old	O
woman	O
with	O
several	O
previous	O
episodes	O
of	O
rhinitis	B-ADVEFFECT
,	O
conjunctivitis	B-ADVEFFECT
and	O
perspiration	B-ADVEFFECT
immediately	O
after	O
the	O
administration	O
of	O
salmon	O
calcitonin	B-DRUG
with	O
nasal	O
spray	O
or	O
intramuscular	O
administration	O
(	O
Calsynar	B-DRUG
)	O
.	O
Minocycline	B-DRUG
as	O
a	O
cause	O
of	O
drug	O
-	O
induced	O
autoimmune	B-ADVEFFECT
hepatitis	I-ADVEFFECT
.	O
Minocycline	B-DRUG
-	O
induced	O
autoimmune	B-ADVEFFECT
hepatitis	I-ADVEFFECT
is	O
usually	O
identical	O
to	O
sporadic	O
autoimmune	O
hepatitis	O
.	O
We	O
describe	O
the	O
clinical	O
and	O
liver	O
biopsy	O
morphologic	O
features	O
for	O
4	O
patients	O
with	O
minocycline	B-DRUG
-	O
induced	O
autoimmune	B-ADVEFFECT
hepatitis	I-ADVEFFECT
(	O
group	O
1	O
)	O
.	O
L	B-DRUG
-	I-DRUG
asparaginase	I-DRUG
-	O
provoked	O
seizures	B-ADVEFFECT
as	O
singular	O
expression	O
of	O
central	B-ADVEFFECT
nervous	I-ADVEFFECT
toxicity	I-ADVEFFECT
.	O
L	B-DRUG
-	I-DRUG
asparaginase	I-DRUG
-	O
provoked	O
seizures	B-ADVEFFECT
as	O
singular	O
expression	O
of	O
central	B-ADVEFFECT
nervous	I-ADVEFFECT
toxicity	I-ADVEFFECT
.	O
Patients	O
treated	O
with	O
L	B-DRUG
-	I-DRUG
asparaginase	I-DRUG
may	O
present	O
with	O
hemorrhagic	B-ADVEFFECT
and	O
thrombotic	B-ADVEFFECT
cerebrovascular	I-ADVEFFECT
events	I-ADVEFFECT
.	O
Patients	O
treated	O
with	O
L	B-DRUG
-	I-DRUG
asparaginase	I-DRUG
may	O
present	O
with	O
hemorrhagic	B-ADVEFFECT
and	O
thrombotic	B-ADVEFFECT
cerebrovascular	I-ADVEFFECT
events	I-ADVEFFECT
.	O
We	O
report	O
a	O
case	O
of	O
seizure	B-ADVEFFECT
associated	O
with	O
L	B-DRUG
-	I-DRUG
asparaginase	I-DRUG
therapy	O
but	O
no	O
evidence	O
of	O
hemorrhagic	B-ADVEFFECT
or	O
thrombotic	B-ADVEFFECT
cerebrovascular	I-ADVEFFECT
events	I-ADVEFFECT
.	O
Eighty	O
-	O
two	O
patients	O
with	O
various	O
malignancies	O
who	O
received	O
imipenem	B-DRUG
/	O
cilastatin	B-DRUG
143	O
times	O
for	O
neutropenic	B-ADVEFFECT
fever	I-ADVEFFECT
between	O
March	O
1994	O
and	O
October	O
1999	O
in	O
Department	O
of	O
Pediatric	O
Oncology	O
,	O
Gazi	O
University	O
,	O
were	O
identified	O
.	O
Eighty	O
-	O
two	O
patients	O
with	O
various	O
malignancies	O
who	O
received	O
imipenem	B-DRUG
/	O
cilastatin	B-DRUG
143	O
times	O
for	O
neutropenic	B-ADVEFFECT
fever	I-ADVEFFECT
between	O
March	O
1994	O
and	O
October	O
1999	O
in	O
Department	O
of	O
Pediatric	O
Oncology	O
,	O
Gazi	O
University	O
,	O
were	O
identified	O
.	O
Incidence	O
of	O
seizures	B-ADVEFFECT
in	O
pediatric	O
cancer	O
patients	O
treated	O
with	O
imipenem	B-DRUG
/	O
cilastatin	B-DRUG
.	O
Incidence	O
of	O
seizures	B-ADVEFFECT
in	O
pediatric	O
cancer	O
patients	O
treated	O
with	O
imipenem	B-DRUG
/	O
cilastatin	B-DRUG
.	O
Proconvulsive	B-ADVEFFECT
tendency	O
of	O
imipenem	B-DRUG
/	O
cilastatin	B-DRUG
is	O
one	O
of	O
its	O
well	O
-	O
known	O
side	O
effects	O
.	O
Proconvulsive	B-ADVEFFECT
tendency	O
of	O
imipenem	B-DRUG
/	O
cilastatin	B-DRUG
is	O
one	O
of	O
its	O
well	O
-	O
known	O
side	O
effects	O
.	O
Three	O
of	O
these	O
patients	O
had	O
convulsions	B-ADVEFFECT
attributed	O
to	O
imipenem	B-DRUG
/	O
cilastatin	B-DRUG
;	O
3.6	O
%	O
of	O
the	O
patients	O
had	O
seizure	B-ADVEFFECT
,	O
or	O
2	O
%	O
of	O
imipenem	B-DRUG
/	O
cilastatin	B-DRUG
administrations	O
was	O
followed	O
by	O
a	O
seizure	O
attack	O
.	O
Three	O
of	O
these	O
patients	O
had	O
convulsions	B-ADVEFFECT
attributed	O
to	O
imipenem	B-DRUG
/	O
cilastatin	B-DRUG
;	O
3.6	O
%	O
of	O
the	O
patients	O
had	O
seizure	B-ADVEFFECT
,	O
or	O
2	O
%	O
of	O
imipenem	B-DRUG
/	O
cilastatin	B-DRUG
administrations	O
was	O
followed	O
by	O
a	O
seizure	O
attack	O
.	O
Three	O
of	O
these	O
patients	O
had	O
convulsions	B-ADVEFFECT
attributed	O
to	O
imipenem	B-DRUG
/	O
cilastatin	B-DRUG
;	O
3.6	O
%	O
of	O
the	O
patients	O
had	O
seizure	B-ADVEFFECT
,	O
or	O
2	O
%	O
of	O
imipenem	B-DRUG
/	O
cilastatin	B-DRUG
administrations	O
was	O
followed	O
by	O
a	O
seizure	O
attack	O
.	O
Three	O
of	O
these	O
patients	O
had	O
convulsions	B-ADVEFFECT
attributed	O
to	O
imipenem	B-DRUG
/	O
cilastatin	B-DRUG
;	O
3.6	O
%	O
of	O
the	O
patients	O
had	O
seizure	B-ADVEFFECT
,	O
or	O
2	O
%	O
of	O
imipenem	B-DRUG
/	O
cilastatin	B-DRUG
administrations	O
was	O
followed	O
by	O
a	O
seizure	O
attack	O
.	O
Three	O
of	O
these	O
patients	O
had	O
convulsions	B-ADVEFFECT
attributed	O
to	O
imipenem	B-DRUG
/	O
cilastatin	B-DRUG
;	O
3.6	O
%	O
of	O
the	O
patients	O
had	O
seizure	B-ADVEFFECT
,	O
or	O
2	O
%	O
of	O
imipenem	B-DRUG
/	O
cilastatin	B-DRUG
administrations	O
was	O
followed	O
by	O
a	O
seizure	O
attack	O
.	O
Three	O
of	O
these	O
patients	O
had	O
convulsions	B-ADVEFFECT
attributed	O
to	O
imipenem	B-DRUG
/	O
cilastatin	B-DRUG
;	O
3.6	O
%	O
of	O
the	O
patients	O
had	O
seizure	B-ADVEFFECT
,	O
or	O
2	O
%	O
of	O
imipenem	B-DRUG
/	O
cilastatin	B-DRUG
administrations	O
was	O
followed	O
by	O
a	O
seizure	O
attack	O
.	O
Gabapentin	B-DRUG
-	O
induced	O
mood	B-ADVEFFECT
changes	I-ADVEFFECT
with	O
hypomanic	B-ADVEFFECT
features	O
in	O
adults	O
.	O
Gabapentin	B-DRUG
-	O
induced	O
mood	B-ADVEFFECT
changes	I-ADVEFFECT
with	O
hypomanic	B-ADVEFFECT
features	O
in	O
adults	O
.	O
We	O
report	O
two	O
adults	O
who	O
received	O
gabapentin	B-DRUG
(	O
GBP	B-DRUG
)	O
and	O
subsequently	O
developed	O
behavioural	B-ADVEFFECT
side	I-ADVEFFECT
effects	I-ADVEFFECT
.	O
We	O
report	O
two	O
adults	O
who	O
received	O
gabapentin	B-DRUG
(	O
GBP	B-DRUG
)	O
and	O
subsequently	O
developed	O
behavioural	B-ADVEFFECT
side	I-ADVEFFECT
effects	I-ADVEFFECT
.	O
Acute	B-ADVEFFECT
pancreatitis	I-ADVEFFECT
in	O
a	O
child	O
with	O
idiopathic	O
ulcerative	O
colitis	O
on	O
long	O
-	O
term	O
5-aminosalicylic	B-DRUG
acid	I-DRUG
therapy	O
.	O
We	O
describe	O
a	O
10-year	O
-	O
old	O
boy	O
with	O
ulcerative	O
colitis	O
who	O
developed	O
acute	B-ADVEFFECT
pancreatitis	I-ADVEFFECT
while	O
on	O
long	O
-	O
term	O
treatment	O
with	O
5-aminosalicylic	B-DRUG
acid	O
.	O
CONCLUSION	O
:	O
Marked	O
visual	B-ADVEFFECT
field	I-ADVEFFECT
constriction	I-ADVEFFECT
appears	O
to	O
be	O
associated	O
with	O
vigabatrin	B-DRUG
therapy	O
.	O
Electro	O
-	O
oculography	O
,	O
electroretinography	O
,	O
visual	O
evoked	O
potentials	O
,	O
and	O
multifocal	O
electroretinography	O
in	O
patients	O
with	O
vigabatrin	B-DRUG
-	O
attributed	O
visual	B-ADVEFFECT
field	I-ADVEFFECT
constriction	I-ADVEFFECT
.	O
PURPOSE	O
:	O
Symptomatic	O
visual	B-ADVEFFECT
field	I-ADVEFFECT
constriction	I-ADVEFFECT
thought	O
to	O
be	O
associated	O
with	O
vigabatrin	B-DRUG
has	O
been	O
reported	O
.	O
The	O
current	O
study	O
investigated	O
the	O
visual	O
fields	O
and	O
visual	O
electrophysiology	O
of	O
eight	O
patients	O
with	O
known	O
vigabatrin	B-DRUG
-	O
attributed	O
visual	B-ADVEFFECT
field	I-ADVEFFECT
loss	I-ADVEFFECT
,	O
three	O
of	O
whom	O
were	O
reported	O
previously	O
.	O
The	O
field	B-ADVEFFECT
defects	I-ADVEFFECT
and	O
some	O
electrophysiological	O
abnormalities	O
persist	O
when	O
vigabatrin	B-DRUG
therapy	O
is	O
withdrawn	O
.	O
Depressive	B-ADVEFFECT
symptoms	I-ADVEFFECT
disappeared	O
after	O
interferon	B-DRUG
therapy	O
was	O
stopped	O
.	O
Treatment	O
of	O
chronic	O
hepatitis	O
C	O
with	O
interferon	B-DRUG
alpha	I-DRUG
(	O
IFN	B-DRUG
-	I-DRUG
alpha	I-DRUG
)	O
is	O
relatively	O
contraindicated	O
in	O
patients	O
with	O
psychiatric	O
disorders	O
because	O
of	O
possible	O
severe	O
psychiatric	B-ADVEFFECT
side	I-ADVEFFECT
effects	I-ADVEFFECT
.	O
Treatment	O
of	O
chronic	O
hepatitis	O
C	O
with	O
interferon	B-DRUG
alpha	I-DRUG
(	O
IFN	B-DRUG
-	I-DRUG
alpha	I-DRUG
)	O
is	O
relatively	O
contraindicated	O
in	O
patients	O
with	O
psychiatric	O
disorders	O
because	O
of	O
possible	O
severe	O
psychiatric	B-ADVEFFECT
side	I-ADVEFFECT
effects	I-ADVEFFECT
.	O
While	O
for	O
ribavirin	O
antidepressant	O
effects	O
are	O
not	O
known	O
,	O
we	O
suppose	O
that	O
antidepressants	O
may	O
prevent	O
changes	B-ADVEFFECT
in	I-ADVEFFECT
serotonergic	I-ADVEFFECT
or	I-ADVEFFECT
noradrenergic	I-ADVEFFECT
neurotransmission	I-ADVEFFECT
caused	O
by	O
IFN	B-DRUG
-	I-DRUG
alpha	I-DRUG
.	O
Intensive	O
high	O
-	O
flux	O
hemodiafiltration	O
is	O
often	O
used	O
in	O
the	O
management	O
of	O
vancomycin	B-ADVEFFECT
toxicity	I-ADVEFFECT
.	O
Management	O
of	O
hypophosphatemia	O
induced	O
by	O
high	O
-	O
flux	O
hemodiafiltration	O
for	O
the	O
treatment	O
of	O
vancomycin	B-DRUG
toxicity	O
:	O
intravenous	O
phosphorus	O
therapy	O
versus	O
use	O
of	O
a	O
phosphorus	O
-	O
enriched	O
dialysate	O
.	O
We	O
describe	O
2	O
children	O
with	O
cerebral	O
palsy	O
who	O
suffered	O
significant	O
morbidity	B-ADVEFFECT
immediately	O
after	O
treatment	O
with	O
hyperbaric	B-DRUG
oxygen	I-DRUG
.	O
A	O
33-year	O
-	O
old	O
male	O
presented	O
with	O
brown	B-ADVEFFECT
discolouration	I-ADVEFFECT
of	I-ADVEFFECT
the	I-ADVEFFECT
fingernails	I-ADVEFFECT
following	O
the	O
application	O
of	O
4	B-DRUG
%	I-DRUG
hydroquinone	I-DRUG
in	I-DRUG
sorbolene	I-DRUG
cream	I-DRUG
and	O
0.1	B-DRUG
%	I-DRUG
tretinoin	I-DRUG
cream	I-DRUG
to	O
the	O
face	O
intermittently	O
for	O
9	O
months	O
.	O
A	O
33-year	O
-	O
old	O
male	O
presented	O
with	O
brown	B-ADVEFFECT
discolouration	I-ADVEFFECT
of	I-ADVEFFECT
the	I-ADVEFFECT
fingernails	I-ADVEFFECT
following	O
the	O
application	O
of	O
4	B-DRUG
%	I-DRUG
hydroquinone	I-DRUG
in	I-DRUG
sorbolene	I-DRUG
cream	I-DRUG
and	O
0.1	B-DRUG
%	I-DRUG
tretinoin	I-DRUG
cream	I-DRUG
to	O
the	O
face	O
intermittently	O
for	O
9	O
months	O
.	O
Nail	B-ADVEFFECT
staining	I-ADVEFFECT
from	O
hydroquinone	B-DRUG
cream	O
.	O
Gangrene	B-ADVEFFECT
of	O
the	O
fingertips	O
after	O
bleomycin	B-DRUG
and	O
methotrexate	B-DRUG
.	O
Gangrene	B-ADVEFFECT
of	O
the	O
fingertips	O
after	O
bleomycin	B-DRUG
and	O
methotrexate	B-DRUG
.	O
This	O
supports	O
the	O
well	O
-	O
reported	O
potential	O
of	O
bleomycin	B-DRUG
to	O
trigger	O
acral	B-ADVEFFECT
vascular	I-ADVEFFECT
toxicity	I-ADVEFFECT
.	O
We	O
describe	O
a	O
57-year	O
-	O
old	O
man	O
with	O
acral	O
erythrocyanosis	O
progressing	O
to	O
acute	B-ADVEFFECT
digital	I-ADVEFFECT
ischemia	I-ADVEFFECT
and	O
gangrene	B-ADVEFFECT
that	O
developed	O
after	O
combined	O
chemotherapy	O
(	O
bleomycin	B-DRUG
and	O
methotrexate	B-DRUG
)	O
used	O
to	O
treat	O
a	O
metastatic	O
squamous	O
cell	O
carcinoma	O
of	O
the	O
hypopharynx	O
.	O
We	O
describe	O
a	O
57-year	O
-	O
old	O
man	O
with	O
acral	O
erythrocyanosis	O
progressing	O
to	O
acute	B-ADVEFFECT
digital	I-ADVEFFECT
ischemia	I-ADVEFFECT
and	O
gangrene	B-ADVEFFECT
that	O
developed	O
after	O
combined	O
chemotherapy	O
(	O
bleomycin	B-DRUG
and	O
methotrexate	B-DRUG
)	O
used	O
to	O
treat	O
a	O
metastatic	O
squamous	O
cell	O
carcinoma	O
of	O
the	O
hypopharynx	O
.	O
We	O
describe	O
a	O
57-year	O
-	O
old	O
man	O
with	O
acral	O
erythrocyanosis	O
progressing	O
to	O
acute	B-ADVEFFECT
digital	I-ADVEFFECT
ischemia	I-ADVEFFECT
and	O
gangrene	B-ADVEFFECT
that	O
developed	O
after	O
combined	O
chemotherapy	O
(	O
bleomycin	B-DRUG
and	O
methotrexate	B-DRUG
)	O
used	O
to	O
treat	O
a	O
metastatic	O
squamous	O
cell	O
carcinoma	O
of	O
the	O
hypopharynx	O
.	O
We	O
describe	O
a	O
57-year	O
-	O
old	O
man	O
with	O
acral	O
erythrocyanosis	O
progressing	O
to	O
acute	B-ADVEFFECT
digital	I-ADVEFFECT
ischemia	I-ADVEFFECT
and	O
gangrene	B-ADVEFFECT
that	O
developed	O
after	O
combined	O
chemotherapy	O
(	O
bleomycin	B-DRUG
and	O
methotrexate	B-DRUG
)	O
used	O
to	O
treat	O
a	O
metastatic	O
squamous	O
cell	O
carcinoma	O
of	O
the	O
hypopharynx	O
.	O
Diarrhea	B-ADVEFFECT
-	I-ADVEFFECT
associated	I-ADVEFFECT
over	I-ADVEFFECT
-	I-ADVEFFECT
anticoagulation	I-ADVEFFECT
in	O
a	O
patient	O
taking	O
warfarin	B-DRUG
:	O
therapeutic	O
role	O
of	O
cholestyramine	O
.	O
We	O
present	O
a	O
case	O
of	O
significant	O
over	B-ADVEFFECT
-	I-ADVEFFECT
anticoagulation	I-ADVEFFECT
temporally	O
associated	O
with	O
a	O
bout	O
of	O
protracted	O
diarrhea	B-ADVEFFECT
in	O
a	O
patient	O
on	O
warfarin	B-DRUG
therapy	O
.	O
We	O
present	O
a	O
case	O
of	O
significant	O
over	B-ADVEFFECT
-	I-ADVEFFECT
anticoagulation	I-ADVEFFECT
temporally	O
associated	O
with	O
a	O
bout	O
of	O
protracted	O
diarrhea	B-ADVEFFECT
in	O
a	O
patient	O
on	O
warfarin	B-DRUG
therapy	O
.	O
MI	B-ADVEFFECT
related	O
to	O
the	O
use	O
of	O
activated	O
and	O
non	O
-	O
activated	O
PCCs	B-DRUG
predominantly	O
affects	O
young	O
patients	O
who	O
often	O
have	O
no	O
preceding	O
history	O
of	O
,	O
or	O
risk	O
factors	O
for	O
,	O
MI	B-ADVEFFECT
and	O
tends	O
to	O
be	O
associated	O
with	O
large	O
cumulative	O
doses	O
of	O
concentrate	O
.	O
Recombinant	O
VIIa	O
concentrate	O
in	O
the	O
management	O
of	O
bleeding	O
following	O
prothrombin	B-DRUG
complex	I-DRUG
concentrate	I-DRUG
-	O
related	O
myocardial	B-ADVEFFECT
infarction	I-ADVEFFECT
in	O
patients	O
with	O
haemophilia	O
and	O
inhibitors	O
.	O
We	O
have	O
safely	O
used	O
recombinant	O
factor	O
VIIa	O
to	O
treat	O
bleeding	O
in	O
the	O
immediate	O
and	O
long	O
-	O
term	O
period	O
following	O
PCC	B-DRUG
-	O
related	O
MI	B-ADVEFFECT
.	O
Even	O
after	O
a	O
strict	O
warning	O
,	O
he	O
took	O
another	O
quinine	O
tablet	O
that	O
evening	O
,	O
which	O
triggered	O
his	O
fifth	O
episode	O
of	O
severe	O
thrombocytopenia	B-ADVEFFECT
,	O
and	O
confirmed	O
the	O
etiology	O
of	O
quinine	B-DRUG
-	O
induced	O
thrombocytopenia	B-ADVEFFECT
.	O
Even	O
after	O
a	O
strict	O
warning	O
,	O
he	O
took	O
another	O
quinine	O
tablet	O
that	O
evening	O
,	O
which	O
triggered	O
his	O
fifth	O
episode	O
of	O
severe	O
thrombocytopenia	B-ADVEFFECT
,	O
and	O
confirmed	O
the	O
etiology	O
of	O
quinine	B-DRUG
-	O
induced	O
thrombocytopenia	B-ADVEFFECT
.	O
Even	O
after	O
a	O
strict	O
warning	O
,	O
he	O
took	O
another	O
quinine	O
tablet	O
that	O
evening	O
,	O
which	O
triggered	O
his	O
fifth	O
episode	O
of	O
severe	O
thrombocytopenia	B-ADVEFFECT
,	O
and	O
confirmed	O
the	O
etiology	O
of	O
quinine	B-DRUG
-	O
induced	O
thrombocytopenia	B-ADVEFFECT
.	O
Occult	O
quinine	B-DRUG
-	O
induced	O
thrombocytopenia	B-ADVEFFECT
.	O
Only	O
after	O
three	O
subsequent	O
episodes	O
of	O
severe	O
,	O
symptomatic	O
thrombocytopenia	B-ADVEFFECT
over	O
the	O
next	O
four	O
weeks	O
did	O
he	O
say	O
,	O
upon	O
repeat	O
questioning	O
,	O
that	O
he	O
had	O
continued	O
to	O
take	O
quinine	B-DRUG
for	O
night	O
leg	O
cramps	O
.	O
An	O
8-year	O
-	O
old	O
child	O
with	O
familial	O
Mediterranean	O
fever	O
exhibited	O
signs	O
of	O
colchicine	B-ADVEFFECT
intoxication	I-ADVEFFECT
while	O
receiving	O
prophylactic	O
doses	O
of	O
the	O
drug	O
.	O
CONCLUSION	O
:	O
To	O
the	O
best	O
of	O
our	O
knowledge	O
,	O
this	O
is	O
the	O
first	O
time	O
colchicine	B-ADVEFFECT
intoxication	I-ADVEFFECT
in	O
this	O
age	O
group	O
has	O
been	O
described	O
in	O
the	O
English	O
literature	O
.	O
Near	B-ADVEFFECT
fatal	I-ADVEFFECT
acute	O
colchicine	B-ADVEFFECT
intoxication	I-ADVEFFECT
in	O
a	O
child	O
.	O
Near	B-ADVEFFECT
fatal	I-ADVEFFECT
acute	O
colchicine	B-DRUG
intoxication	O
in	O
a	O
child	O
.	O
Acute	B-ADVEFFECT
myeloid	I-ADVEFFECT
leukemia	I-ADVEFFECT
and	O
lung	B-ADVEFFECT
cancer	I-ADVEFFECT
occurring	O
in	O
a	O
chronic	O
lymphocytic	O
leukemia	O
patient	O
treated	O
with	O
fludarabine	B-DRUG
and	O
autologous	O
peripheral	O
blood	O
stem	O
-	O
cell	O
transplantation	O
.	O
Acute	B-ADVEFFECT
myeloid	I-ADVEFFECT
leukemia	I-ADVEFFECT
and	O
lung	B-ADVEFFECT
cancer	I-ADVEFFECT
occurring	O
in	O
a	O
chronic	O
lymphocytic	O
leukemia	O
patient	O
treated	O
with	O
fludarabine	B-DRUG
and	O
autologous	O
peripheral	O
blood	O
stem	O
-	O
cell	O
transplantation	O
.	O
We	O
describe	O
the	O
exceptional	O
development	O
of	O
AML	B-ADVEFFECT
and	O
lung	B-ADVEFFECT
cancer	I-ADVEFFECT
in	O
a	O
patient	O
with	O
previously	O
diagnosed	O
CLL	O
in	O
minimal	O
residual	O
disease	O
status	O
after	O
fludarabine	B-DRUG
treatment	O
followed	O
by	O
autologous	O
peripheral	O
blood	O
stem	O
-	O
cell	O
transplantation	O
.	O
We	O
describe	O
the	O
exceptional	O
development	O
of	O
AML	B-ADVEFFECT
and	O
lung	B-ADVEFFECT
cancer	I-ADVEFFECT
in	O
a	O
patient	O
with	O
previously	O
diagnosed	O
CLL	O
in	O
minimal	O
residual	O
disease	O
status	O
after	O
fludarabine	B-DRUG
treatment	O
followed	O
by	O
autologous	O
peripheral	O
blood	O
stem	O
-	O
cell	O
transplantation	O
.	O
In	O
2	O
of	O
the	O
3	O
cases	O
the	O
patients	O
were	O
also	O
taking	O
lithium	B-DRUG
carbonate	O
and	O
beta	O
-	O
blockers	O
,	O
both	O
of	O
which	O
could	O
have	O
contributed	O
to	O
the	O
incontinence	B-ADVEFFECT
.	O
In	O
the	O
present	O
paper	O
the	O
authors	O
describe	O
2	O
female	O
patients	O
who	O
developed	O
incontinence	B-ADVEFFECT
secondary	O
to	O
the	O
selective	O
serotonin	O
reuptake	O
inhibitors	O
paroxetine	B-DRUG
and	O
sertraline	B-DRUG
,	O
as	O
well	O
as	O
a	O
third	O
who	O
developed	O
this	O
side	O
effect	O
on	O
venlafaxine	B-DRUG
.	O
In	O
the	O
present	O
paper	O
the	O
authors	O
describe	O
2	O
female	O
patients	O
who	O
developed	O
incontinence	B-ADVEFFECT
secondary	O
to	O
the	O
selective	O
serotonin	O
reuptake	O
inhibitors	O
paroxetine	B-DRUG
and	O
sertraline	B-DRUG
,	O
as	O
well	O
as	O
a	O
third	O
who	O
developed	O
this	O
side	O
effect	O
on	O
venlafaxine	B-DRUG
.	O
In	O
the	O
present	O
paper	O
the	O
authors	O
describe	O
2	O
female	O
patients	O
who	O
developed	O
incontinence	B-ADVEFFECT
secondary	O
to	O
the	O
selective	O
serotonin	O
reuptake	O
inhibitors	O
paroxetine	B-DRUG
and	O
sertraline	B-DRUG
,	O
as	O
well	O
as	O
a	O
third	O
who	O
developed	O
this	O
side	O
effect	O
on	O
venlafaxine	B-DRUG
.	O
This	O
concerns	O
2	O
male	O
patients	O
who	O
experienced	O
incontinence	B-ADVEFFECT
while	O
taking	O
venlafaxine	B-DRUG
.	O
Case	O
studies	O
in	O
heparin	B-DRUG
-	O
induced	O
thrombocytopenia	B-ADVEFFECT
.	O
Major	O
points	O
illustrated	O
are	O
,	O
(	O
1	O
)	O
occurrence	O
of	O
HIT	B-ADVEFFECT
with	O
any	O
dose	O
or	O
form	O
of	O
heparin	B-DRUG
;	O
(	O
2	O
)	O
misperceptions	O
on	O
the	O
diagnostic	O
criteria	O
;	O
(	O
3	O
)	O
correct	O
(	O
thrombin	O
inhibitors	O
)	O
and	O
incorrect	O
(	O
platelet	O
transfusions	O
and	O
warfarin	O
)	O
management	O
;	O
(	O
4	O
)	O
influence	O
of	O
management	O
strategy	O
on	O
clinical	O
outcomes	O
;	O
(	O
5	O
)	O
severity	O
of	O
the	O
syndrome	O
;	O
and	O
(	O
6	O
)	O
potential	O
for	O
both	O
anamnestic	O
response	O
to	O
heparin	B-DRUG
and	O
disappearance	O
of	O
HIT	B-ADVEFFECT
antibodies	O
over	O
time	O
.	O
Type	O
II	O
heparin	O
-	O
induced	O
thrombocytopenia	B-ADVEFFECT
(	O
HIT	B-ADVEFFECT
)	O
is	O
an	O
immunological	O
disorder	O
characterized	O
by	O
antibodies	O
to	O
heparin	B-DRUG
-	O
platelet	O
factor	O
4	O
complexes	O
and	O
a	O
high	O
risk	O
of	O
thrombotic	O
complications	O
.	O
After	O
several	O
unrevealing	O
medical	O
work	O
-	O
ups	O
,	O
he	O
was	O
found	O
to	O
have	O
a	O
high	B-ADVEFFECT
blood	I-ADVEFFECT
lead	I-ADVEFFECT
level	I-ADVEFFECT
(	O
122	O
microg	O
/	O
dL	O
)	O
;	O
he	O
has	O
a	O
history	O
of	O
scraping	O
and	O
sanding	O
lead	B-DRUG
paint	O
without	O
adequate	O
protective	O
measures	O
.	O
It	O
also	O
highlights	O
a	O
current	O
major	O
etiologic	O
question	O
,	O
that	O
is	O
,	O
whether	O
and	O
to	O
what	O
degree	O
lead	B-DRUG
exposure	O
contributes	O
to	O
the	O
development	O
of	O
hypertension	B-ADVEFFECT
,	O
and	O
raises	O
the	O
issue	O
of	O
whether	O
lead	B-ADVEFFECT
-	I-ADVEFFECT
induced	I-ADVEFFECT
hypertension	I-ADVEFFECT
constitutes	O
a	O
subset	O
of	O
hypertension	B-ADVEFFECT
that	O
is	O
especially	O
amenable	O
to	O
therapy	O
with	O
dietary	O
calcium	O
.	O
It	O
also	O
highlights	O
a	O
current	O
major	O
etiologic	O
question	O
,	O
that	O
is	O
,	O
whether	O
and	O
to	O
what	O
degree	O
lead	B-DRUG
exposure	O
contributes	O
to	O
the	O
development	O
of	O
hypertension	B-ADVEFFECT
,	O
and	O
raises	O
the	O
issue	O
of	O
whether	O
lead	B-ADVEFFECT
-	I-ADVEFFECT
induced	I-ADVEFFECT
hypertension	I-ADVEFFECT
constitutes	O
a	O
subset	O
of	O
hypertension	B-ADVEFFECT
that	O
is	O
especially	O
amenable	O
to	O
therapy	O
with	O
dietary	O
calcium	O
.	O
Poorly	O
controlled	O
hypertension	B-ADVEFFECT
in	O
a	O
painter	O
with	O
chronic	O
lead	B-ADVEFFECT
toxicity	I-ADVEFFECT
.	O
This	O
case	O
demonstrates	O
an	O
occupational	O
activity	O
(	O
construction	O
)	O
that	O
has	O
now	O
become	O
the	O
dominant	O
source	O
of	O
lead	B-DRUG
exposure	O
for	O
U.S.	O
adults	O
,	O
the	O
importance	O
of	O
a	O
good	O
occupational	O
history	O
to	O
suspecting	O
and	O
making	O
a	O
diagnosis	O
,	O
the	O
possible	O
outcomes	O
of	O
chronic	O
lead	B-ADVEFFECT
toxicity	I-ADVEFFECT
,	O
and	O
the	O
importance	O
of	O
preventing	O
further	O
exposure	O
and	O
using	O
proper	O
methods	O
to	O
treat	O
acute	O
toxicity	O
.	O
Severe	B-ADVEFFECT
rash	I-ADVEFFECT
,	O
including	O
the	O
Stevens	B-ADVEFFECT
-	I-ADVEFFECT
Johnson	I-ADVEFFECT
syndrome	I-ADVEFFECT
(	O
SJS	B-ADVEFFECT
)	O
,	O
is	O
the	O
major	O
toxicity	O
of	O
nevirapine	B-DRUG
and	O
is	O
described	O
in	O
the	O
package	O
labeling	O
with	O
a	O
prominent	O
,	O
boxed	O
warning	O
.	O
Severe	B-ADVEFFECT
rash	I-ADVEFFECT
,	O
including	O
the	O
Stevens	B-ADVEFFECT
-	I-ADVEFFECT
Johnson	I-ADVEFFECT
syndrome	I-ADVEFFECT
(	O
SJS	B-ADVEFFECT
)	O
,	O
is	O
the	O
major	O
toxicity	O
of	O
nevirapine	B-DRUG
and	O
is	O
described	O
in	O
the	O
package	O
labeling	O
with	O
a	O
prominent	O
,	O
boxed	O
warning	O
.	O
Severe	B-ADVEFFECT
rash	I-ADVEFFECT
,	O
including	O
the	O
Stevens	B-ADVEFFECT
-	I-ADVEFFECT
Johnson	I-ADVEFFECT
syndrome	I-ADVEFFECT
(	O
SJS	B-ADVEFFECT
)	O
,	O
is	O
the	O
major	O
toxicity	O
of	O
nevirapine	B-DRUG
and	O
is	O
described	O
in	O
the	O
package	O
labeling	O
with	O
a	O
prominent	O
,	O
boxed	O
warning	O
.	O
Stevens	B-ADVEFFECT
-	I-ADVEFFECT
Johnson	I-ADVEFFECT
syndrome	I-ADVEFFECT
caused	O
by	O
the	O
antiretroviral	O
drug	O
nevirapine	B-DRUG
.	O
Though	O
physicians	O
treating	O
large	O
populations	O
of	O
patients	O
with	O
HIV	O
are	O
well	O
aware	O
of	O
this	O
complication	O
,	O
only	O
one	O
other	O
report	O
of	O
nevirapine	B-DRUG
-	O
associated	O
SJS	B-ADVEFFECT
has	O
been	O
documented	O
in	O
the	O
dermatology	O
literature	O
.	O
We	O
describe	O
2	O
cases	O
of	O
SJS	B-ADVEFFECT
related	O
to	O
nevirapine	B-DRUG
use	O
and	O
review	O
the	O
literature	O
on	O
this	O
newly	O
recognized	O
association	O
.	O
Oral	O
intake	O
and	O
acarbose	B-DRUG
were	O
withheld	O
and	O
the	O
ileus	B-ADVEFFECT
spontaneously	O
resolved	O
after	O
2	O
days	O
.	O
There	O
is	O
evidence	O
that	O
the	O
angiotensin	O
II	O
receptor	O
antagonist	O
,	O
losartan	B-DRUG
,	O
increases	B-ADVEFFECT
urate	I-ADVEFFECT
excretion	I-ADVEFFECT
by	O
reducing	O
reabsorption	O
of	O
urate	O
in	O
the	O
renal	O
proximal	O
tubule	O
.	O
Atrial	B-ADVEFFECT
fibrillation	I-ADVEFFECT
occurring	O
in	O
a	O
patient	O
taking	O
etanercept	B-DRUG
plus	O
methotrexate	B-DRUG
for	O
rheumatoid	O
arthritis	O
.	O
Atrial	B-ADVEFFECT
fibrillation	I-ADVEFFECT
occurring	O
in	O
a	O
patient	O
taking	O
etanercept	B-DRUG
plus	O
methotrexate	B-DRUG
for	O
rheumatoid	O
arthritis	O
.	O
A	O
review	O
of	O
the	O
literature	O
revealed	O
two	O
other	O
cases	O
of	O
hepatic	B-ADVEFFECT
angiosarcoma	I-ADVEFFECT
in	O
patients	O
after	O
long	O
-	O
term	O
cyclophosphamide	B-DRUG
treatment	O
.	O
Hepatic	B-ADVEFFECT
angiosarcoma	I-ADVEFFECT
occurring	O
after	O
cyclophosphamide	B-DRUG
therapy	O
:	O
case	O
report	O
and	O
review	O
of	O
the	O
literature	O
.	O
We	O
propose	O
that	O
cyclophosphamide	B-DRUG
be	O
added	O
to	O
the	O
list	O
of	O
exposures	O
potentially	O
associated	O
with	O
hepatic	B-ADVEFFECT
angiosarcoma	I-ADVEFFECT
.	O
ARA	B-DRUG
-	I-DRUG
C	I-DRUG
is	O
frequently	O
associated	O
with	O
dermatologic	B-ADVEFFECT
toxicity	I-ADVEFFECT
,	O
but	O
this	O
is	O
only	O
the	O
second	O
case	O
of	O
toxic	B-ADVEFFECT
epidermal	I-ADVEFFECT
necrolysis	I-ADVEFFECT
described	O
in	O
connection	O
with	O
this	O
drug	O
.	O
ARA	B-DRUG
-	I-DRUG
C	I-DRUG
is	O
frequently	O
associated	O
with	O
dermatologic	B-ADVEFFECT
toxicity	I-ADVEFFECT
,	O
but	O
this	O
is	O
only	O
the	O
second	O
case	O
of	O
toxic	B-ADVEFFECT
epidermal	I-ADVEFFECT
necrolysis	I-ADVEFFECT
described	O
in	O
connection	O
with	O
this	O
drug	O
.	O
On	O
the	O
fifth	O
day	O
after	O
administration	O
of	O
a	O
high	O
dose	O
of	O
ARA	B-DRUG
-	I-DRUG
C	I-DRUG
(	O
2	O
g	O
/	O
m2	O
intravenously	O
every	O
12	O
hours	O
)	O
,	O
she	O
developed	O
bullous	B-ADVEFFECT
lesions	I-ADVEFFECT
on	I-ADVEFFECT
the	I-ADVEFFECT
hands	I-ADVEFFECT
and	I-ADVEFFECT
soles	I-ADVEFFECT
that	I-ADVEFFECT
disseminated	I-ADVEFFECT
,	I-ADVEFFECT
evolving	I-ADVEFFECT
to	I-ADVEFFECT
necrosis	I-ADVEFFECT
,	O
sepsis	B-ADVEFFECT
,	O
and	O
death	B-ADVEFFECT
on	O
the	O
22nd	O
day	O
.	O
On	O
the	O
fifth	O
day	O
after	O
administration	O
of	O
a	O
high	O
dose	O
of	O
ARA	B-DRUG
-	I-DRUG
C	I-DRUG
(	O
2	O
g	O
/	O
m2	O
intravenously	O
every	O
12	O
hours	O
)	O
,	O
she	O
developed	O
bullous	B-ADVEFFECT
lesions	I-ADVEFFECT
on	I-ADVEFFECT
the	I-ADVEFFECT
hands	I-ADVEFFECT
and	I-ADVEFFECT
soles	I-ADVEFFECT
that	I-ADVEFFECT
disseminated	I-ADVEFFECT
,	I-ADVEFFECT
evolving	I-ADVEFFECT
to	I-ADVEFFECT
necrosis	I-ADVEFFECT
,	O
sepsis	B-ADVEFFECT
,	O
and	O
death	B-ADVEFFECT
on	O
the	O
22nd	O
day	O
.	O
On	O
the	O
fifth	O
day	O
after	O
administration	O
of	O
a	O
high	O
dose	O
of	O
ARA	B-DRUG
-	I-DRUG
C	I-DRUG
(	O
2	O
g	O
/	O
m2	O
intravenously	O
every	O
12	O
hours	O
)	O
,	O
she	O
developed	O
bullous	B-ADVEFFECT
lesions	I-ADVEFFECT
on	I-ADVEFFECT
the	I-ADVEFFECT
hands	I-ADVEFFECT
and	I-ADVEFFECT
soles	I-ADVEFFECT
that	I-ADVEFFECT
disseminated	I-ADVEFFECT
,	I-ADVEFFECT
evolving	I-ADVEFFECT
to	I-ADVEFFECT
necrosis	I-ADVEFFECT
,	O
sepsis	B-ADVEFFECT
,	O
and	O
death	B-ADVEFFECT
on	O
the	O
22nd	O
day	O
.	O
Toxic	B-ADVEFFECT
epidermal	I-ADVEFFECT
necrolysis	I-ADVEFFECT
after	O
the	O
use	O
of	O
high	O
-	O
dose	O
cytosine	B-ADVEFFECT
arabinoside	I-ADVEFFECT
.	O
We	O
report	O
a	O
fatal	O
case	O
of	O
toxic	B-ADVEFFECT
epidermal	I-ADVEFFECT
necrolysis	I-ADVEFFECT
(	O
TEN	B-ADVEFFECT
)	O
resulting	O
from	O
a	O
high	O
dose	O
of	O
cytosine	B-DRUG
arabinoside	I-DRUG
(	O
ARA	B-DRUG
-	I-DRUG
C	I-DRUG
)	O
.	O
We	O
report	O
a	O
fatal	O
case	O
of	O
toxic	B-ADVEFFECT
epidermal	I-ADVEFFECT
necrolysis	I-ADVEFFECT
(	O
TEN	B-ADVEFFECT
)	O
resulting	O
from	O
a	O
high	O
dose	O
of	O
cytosine	B-DRUG
arabinoside	I-DRUG
(	O
ARA	B-DRUG
-	I-DRUG
C	I-DRUG
)	O
.	O
We	O
report	O
a	O
fatal	O
case	O
of	O
toxic	B-ADVEFFECT
epidermal	I-ADVEFFECT
necrolysis	I-ADVEFFECT
(	O
TEN	B-ADVEFFECT
)	O
resulting	O
from	O
a	O
high	O
dose	O
of	O
cytosine	B-DRUG
arabinoside	I-DRUG
(	O
ARA	B-DRUG
-	I-DRUG
C	I-DRUG
)	O
.	O
We	O
report	O
a	O
fatal	O
case	O
of	O
toxic	B-ADVEFFECT
epidermal	I-ADVEFFECT
necrolysis	I-ADVEFFECT
(	O
TEN	B-ADVEFFECT
)	O
resulting	O
from	O
a	O
high	O
dose	O
of	O
cytosine	B-DRUG
arabinoside	I-DRUG
(	O
ARA	B-DRUG
-	I-DRUG
C	I-DRUG
)	O
.	O
Quetiapine	B-DRUG
and	O
obsessive	B-ADVEFFECT
-	I-ADVEFFECT
compulsive	I-ADVEFFECT
symptoms	I-ADVEFFECT
(	O
OCS	B-ADVEFFECT
)	O
:	O
case	O
report	O
and	O
review	O
of	O
atypical	O
antipsychotic	O
-	O
induced	O
OCS	B-ADVEFFECT
.	O
Quetiapine	B-DRUG
and	O
obsessive	B-ADVEFFECT
-	I-ADVEFFECT
compulsive	I-ADVEFFECT
symptoms	I-ADVEFFECT
(	O
OCS	B-ADVEFFECT
)	O
:	O
case	O
report	O
and	O
review	O
of	O
atypical	O
antipsychotic	O
-	O
induced	O
OCS	B-ADVEFFECT
.	O
Quetiapine	B-DRUG
and	O
obsessive	B-ADVEFFECT
-	I-ADVEFFECT
compulsive	I-ADVEFFECT
symptoms	I-ADVEFFECT
(	O
OCS	B-ADVEFFECT
)	O
:	O
case	O
report	O
and	O
review	O
of	O
atypical	O
antipsychotic	O
-	O
induced	O
OCS	B-ADVEFFECT
.	O
The	O
first	O
known	O
report	O
of	O
quetiapine	B-DRUG
exacerbating	B-ADVEFFECT
OCS	I-ADVEFFECT
in	O
a	O
43-year	O
-	O
old	O
man	O
with	O
obsessive	O
-	O
compulsive	O
disorder	O
(	O
OCD	O
)	O
,	O
trichotillomania	O
,	O
delusional	O
disorder	O
and	O
bipolar	O
II	O
disorder	O
is	O
presented	O
.	O
He	O
was	O
diagnosed	O
with	O
possible	O
serotonin	B-ADVEFFECT
syndrome	I-ADVEFFECT
;	O
his	O
symptoms	O
resolved	O
after	O
clomipramine	B-DRUG
was	O
stopped	O
but	O
before	O
clozapine	B-DRUG
was	O
restarted	O
eight	O
days	O
later	O
.	O
OBJECTIVE	O
:	O
To	O
report	O
on	O
the	O
possible	O
development	O
of	O
serotonin	B-ADVEFFECT
syndrome	I-ADVEFFECT
in	O
a	O
patient	O
receiving	O
clomipramine	B-DRUG
after	O
clozapine	B-DRUG
was	O
withdrawn	O
from	O
the	O
treatment	O
regimen	O
.	O
OBJECTIVE	O
:	O
To	O
report	O
on	O
the	O
possible	O
development	O
of	O
serotonin	B-ADVEFFECT
syndrome	I-ADVEFFECT
in	O
a	O
patient	O
receiving	O
clomipramine	B-DRUG
after	O
clozapine	B-DRUG
was	O
withdrawn	O
from	O
the	O
treatment	O
regimen	O
.	O
Possible	O
serotonin	B-ADVEFFECT
syndrome	I-ADVEFFECT
associated	O
with	O
clomipramine	B-DRUG
after	O
withdrawal	O
of	O
clozapine	B-DRUG
.	O
Possible	O
serotonin	O
syndrome	B-ADVEFFECT
associated	I-ADVEFFECT
with	O
clomipramine	O
after	B-DRUG
withdrawal	O
of	O
clozapine	O
.	B-DRUG
The	O
day	O
after	O
clozapine	B-DRUG
was	O
stopped	O
,	O
while	O
he	O
was	O
still	O
receiving	O
clomipramine	B-DRUG
150	O
mg	O
/	O
d	O
,	O
he	O
began	O
behaving	B-ADVEFFECT
oddly	I-ADVEFFECT
,	O
started	O
sweating	B-ADVEFFECT
profusely	I-ADVEFFECT
,	O
shivering	B-ADVEFFECT
,	O
and	O
became	O
tremulous	B-ADVEFFECT
,	O
agitated	B-ADVEFFECT
,	O
and	O
confused	B-ADVEFFECT
.	O
The	O
day	O
after	O
clozapine	B-DRUG
was	O
stopped	O
,	O
while	O
he	O
was	O
still	O
receiving	O
clomipramine	B-DRUG
150	O
mg	O
/	O
d	O
,	O
he	O
began	O
behaving	B-ADVEFFECT
oddly	I-ADVEFFECT
,	O
started	O
sweating	B-ADVEFFECT
profusely	I-ADVEFFECT
,	O
shivering	B-ADVEFFECT
,	O
and	O
became	O
tremulous	B-ADVEFFECT
,	O
agitated	B-ADVEFFECT
,	O
and	O
confused	B-ADVEFFECT
.	O
The	O
day	O
after	O
clozapine	B-DRUG
was	O
stopped	O
,	O
while	O
he	O
was	O
still	O
receiving	O
clomipramine	B-DRUG
150	O
mg	O
/	O
d	O
,	O
he	O
began	O
behaving	B-ADVEFFECT
oddly	I-ADVEFFECT
,	O
started	O
sweating	B-ADVEFFECT
profusely	I-ADVEFFECT
,	O
shivering	B-ADVEFFECT
,	O
and	O
became	O
tremulous	B-ADVEFFECT
,	O
agitated	B-ADVEFFECT
,	O
and	O
confused	B-ADVEFFECT
.	O
The	O
day	O
after	O
clozapine	B-DRUG
was	O
stopped	O
,	O
while	O
he	O
was	O
still	O
receiving	O
clomipramine	B-DRUG
150	O
mg	O
/	O
d	O
,	O
he	O
began	O
behaving	B-ADVEFFECT
oddly	I-ADVEFFECT
,	O
started	O
sweating	B-ADVEFFECT
profusely	I-ADVEFFECT
,	O
shivering	B-ADVEFFECT
,	O
and	O
became	O
tremulous	B-ADVEFFECT
,	O
agitated	B-ADVEFFECT
,	O
and	O
confused	B-ADVEFFECT
.	O
The	O
day	O
after	O
clozapine	B-DRUG
was	O
stopped	O
,	O
while	O
he	O
was	O
still	O
receiving	O
clomipramine	B-DRUG
150	O
mg	O
/	O
d	O
,	O
he	O
began	O
behaving	B-ADVEFFECT
oddly	I-ADVEFFECT
,	O
started	O
sweating	B-ADVEFFECT
profusely	I-ADVEFFECT
,	O
shivering	B-ADVEFFECT
,	O
and	O
became	O
tremulous	B-ADVEFFECT
,	O
agitated	B-ADVEFFECT
,	O
and	O
confused	B-ADVEFFECT
.	O
The	O
day	O
after	O
clozapine	B-DRUG
was	O
stopped	O
,	O
while	O
he	O
was	O
still	O
receiving	O
clomipramine	B-DRUG
150	O
mg	O
/	O
d	O
,	O
he	O
began	O
behaving	B-ADVEFFECT
oddly	I-ADVEFFECT
,	O
started	O
sweating	B-ADVEFFECT
profusely	I-ADVEFFECT
,	O
shivering	B-ADVEFFECT
,	O
and	O
became	O
tremulous	B-ADVEFFECT
,	O
agitated	B-ADVEFFECT
,	O
and	O
confused	B-ADVEFFECT
.	O
The	O
day	O
after	O
clozapine	B-DRUG
was	O
stopped	O
,	O
while	O
he	O
was	O
still	O
receiving	O
clomipramine	B-DRUG
150	O
mg	O
/	O
d	O
,	O
he	O
began	O
behaving	B-ADVEFFECT
oddly	I-ADVEFFECT
,	O
started	O
sweating	B-ADVEFFECT
profusely	I-ADVEFFECT
,	O
shivering	B-ADVEFFECT
,	O
and	O
became	O
tremulous	B-ADVEFFECT
,	O
agitated	B-ADVEFFECT
,	O
and	O
confused	B-ADVEFFECT
.	O
The	O
day	O
after	O
clozapine	B-DRUG
was	O
stopped	O
,	O
while	O
he	O
was	O
still	O
receiving	O
clomipramine	B-DRUG
150	O
mg	O
/	O
d	O
,	O
he	O
began	O
behaving	B-ADVEFFECT
oddly	I-ADVEFFECT
,	O
started	O
sweating	B-ADVEFFECT
profusely	I-ADVEFFECT
,	O
shivering	B-ADVEFFECT
,	O
and	O
became	O
tremulous	B-ADVEFFECT
,	O
agitated	B-ADVEFFECT
,	O
and	O
confused	B-ADVEFFECT
.	O
The	O
day	O
after	O
clozapine	B-DRUG
was	O
stopped	O
,	O
while	O
he	O
was	O
still	O
receiving	O
clomipramine	B-DRUG
150	O
mg	O
/	O
d	O
,	O
he	O
began	O
behaving	B-ADVEFFECT
oddly	I-ADVEFFECT
,	O
started	O
sweating	B-ADVEFFECT
profusely	I-ADVEFFECT
,	O
shivering	B-ADVEFFECT
,	O
and	O
became	O
tremulous	B-ADVEFFECT
,	O
agitated	B-ADVEFFECT
,	O
and	O
confused	B-ADVEFFECT
.	O
The	O
day	O
after	O
clozapine	B-DRUG
was	O
stopped	O
,	O
while	O
he	O
was	O
still	O
receiving	O
clomipramine	B-DRUG
150	O
mg	O
/	O
d	O
,	O
he	O
began	O
behaving	B-ADVEFFECT
oddly	I-ADVEFFECT
,	O
started	O
sweating	B-ADVEFFECT
profusely	I-ADVEFFECT
,	O
shivering	B-ADVEFFECT
,	O
and	O
became	O
tremulous	B-ADVEFFECT
,	O
agitated	B-ADVEFFECT
,	O
and	O
confused	B-ADVEFFECT
.	O
The	O
day	O
after	O
clozapine	B-DRUG
was	O
stopped	O
,	O
while	O
he	O
was	O
still	O
receiving	O
clomipramine	B-DRUG
150	O
mg	O
/	O
d	O
,	O
he	O
began	O
behaving	B-ADVEFFECT
oddly	I-ADVEFFECT
,	O
started	O
sweating	B-ADVEFFECT
profusely	I-ADVEFFECT
,	O
shivering	B-ADVEFFECT
,	O
and	O
became	O
tremulous	B-ADVEFFECT
,	O
agitated	B-ADVEFFECT
,	O
and	O
confused	B-ADVEFFECT
.	O
The	O
day	O
after	O
clozapine	B-DRUG
was	O
stopped	O
,	O
while	O
he	O
was	O
still	O
receiving	O
clomipramine	B-DRUG
150	O
mg	O
/	O
d	O
,	O
he	O
began	O
behaving	B-ADVEFFECT
oddly	I-ADVEFFECT
,	O
started	O
sweating	B-ADVEFFECT
profusely	I-ADVEFFECT
,	O
shivering	B-ADVEFFECT
,	O
and	O
became	O
tremulous	B-ADVEFFECT
,	O
agitated	B-ADVEFFECT
,	O
and	O
confused	B-ADVEFFECT
.	O
Quinine	B-DRUG
induced	O
coagulopathy	B-ADVEFFECT
--	O
a	O
near	O
fatal	O
experience	O
.	O
The	O
cause	O
of	O
his	O
bleeding	O
was	O
a	O
severe	B-ADVEFFECT
thrombocytopoaenia	I-ADVEFFECT
,	O
induced	O
by	O
chronic	O
ingestion	O
of	O
quinine	B-DRUG
.	O
Dose	O
-	O
dependent	O
olanzapine	B-DRUG
-	O
associated	O
leukopenia	B-ADVEFFECT
:	O
three	O
case	O
reports	O
.	O
These	O
cases	O
suggest	O
the	O
possibility	O
that	O
,	O
in	O
some	O
patients	O
,	O
leukopenia	B-ADVEFFECT
or	O
agranulocytosis	B-ADVEFFECT
during	O
olanzapine	B-DRUG
treatment	O
might	O
be	O
dose	O
-	O
related	O
.	O
These	O
cases	O
suggest	O
the	O
possibility	O
that	O
,	O
in	O
some	O
patients	O
,	O
leukopenia	B-ADVEFFECT
or	O
agranulocytosis	B-ADVEFFECT
during	O
olanzapine	B-DRUG
treatment	O
might	O
be	O
dose	O
-	O
related	O
.	O
We	O
report	O
three	O
cases	O
of	O
patients	O
who	O
developed	O
leukopenia	B-ADVEFFECT
during	O
olanzapine	B-DRUG
treatment	O
.	O
CONCLUSION	O
:	O
This	O
case	O
illustrates	O
a	O
potential	O
link	O
between	O
dermatologic	B-ADVEFFECT
and	I-ADVEFFECT
ocular	I-ADVEFFECT
5-FU	I-ADVEFFECT
toxicities	I-ADVEFFECT
.	O
Differential	O
diagnoses	O
included	O
ocular	O
rosacea	O
with	O
cicatrizing	O
conjunctivitis	O
and	O
5-FU	B-DRUG
-	O
induced	O
ectropion	B-ADVEFFECT
.	O
DISCUSSION	O
:	O
Patients	O
with	O
5-FU	B-DRUG
-	O
induced	O
ectropion	B-ADVEFFECT
experience	O
tender	B-ADVEFFECT
,	O
red	B-ADVEFFECT
,	O
scaled	B-ADVEFFECT
lids	I-ADVEFFECT
,	O
making	O
contact	O
lens	O
wear	O
difficult	O
.	O
DISCUSSION	O
:	O
Patients	O
with	O
5-FU	B-DRUG
-	O
induced	O
ectropion	B-ADVEFFECT
experience	O
tender	B-ADVEFFECT
,	O
red	B-ADVEFFECT
,	O
scaled	B-ADVEFFECT
lids	I-ADVEFFECT
,	O
making	O
contact	O
lens	O
wear	O
difficult	O
.	O
Ectropion	B-ADVEFFECT
secondary	O
to	O
bolus	O
injection	O
of	O
5-fluorouracil	B-DRUG
.	O
Exacerbation	O
of	O
5-FU	B-DRUG
dermatologic	B-ADVEFFECT
toxicities	I-ADVEFFECT
in	O
patients	O
with	O
preexisting	O
conditions	O
suggests	O
the	O
importance	O
of	O
aggressive	O
ocular	O
prophylaxis	O
,	O
using	O
frequent	O
ocular	O
lubrication	O
and	O
topical	O
steroid	O
preparations	O
with	O
concurrent	O
medical	O
management	O
of	O
pre	O
-	O
existing	O
dermatologic	O
conditions	O
.	O
Presented	O
is	O
a	O
case	O
of	O
acute	B-ADVEFFECT
renal	I-ADVEFFECT
failure	I-ADVEFFECT
induced	O
by	O
acetazolamide	B-DRUG
therapy	O
for	O
glaucoma	O
.	O
Renal	B-ADVEFFECT
failure	I-ADVEFFECT
associated	O
with	O
acetazolamide	B-DRUG
therapy	O
for	O
glaucoma	O
.	O
This	O
sulfonamide	O
like	O
nephropathy	O
should	O
be	O
differentiated	O
from	O
acetazolamide	B-DRUG
-	O
related	O
calcium	B-ADVEFFECT
phosphate	I-ADVEFFECT
nephrolithiasis	I-ADVEFFECT
.	O
Ischaemic	B-ADVEFFECT
colitis	I-ADVEFFECT
in	O
a	O
patient	O
taking	O
meloxicam	B-DRUG
.	O
Symptoms	O
and	O
endoscopic	B-ADVEFFECT
lesions	I-ADVEFFECT
quickly	O
regressed	O
within	O
1	O
week	O
of	O
meloxicam	B-DRUG
withdrawal	O
.	O
We	O
describe	O
a	O
patient	O
who	O
presented	O
with	O
bloody	B-ADVEFFECT
diarrhoea	I-ADVEFFECT
after	O
15	O
mg	O
meloxicam	B-DRUG
daily	O
for	O
10	O
days	O
for	O
osteoarthritis	O
.	O
We	O
suggest	O
that	O
meloxicam	B-DRUG
might	O
have	O
intestinal	B-ADVEFFECT
toxic	I-ADVEFFECT
effects	I-ADVEFFECT
when	O
taken	O
in	O
high	O
doses	O
,	O
because	O
of	O
reduced	O
COX-2	O
selectivity	O
.	O
As	O
these	O
cases	O
revealed	O
,	O
close	O
monitoring	O
of	O
blood	O
chemistry	O
is	O
mandatory	O
after	O
starting	O
spironolactone	B-DRUG
,	O
and	O
patients	O
should	O
be	O
advised	O
to	O
stop	O
spironolactone	B-DRUG
immediately	O
if	O
diarrhoea	B-DRUG
develops	O
.	O
In	O
patients	O
with	O
chronic	O
heart	O
failure	O
,	O
spironolactone	B-DRUG
added	O
to	O
conventional	O
treatment	O
may	O
lead	O
to	O
serious	B-ADVEFFECT
and	I-ADVEFFECT
,	I-ADVEFFECT
occasionally	I-ADVEFFECT
,	I-ADVEFFECT
fatal	I-ADVEFFECT
hyperkalaemia	I-ADVEFFECT
.	O
In	O
some	O
cases	O
this	O
seems	O
to	O
happen	O
because	O
spironolactone	B-DRUG
causes	O
diarrhoea	B-ADVEFFECT
.	O
Serious	B-ADVEFFECT
adverse	I-ADVEFFECT
events	I-ADVEFFECT
experienced	O
by	O
patients	O
with	O
chronic	O
heart	O
failure	O
taking	O
spironolactone	B-DRUG
.	O
We	O
report	O
a	O
patient	O
with	O
advanced	O
colonic	O
carcinoma	O
who	O
was	O
treated	O
with	O
concomitant	O
chemoirradiation	O
with	O
oxaliplatin	B-DRUG
and	O
developed	O
a	O
peculiar	O
dermnatitis	B-ADVEFFECT
in	O
the	O
irradiated	O
field	O
after	O
being	O
exposed	O
to	O
subsequent	O
chemotherapy	O
with	O
oxaliplatin	B-DRUG
.	O
An	O
11-year	O
-	O
old	O
boy	O
developed	O
a	O
severe	B-ADVEFFECT
enteropathy	I-ADVEFFECT
2	O
years	O
after	O
initiation	O
of	O
clofazimine	B-DRUG
treatment	O
for	O
graft	O
-	O
versus	O
-	O
host	O
disease	O
.	O
Clofazimine	B-DRUG
enteropathy	B-ADVEFFECT
caused	O
by	O
crystal	O
deposition	O
can	O
be	O
life	B-ADVEFFECT
-	I-ADVEFFECT
threatening	I-ADVEFFECT
.	O
Clofazimine	B-DRUG
enteropathy	B-ADVEFFECT
caused	O
by	O
crystal	O
deposition	O
can	O
be	O
life	B-ADVEFFECT
-	I-ADVEFFECT
threatening	I-ADVEFFECT
.	O
Clofazimine	B-DRUG
enteropathy	B-ADVEFFECT
in	O
a	O
pediatric	O
bone	O
marrow	O
transplant	O
recipient	O
.	O
She	O
developed	O
a	O
severe	B-ADVEFFECT
urticarial	I-ADVEFFECT
rash	I-ADVEFFECT
3	O
weeks	O
following	O
initiation	O
of	O
therapy	O
with	O
Enoxaparin	B-DRUG
.	O
We	O
cared	O
for	O
a	O
patient	O
with	O
progressive	O
renal	O
impairment	O
who	O
presented	O
with	O
blurred	B-ADVEFFECT
vision	I-ADVEFFECT
,	O
QRS	B-ADVEFFECT
broadening	I-ADVEFFECT
and	O
cardiac	B-ADVEFFECT
failure	I-ADVEFFECT
due	O
to	O
chronic	O
cibenzoline	B-DRUG
intoxication	O
.	O
We	O
cared	O
for	O
a	O
patient	O
with	O
progressive	O
renal	O
impairment	O
who	O
presented	O
with	O
blurred	B-ADVEFFECT
vision	I-ADVEFFECT
,	O
QRS	B-ADVEFFECT
broadening	I-ADVEFFECT
and	O
cardiac	B-ADVEFFECT
failure	I-ADVEFFECT
due	O
to	O
chronic	O
cibenzoline	B-DRUG
intoxication	O
.	O
We	O
cared	O
for	O
a	O
patient	O
with	O
progressive	O
renal	O
impairment	O
who	O
presented	O
with	O
blurred	B-ADVEFFECT
vision	I-ADVEFFECT
,	O
QRS	B-ADVEFFECT
broadening	I-ADVEFFECT
and	O
cardiac	B-ADVEFFECT
failure	I-ADVEFFECT
due	O
to	O
chronic	O
cibenzoline	B-ADVEFFECT
intoxication	I-ADVEFFECT
.	O
We	O
cared	O
for	O
a	O
patient	O
with	O
progressive	O
renal	O
impairment	O
who	O
presented	O
with	O
blurred	B-ADVEFFECT
vision	I-ADVEFFECT
,	O
QRS	B-ADVEFFECT
broadening	I-ADVEFFECT
and	O
cardiac	B-ADVEFFECT
failure	I-ADVEFFECT
due	O
to	O
chronic	O
cibenzoline	B-ADVEFFECT
intoxication	I-ADVEFFECT
.	O
Indolent	O
aspergillus	B-ADVEFFECT
arthritis	I-ADVEFFECT
complicating	O
fludarabine	B-DRUG
-	O
based	O
non	O
-	O
myeloablative	O
stem	O
cell	O
transplantation	O
.	O
We	O
describe	O
two	O
patients	O
with	O
aspergillus	B-ADVEFFECT
arthritis	I-ADVEFFECT
of	I-ADVEFFECT
the	I-ADVEFFECT
knee	I-ADVEFFECT
joint	I-ADVEFFECT
following	O
fludarabine	B-DRUG
-	O
based	O
non	O
-	O
myeloablative	O
stem	O
cell	O
transplantation	O
.	O
CONCLUSION	O
:	O
The	O
present	O
findings	O
suggest	O
that	O
fluvoxamine	B-DRUG
can	O
cause	O
increased	B-ADVEFFECT
libido	I-ADVEFFECT
in	O
some	O
patients	O
.	O
Increased	B-ADVEFFECT
libido	I-ADVEFFECT
in	O
a	O
woman	O
treated	O
with	O
fluvoxamine	B-DRUG
:	O
a	O
case	O
report	O
.	O
OBJECTIVE	O
:	O
The	O
aim	O
of	O
this	O
paper	O
is	O
to	O
describe	O
a	O
case	O
of	O
increased	B-ADVEFFECT
libido	I-ADVEFFECT
during	O
fluvoxamine	B-DRUG
therapy	O
.	O
RESULTS	O
:	O
The	O
patient	O
,	O
a	O
27-year	O
-	O
old	O
married	O
Japanese	O
woman	O
with	O
borderline	O
personality	O
disorder	O
,	O
developed	O
an	O
increased	B-ADVEFFECT
libido	I-ADVEFFECT
with	O
the	O
administration	O
of	O
fluvoxamine	B-DRUG
.	O
The	O
increased	B-ADVEFFECT
libido	I-ADVEFFECT
disappeared	O
after	O
fluvoxamine	B-DRUG
was	O
discontinued	O
.	O
An	O
infant	O
who	O
developed	O
pancreatitis	B-ADVEFFECT
during	O
meglumine	B-DRUG
antimoniate	I-DRUG
treatment	O
for	O
visceral	O
leishmaniasis	O
and	O
who	O
was	O
successfully	O
treated	O
with	O
a	O
combination	O
of	O
allopurinol	O
and	O
ketoconazole	O
is	O
reported	O
.	O
Successful	O
treatment	O
of	O
visceral	O
leishmaniasis	O
with	O
allopurinol	O
plus	O
ketoconazole	O
in	O
an	O
infant	O
who	O
developed	O
pancreatitis	B-ADVEFFECT
caused	O
by	O
meglumine	B-DRUG
antimoniate	I-DRUG
.	O
CONCLUSIONS	O
:	O
This	O
case	O
report	O
showed	O
that	O
the	O
clinical	O
appearance	O
of	O
Hashimoto	B-ADVEFFECT
's	I-ADVEFFECT
disease	I-ADVEFFECT
after	O
IFN	B-DRUG
-	I-DRUG
alpha	I-DRUG
therapy	O
for	O
chronic	O
C	O
hepatitis	O
in	O
our	O
patient	O
was	O
associated	O
with	O
a	O
specific	O
genetic	O
predisposition	O
(	O
DR5	O
)	O
for	O
this	O
pathology	O
.	O
Further	O
studies	O
are	O
necessary	O
to	O
evaluate	O
whether	O
the	O
study	O
of	O
HLA	O
antigens	O
may	O
be	O
a	O
very	O
useful	O
tool	O
to	O
detect	O
the	O
patients	O
with	O
a	O
predisposition	O
to	O
develop	O
autoimmune	B-ADVEFFECT
thyroiditis	I-ADVEFFECT
,	O
in	O
order	O
to	O
make	O
a	O
early	O
diagnosis	O
of	O
thyroid	B-ADVEFFECT
disorders	I-ADVEFFECT
during	O
the	O
IFN	B-DRUG
-	I-DRUG
alpha	I-DRUG
treatment	O
.	O
Further	O
studies	O
are	O
necessary	O
to	O
evaluate	O
whether	O
the	O
study	O
of	O
HLA	O
antigens	O
may	O
be	O
a	O
very	O
useful	O
tool	O
to	O
detect	O
the	O
patients	O
with	O
a	O
predisposition	O
to	O
develop	O
autoimmune	B-ADVEFFECT
thyroiditis	I-ADVEFFECT
,	O
in	O
order	O
to	O
make	O
a	O
early	O
diagnosis	O
of	O
thyroid	B-ADVEFFECT
disorders	I-ADVEFFECT
during	O
the	O
IFN	B-DRUG
-	I-DRUG
alpha	I-DRUG
treatment	O
.	O
Hashimoto	B-ADVEFFECT
's	I-ADVEFFECT
disease	I-ADVEFFECT
during	O
interferon	B-DRUG
-	I-DRUG
alpha	I-DRUG
therapy	O
in	O
a	O
patient	O
with	O
pre	O
-	O
treatment	O
negative	O
anti	O
-	O
thyroid	O
autoantibodies	O
and	O
with	O
the	O
specific	O
genetic	O
susceptibility	O
to	O
the	O
thyroid	O
disease	O
.	O
OBJECTIVES	O
:	O
The	O
authors	O
described	O
a	O
case	O
of	O
Hashimoto	B-ADVEFFECT
's	I-ADVEFFECT
disease	I-ADVEFFECT
during	O
interferon	B-DRUG
-	I-DRUG
alpha	I-DRUG
(	O
IFN	B-DRUG
-	I-DRUG
alpha	I-DRUG
)	O
treatment	O
for	O
chronic	O
viral	O
C	O
hepatitis	O
in	O
a	O
patient	O
with	O
the	O
specific	O
genetic	O
susceptibility	O
associated	O
with	O
the	O
thyroid	O
disease	O
.	O
OBJECTIVES	O
:	O
The	O
authors	O
described	O
a	O
case	O
of	O
Hashimoto	B-ADVEFFECT
's	I-ADVEFFECT
disease	I-ADVEFFECT
during	O
interferon	B-DRUG
-	I-DRUG
alpha	I-DRUG
(	O
IFN	B-DRUG
-	I-DRUG
alpha	I-DRUG
)	O
treatment	O
for	O
chronic	O
viral	O
C	O
hepatitis	O
in	O
a	O
patient	O
with	O
the	O
specific	O
genetic	O
susceptibility	O
associated	O
with	O
the	O
thyroid	O
disease	O
.	O
During	O
dose	O
-	O
finding	O
studies	O
for	O
intravenous	O
proton	O
pump	O
inhibitors	O
omeprazole	B-DRUG
and	O
pantoprazole	B-DRUG
,	O
three	O
of	O
six	O
young	O
female	O
volunteers	O
receiving	O
omeprazole	B-DRUG
and	O
two	O
young	O
female	O
volunteers	O
receiving	O
pantoprazole	B-DRUG
developed	O
peripheral	B-ADVEFFECT
edema	I-ADVEFFECT
within	O
8	O
hr	O
when	O
high	O
doses	O
of	O
the	O
proton	O
pump	O
inhibitors	O
were	O
applied	O
by	O
continuous	O
infusion	O
together	O
with	O
large	O
volumes	O
of	O
fluid	O
.	O
During	O
dose	O
-	O
finding	O
studies	O
for	O
intravenous	O
proton	O
pump	O
inhibitors	O
omeprazole	B-DRUG
and	O
pantoprazole	B-DRUG
,	O
three	O
of	O
six	O
young	O
female	O
volunteers	O
receiving	O
omeprazole	B-DRUG
and	O
two	O
young	O
female	O
volunteers	O
receiving	O
pantoprazole	B-DRUG
developed	O
peripheral	B-ADVEFFECT
edema	I-ADVEFFECT
within	O
8	O
hr	O
when	O
high	O
doses	O
of	O
the	O
proton	O
pump	O
inhibitors	O
were	O
applied	O
by	O
continuous	O
infusion	O
together	O
with	O
large	O
volumes	O
of	O
fluid	O
.	O
Pheripheral	B-ADVEFFECT
edema	I-ADVEFFECT
was	O
observed	O
in	O
five	O
female	O
patients	O
after	O
taking	O
proton	O
pump	O
inhibitors	O
omeprazole	B-DRUG
,	O
lansoprazole	B-DRUG
,	O
or	O
pantoprazole	B-DRUG
for	O
7	O
-	O
15	O
days	O
for	O
peptic	O
acid	O
diseases	O
in	O
recommended	O
standard	O
doses	O
.	O
Pheripheral	B-ADVEFFECT
edema	I-ADVEFFECT
was	O
observed	O
in	O
five	O
female	O
patients	O
after	O
taking	O
proton	O
pump	O
inhibitors	O
omeprazole	B-DRUG
,	O
lansoprazole	B-DRUG
,	O
or	O
pantoprazole	B-DRUG
for	O
7	O
-	O
15	O
days	O
for	O
peptic	O
acid	O
diseases	O
in	O
recommended	O
standard	O
doses	O
.	O
Pheripheral	B-ADVEFFECT
edema	I-ADVEFFECT
was	O
observed	O
in	O
five	O
female	O
patients	O
after	O
taking	O
proton	O
pump	O
inhibitors	O
omeprazole	B-DRUG
,	O
lansoprazole	B-DRUG
,	O
or	O
pantoprazole	B-DRUG
for	O
7	O
-	O
15	O
days	O
for	O
peptic	O
acid	O
diseases	O
in	O
recommended	O
standard	O
doses	O
.	O
Motor	B-ADVEFFECT
fluctuations	I-ADVEFFECT
appear	O
after	O
2	O
-	O
3	O
years	O
of	O
levodopa	B-DRUG
treatment	O
,	O
and	O
affect	O
at	O
least	O
50	O
%	O
of	O
patients	O
after	O
five	O
years	O
.	O
CONCLUSION	O
:	O
Significant	O
weight	B-ADVEFFECT
loss	I-ADVEFFECT
is	O
a	O
potential	O
adverse	O
event	O
in	O
patients	O
with	O
rheumatoid	O
arthritis	O
treated	O
with	O
leflunomide	B-DRUG
.	O
Leflunomide	B-DRUG
-	O
associated	O
weight	B-ADVEFFECT
loss	I-ADVEFFECT
in	O
rheumatoid	O
arthritis	O
.	O
METHODS	O
:	O
We	O
queried	O
35	O
rheumatologists	O
at	O
the	O
Robert	O
Breck	O
Brigham	O
Arthritis	O
Center	O
to	O
determine	O
if	O
weight	B-ADVEFFECT
loss	I-ADVEFFECT
had	O
occurred	O
as	O
an	O
adverse	O
event	O
in	O
patients	O
treated	O
with	O
leflunomide	B-DRUG
between	O
November	O
1998	O
and	O
January	O
2000	O
.	O
OBJECTIVE	O
:	O
To	O
determine	O
the	O
frequency	O
of	O
weight	B-ADVEFFECT
loss	I-ADVEFFECT
in	O
patients	O
treated	O
with	O
leflunomide	B-DRUG
for	O
rheumatoid	O
arthritis	O
at	O
an	O
arthritis	O
referral	O
center	O
.	O
RESULTS	O
:	O
Five	O
of	O
70	O
patients	O
who	O
had	O
begun	O
leflunomide	B-DRUG
therapy	O
had	O
significant	O
weight	B-ADVEFFECT
loss	I-ADVEFFECT
that	O
could	O
not	O
be	O
linked	O
to	O
other	O
identifiable	O
etiologies	O
.	O
It	O
is	O
increasingly	O
recognized	O
that	O
dose	O
adjustment	O
of	O
oral	O
valacyclovir	B-DRUG
in	O
renal	O
failure	O
is	O
necessary	O
to	O
avoid	O
neurotoxicity	B-ADVEFFECT
.	O
Neurotoxicity	B-ADVEFFECT
of	O
valacyclovir	B-DRUG
in	O
peritoneal	O
dialysis	O
:	O
a	O
pharmacokinetic	O
study	O
.	O
She	O
developed	O
neurotoxicity	B-ADVEFFECT
with	O
an	O
adjustment	O
dosage	O
of	O
valacyclovir	B-DRUG
for	O
a	O
cutaneous	O
zoster	O
infection	O
.	O
Avascular	B-ADVEFFECT
necrosis	I-ADVEFFECT
of	I-ADVEFFECT
the	I-ADVEFFECT
femoral	I-ADVEFFECT
head	I-ADVEFFECT
in	O
patients	O
with	O
prostate	O
cancer	O
treated	O
with	O
cyproterone	B-DRUG
acetate	I-DRUG
and	O
radiotherapy	O
.	O
We	O
report	O
the	O
case	O
histories	O
of	O
two	O
patients	O
with	O
histologically	O
confirmed	O
adenocarcinoma	O
of	O
the	O
prostate	O
,	O
both	O
of	O
whom	O
had	O
been	O
treated	O
with	O
steroidal	O
anti	O
-	O
androgen	O
therapy	O
in	O
the	O
form	O
of	O
cyproterone	B-DRUG
acetate	I-DRUG
prior	O
to	O
radical	O
or	O
palliative	O
pelvic	O
irradiation	O
,	O
and	O
who	O
subsequently	O
developed	O
femoral	B-ADVEFFECT
head	I-ADVEFFECT
avascular	I-ADVEFFECT
necrosis	I-ADVEFFECT
.	O
Levofloxacin	B-DRUG
induced	O
polymorphic	B-ADVEFFECT
ventricular	I-ADVEFFECT
tachycardia	I-ADVEFFECT
with	O
normal	O
QT	O
interval	O
.	O
We	O
report	O
the	O
first	O
case	O
of	O
polymorphic	B-ADVEFFECT
ventricular	I-ADVEFFECT
tachycardia	I-ADVEFFECT
with	O
normal	O
QT	O
interval	O
associated	O
with	O
the	O
oral	O
use	O
of	O
levofloxacin	B-DRUG
in	O
the	O
absence	O
of	O
other	O
etiologies	O
known	O
to	O
cause	O
these	O
arrhythmias	O
.	O
So	O
far	O
,	O
few	O
cases	O
of	O
pulmonary	B-ADVEFFECT
side	I-ADVEFFECT
effects	I-ADVEFFECT
caused	O
by	O
ticlopidine	B-DRUG
have	O
been	O
reported	O
.	O
Special	O
care	O
should	O
be	O
taken	O
when	O
pulmonary	B-ADVEFFECT
symptoms	I-ADVEFFECT
appear	O
in	O
association	O
with	O
ticlopidine	B-DRUG
treatment	O
.	O
Ticlopidine	B-DRUG
-	O
induced	O
interstitial	B-ADVEFFECT
pulmonary	I-ADVEFFECT
disease	I-ADVEFFECT
:	O
a	O
case	O
report	O
.	O
We	O
report	O
a	O
case	O
of	O
interstitial	B-ADVEFFECT
pulmonary	I-ADVEFFECT
disease	I-ADVEFFECT
that	O
occurred	O
together	O
with	O
lymphocytic	B-ADVEFFECT
colitis	I-ADVEFFECT
during	O
treatment	O
with	O
ticlopidine	B-DRUG
.	O
We	O
report	O
a	O
case	O
of	O
interstitial	B-ADVEFFECT
pulmonary	I-ADVEFFECT
disease	I-ADVEFFECT
that	O
occurred	O
together	O
with	O
lymphocytic	B-ADVEFFECT
colitis	I-ADVEFFECT
during	O
treatment	O
with	O
ticlopidine	B-DRUG
.	O
A	O
patient	O
that	O
received	O
methadone	B-DRUG
for	O
cancer	O
-	O
associated	O
pain	O
developed	O
myoclonus	B-ADVEFFECT
as	O
a	O
side	O
effect	O
.	O
Methadone	B-DRUG
-	O
induced	O
myoclonus	B-ADVEFFECT
in	O
advanced	O
cancer	O
.	O
OBJECTIVE	O
:	O
To	O
report	O
a	O
case	O
of	O
fatal	B-ADVEFFECT
hyperkalemia	I-ADVEFFECT
owing	O
to	O
succinylcholine	B-DRUG
administration	O
in	O
a	O
patient	O
with	O
mucositis	O
secondary	O
to	O
chemotherapy	O
.	O
Succinylcholine	B-DRUG
-	O
induced	O
hyperkalemia	B-ADVEFFECT
in	O
a	O
patient	O
with	O
mucositis	O
secondary	O
to	O
chemotherapy	O
.	O
We	O
believe	O
that	O
mucositis	O
was	O
a	O
contributing	O
factor	O
to	O
this	O
case	O
of	O
fatal	B-ADVEFFECT
hyperkalemia	I-ADVEFFECT
after	O
administration	O
of	O
succinylcholine	B-DRUG
,	O
with	O
a	O
mechanism	O
similar	O
to	O
that	O
reported	O
with	O
thermal	O
injury	O
.	O
Cutaneous	B-ADVEFFECT
seeding	I-ADVEFFECT
after	O
ultrasound	O
-	O
guided	O
percutaneous	O
ethanol	B-DRUG
injection	I-DRUG
for	O
treatment	O
of	O
hepatocellular	O
carcinoma	O
.	O
We	O
describe	O
a	O
case	O
of	O
needle	O
-	O
track	O
cutaneous	B-ADVEFFECT
seeding	I-ADVEFFECT
of	O
hepatocellular	O
carcinoma	O
(	O
HCC	O
)	O
after	O
sonographically	O
guided	O
percutaneous	O
ethanol	B-DRUG
injection	I-DRUG
(	O
PEI	O
)	O
.	O
Adenosine	B-DRUG
-	O
induced	O
ventricular	B-ADVEFFECT
fibrillation	I-ADVEFFECT
.	O
However	O
,	O
adenosine	B-DRUG
shortens	O
the	O
antegrade	O
refractoriness	O
of	O
accessory	O
atrioventricular	O
connections	O
and	O
may	O
cause	O
acceleration	B-ADVEFFECT
of	I-ADVEFFECT
the	I-ADVEFFECT
ventricular	I-ADVEFFECT
rate	I-ADVEFFECT
during	O
atrial	O
fibrillation	O
.	O
We	O
observed	O
ventricular	B-ADVEFFECT
fibrillation	I-ADVEFFECT
in	O
2	O
patients	O
who	O
presented	O
to	O
the	O
emergency	O
department	O
with	O
pre	O
-	O
excited	O
atrial	O
fibrillation	O
and	O
were	O
given	O
12	O
mg	O
of	O
adenosine	B-DRUG
.	O
After	O
the	O
dose	O
of	O
methylprednisolone	B-DRUG
was	O
reduced	O
from	O
40	O
mg	O
to	O
20	O
mg	O
i.v	O
.	O
q6h	O
and	O
shifted	O
to	O
other	O
anti	O
-	O
asthma	O
treatment	O
by	O
procaterol	O
metered	O
dose	O
inhaler	O
via	O
spacer	O
,	O
the	O
psychotic	B-ADVEFFECT
reaction	I-ADVEFFECT
disappeared	O
a	O
few	O
hours	O
later	O
.	O
Continuous	O
EEG	O
monitoring	O
is	O
helpful	O
in	O
managing	O
seizures	B-ADVEFFECT
that	O
occur	O
as	O
a	O
complication	O
of	O
CBZ	B-DRUG
OD	O
,	O
after	O
the	O
course	O
of	O
recovery	O
or	O
worsening	O
,	O
and	O
in	O
providing	O
assistance	O
with	O
prognosis	O
.	O
Massive	O
CBZ	B-DRUG
OD	O
may	O
produce	O
a	O
reversible	B-ADVEFFECT
encephalopathy	I-ADVEFFECT
that	O
includes	O
cortical	B-ADVEFFECT
hyperexcitability	I-ADVEFFECT
,	O
a	O
profound	B-ADVEFFECT
burst	I-ADVEFFECT
-	I-ADVEFFECT
suppression	I-ADVEFFECT
EEG	I-ADVEFFECT
pattern	I-ADVEFFECT
,	O
and	O
cranial	B-ADVEFFECT
nerve	I-ADVEFFECT
areflexia	I-ADVEFFECT
.	O
Massive	O
CBZ	B-DRUG
OD	O
may	O
produce	O
a	O
reversible	B-ADVEFFECT
encephalopathy	I-ADVEFFECT
that	O
includes	O
cortical	B-ADVEFFECT
hyperexcitability	I-ADVEFFECT
,	O
a	O
profound	B-ADVEFFECT
burst	I-ADVEFFECT
-	I-ADVEFFECT
suppression	I-ADVEFFECT
EEG	I-ADVEFFECT
pattern	I-ADVEFFECT
,	O
and	O
cranial	B-ADVEFFECT
nerve	I-ADVEFFECT
areflexia	I-ADVEFFECT
.	O
Massive	O
CBZ	B-DRUG
OD	O
may	O
produce	O
a	O
reversible	B-ADVEFFECT
encephalopathy	I-ADVEFFECT
that	O
includes	O
cortical	B-ADVEFFECT
hyperexcitability	I-ADVEFFECT
,	O
a	O
profound	B-ADVEFFECT
burst	I-ADVEFFECT
-	I-ADVEFFECT
suppression	I-ADVEFFECT
EEG	I-ADVEFFECT
pattern	I-ADVEFFECT
,	O
and	O
cranial	B-ADVEFFECT
nerve	I-ADVEFFECT
areflexia	I-ADVEFFECT
.	O
Massive	O
CBZ	B-DRUG
OD	O
may	O
produce	O
a	O
reversible	B-ADVEFFECT
encephalopathy	I-ADVEFFECT
that	O
includes	O
cortical	B-ADVEFFECT
hyperexcitability	I-ADVEFFECT
,	O
a	O
profound	B-ADVEFFECT
burst	I-ADVEFFECT
-	I-ADVEFFECT
suppression	I-ADVEFFECT
EEG	I-ADVEFFECT
pattern	I-ADVEFFECT
,	O
and	O
cranial	B-ADVEFFECT
nerve	I-ADVEFFECT
areflexia	I-ADVEFFECT
.	O
Massive	B-ADVEFFECT
plasmocytosis	I-ADVEFFECT
due	O
to	O
methimazole	B-DRUG
-	O
induced	O
bone	B-ADVEFFECT
marrow	I-ADVEFFECT
toxicity	I-ADVEFFECT
.	O
Massive	B-ADVEFFECT
plasmocytosis	I-ADVEFFECT
due	O
to	O
methimazole	B-DRUG
-	O
induced	O
bone	B-ADVEFFECT
marrow	I-ADVEFFECT
toxicity	I-ADVEFFECT
.	O
To	O
our	O
knowledge	O
this	O
is	O
the	O
first	O
report	O
of	O
pancytopenia	B-ADVEFFECT
due	O
to	O
MMI	B-DRUG
,	O
where	O
the	O
usual	O
hypoplasia	O
found	O
is	O
replaced	O
by	O
massive	B-ADVEFFECT
plasmocytosis	I-ADVEFFECT
.	O
To	O
our	O
knowledge	O
this	O
is	O
the	O
first	O
report	O
of	O
pancytopenia	B-ADVEFFECT
due	O
to	O
MMI	B-DRUG
,	O
where	O
the	O
usual	O
hypoplasia	O
found	O
is	O
replaced	O
by	O
massive	B-ADVEFFECT
plasmocytosis	I-ADVEFFECT
.	O
We	O
report	O
a	O
case	O
of	O
fulminant	B-ADVEFFECT
hepatic	I-ADVEFFECT
failure	I-ADVEFFECT
associated	O
with	O
didanosine	B-DRUG
and	O
masquerading	O
as	O
a	O
surgical	O
abdomen	O
and	O
compare	O
the	O
clinical	O
,	O
biologic	O
,	O
histologic	O
,	O
and	O
ultrastructural	O
findings	O
with	O
reports	O
described	O
previously	O
.	O
This	O
report	O
details	O
a	O
case	O
of	O
bilateral	B-ADVEFFECT
avascular	I-ADVEFFECT
necrosis	I-ADVEFFECT
of	I-ADVEFFECT
the	I-ADVEFFECT
femoral	I-ADVEFFECT
heads	I-ADVEFFECT
in	O
a	O
patient	O
receiving	O
'	O
standard	O
'	O
doses	O
of	O
dexamethasone	B-DRUG
as	O
part	O
of	O
the	O
antiemetic	O
regimen	O
used	O
in	O
cisplatin	O
-	O
based	O
combination	O
chemotherapy	O
.	O
Although	O
no	O
coagulation	O
study	O
was	O
done	O
and	O
the	O
Meckel	O
's	O
diverticulum	O
is	O
normally	O
associated	O
with	O
bleeding	O
,	O
the	O
particular	O
intensity	O
of	O
the	O
following	O
hemorrhage	B-ADVEFFECT
may	O
have	O
been	O
favored	O
by	O
metformin	B-DRUG
.	O
An	O
obese	O
patient	O
,	O
not	O
diabetic	O
,	O
treated	O
with	O
metformin	B-DRUG
for	O
some	O
weeks	O
,	O
was	O
referred	O
to	O
us	O
with	O
severe	B-ADVEFFECT
inferior	I-ADVEFFECT
digestive	I-ADVEFFECT
hemorrhage	I-ADVEFFECT
,	O
diagnosed	O
with	O
Meckel	O
's	O
diverticulum	O
.	O
Digestive	B-ADVEFFECT
hemorrhage	I-ADVEFFECT
caused	O
by	O
a	O
Meckel	O
's	O
diverticulum	O
in	O
a	O
metformin	B-DRUG
-	O
treated	O
patient	O
:	O
is	O
there	O
any	O
connection	O
?	O
.	O
Ulcer	B-ADVEFFECT
became	I-ADVEFFECT
worse	I-ADVEFFECT
after	O
tobramycin	B-DRUG
and	O
gentamycin	B-DRUG
treatment	O
for	O
2	O
days	O
.	O
Ulcer	B-ADVEFFECT
became	I-ADVEFFECT
worse	I-ADVEFFECT
after	O
tobramycin	B-DRUG
and	O
gentamycin	B-DRUG
treatment	O
for	O
2	O
days	O
.	O
Possible	O
linkage	O
of	O
amprenavir	B-DRUG
with	O
intracranial	B-ADVEFFECT
bleeding	I-ADVEFFECT
in	O
an	O
HIV	O
-	O
infected	O
hemophiliac	O
.	O
The	O
bleeding	B-ADVEFFECT
resolved	O
on	O
discontinuation	O
of	O
APV	B-DRUG
.	O
We	O
report	O
the	O
occurrence	O
of	O
spontaneous	O
intracranial	B-ADVEFFECT
bleeding	I-ADVEFFECT
in	O
an	O
human	O
immunodeficiency	O
virus	O
(	O
HIV)-infected	O
adolescent	O
with	O
hemophilia	O
A	O
who	O
was	O
receiving	O
amprenavir	B-DRUG
(	O
APV	B-DRUG
)	O
.	O
According	O
to	O
the	O
Naranjo	O
probability	O
scale	O
,	O
the	O
relationship	O
of	O
gemcitabine	B-DRUG
treatment	O
with	O
cutaneous	B-ADVEFFECT
eruption	I-ADVEFFECT
in	O
our	O
patient	O
is	O
possible	O
.	O
CONCLUSIONS	O
:	O
We	O
report	O
the	O
first	O
case	O
of	O
gemcitabine	O
-	O
induced	O
LABD	B-ADVEFFECT
.	O
Linear	B-ADVEFFECT
immunoglobulin	I-ADVEFFECT
A	I-ADVEFFECT
bullous	I-ADVEFFECT
dermatosis	I-ADVEFFECT
induced	O
by	O
gemcitabine	B-DRUG
.	O
OBJECTIVE	O
:	O
To	O
report	O
a	O
case	O
of	O
linear	B-ADVEFFECT
immunoglobulin	I-ADVEFFECT
(	I-ADVEFFECT
Ig	I-ADVEFFECT
)	I-ADVEFFECT
A	I-ADVEFFECT
bullous	I-ADVEFFECT
dermatosis	I-ADVEFFECT
(	O
LABD	B-ADVEFFECT
)	O
induced	O
by	O
gemcitabine	B-DRUG
.	O
OBJECTIVE	O
:	O
To	O
report	O
a	O
case	O
of	O
linear	B-ADVEFFECT
immunoglobulin	I-ADVEFFECT
(	I-ADVEFFECT
Ig	I-ADVEFFECT
)	I-ADVEFFECT
A	I-ADVEFFECT
bullous	I-ADVEFFECT
dermatosis	I-ADVEFFECT
(	O
LABD	B-ADVEFFECT
)	O
induced	O
by	O
gemcitabine	B-DRUG
.	O
Twenty	O
-	O
four	O
hours	O
after	O
the	O
administration	O
of	O
gemcitabine	B-DRUG
,	O
a	O
symmetric	B-ADVEFFECT
,	I-ADVEFFECT
bullous	I-ADVEFFECT
,	I-ADVEFFECT
herpetiform	I-ADVEFFECT
eruption	I-ADVEFFECT
appeared	O
on	O
his	O
trunk	O
and	O
upper	O
limbs	O
.	O
Vancomycin	B-DRUG
is	O
the	O
most	O
frequently	O
implicated	O
drug	O
,	O
but	O
other	O
agents	O
have	O
been	O
reported	O
to	O
cause	O
LABD	B-ADVEFFECT
.	O
Although	O
taxol	B-DRUG
has	O
shown	O
significant	O
activity	O
in	O
advanced	O
ovarian	O
cancer	O
,	O
peripheral	B-ADVEFFECT
neuropathy	I-ADVEFFECT
is	O
likely	O
to	O
become	O
the	O
major	O
dose	O
-	O
limiting	O
toxicity	O
.	O
A	O
rare	O
case	O
of	O
advanced	O
ovarian	O
carcinoma	O
who	O
developed	O
difficulty	B-ADVEFFECT
walking	I-ADVEFFECT
25	O
days	O
after	O
treatment	O
with	O
weekly	O
paclitaxel	B-DRUG
.	O
We	O
describe	O
a	O
case	O
of	O
advanced	O
ovarian	O
carcinoma	O
who	O
developed	O
difficulty	B-ADVEFFECT
walking	I-ADVEFFECT
because	O
of	O
marked	B-ADVEFFECT
pain	I-ADVEFFECT
in	O
the	O
lower	O
extremities	O
and	O
loss	B-ADVEFFECT
of	I-ADVEFFECT
proprioception	I-ADVEFFECT
25	O
days	O
after	O
treatment	O
with	O
weekly	O
taxol	B-DRUG
(	O
80	O
mg	O
/	O
m(2)x3	O
)	O
.	O
We	O
describe	O
a	O
case	O
of	O
advanced	O
ovarian	O
carcinoma	O
who	O
developed	O
difficulty	B-ADVEFFECT
walking	I-ADVEFFECT
because	O
of	O
marked	B-ADVEFFECT
pain	I-ADVEFFECT
in	O
the	O
lower	O
extremities	O
and	O
loss	B-ADVEFFECT
of	I-ADVEFFECT
proprioception	I-ADVEFFECT
25	O
days	O
after	O
treatment	O
with	O
weekly	O
taxol	B-DRUG
(	O
80	O
mg	O
/	O
m(2)x3	O
)	O
.	O
We	O
describe	O
a	O
case	O
of	O
advanced	O
ovarian	O
carcinoma	O
who	O
developed	O
difficulty	B-ADVEFFECT
walking	I-ADVEFFECT
because	O
of	O
marked	B-ADVEFFECT
pain	I-ADVEFFECT
in	O
the	O
lower	O
extremities	O
and	O
loss	B-ADVEFFECT
of	I-ADVEFFECT
proprioception	I-ADVEFFECT
25	O
days	O
after	O
treatment	O
with	O
weekly	O
taxol	B-DRUG
(	O
80	O
mg	O
/	O
m(2)x3	O
)	O
.	O
Relief	O
by	O
naloxone	O
of	O
morphine	B-DRUG
-	O
induced	O
spasm	B-ADVEFFECT
of	O
the	O
sphincter	O
of	O
Oddi	O
in	O
a	O
post	O
-	O
cholecystectomy	O
patient	O
.	O
We	O
present	O
the	O
case	O
of	O
a	O
patient	O
who	O
had	O
undergone	O
cholecystectomy	O
previously	O
,	O
but	O
in	O
whom	O
morphine	B-DRUG
given	O
in	O
the	O
Emergency	O
Department	O
precipitated	O
pain	O
consistent	O
with	O
biliary	B-ADVEFFECT
colic	I-ADVEFFECT
;	O
the	O
pain	B-ADVEFFECT
resolved	O
promptly	O
after	O
administration	O
of	O
naloxone	O
.	O
We	O
present	O
the	O
case	O
of	O
a	O
patient	O
who	O
had	O
undergone	O
cholecystectomy	O
previously	O
,	O
but	O
in	O
whom	O
morphine	B-DRUG
given	O
in	O
the	O
Emergency	O
Department	O
precipitated	O
pain	O
consistent	O
with	O
biliary	B-ADVEFFECT
colic	I-ADVEFFECT
;	O
the	O
pain	B-ADVEFFECT
resolved	O
promptly	O
after	O
administration	O
of	O
naloxone	O
.	O
Myasthenia	B-ADVEFFECT
gravis	I-ADVEFFECT
during	O
low	O
-	O
dose	O
IFN	B-DRUG
-	I-DRUG
alpha	I-DRUG
therapy	O
for	O
chronic	O
hepatitis	O
C	O
.	O
A	O
patient	O
with	O
rheumatoid	O
arthritis	O
developed	O
an	O
acute	O
intrahepatic	B-ADVEFFECT
cholestasis	I-ADVEFFECT
after	O
100	O
mg	O
of	O
sodium	B-DRUG
aurothiomalate	I-DRUG
.	O
Acute	B-ADVEFFECT
lung	I-ADVEFFECT
injury	I-ADVEFFECT
associated	O
with	O
5-fluorouracil	B-DRUG
and	O
oxaliplatinum	B-DRUG
combined	O
chemotherapy	O
.	O
Acute	B-ADVEFFECT
lung	I-ADVEFFECT
injury	I-ADVEFFECT
associated	O
with	O
5-fluorouracil	B-DRUG
and	O
oxaliplatinum	B-DRUG
combined	O
chemotherapy	O
.	O
Diarrhoea	B-ADVEFFECT
,	O
T	B-ADVEFFECT
-	I-ADVEFFECT
CD4	I-ADVEFFECT
+	I-ADVEFFECT
lymphopenia	I-ADVEFFECT
and	O
bilateral	B-ADVEFFECT
patchy	I-ADVEFFECT
pulmonary	I-ADVEFFECT
infiltrates	I-ADVEFFECT
developed	O
in	O
a	O
male	O
60	O
yrs	O
of	O
age	O
,	O
who	O
was	O
treated	O
with	O
oxaliplatinum	B-DRUG
and	O
5-fluorouracil	B-DRUG
for	O
unresectable	O
rectum	O
carcinoma	O
.	O
Diarrhoea	B-ADVEFFECT
,	O
T	B-ADVEFFECT
-	I-ADVEFFECT
CD4	I-ADVEFFECT
+	I-ADVEFFECT
lymphopenia	I-ADVEFFECT
and	O
bilateral	B-ADVEFFECT
patchy	I-ADVEFFECT
pulmonary	I-ADVEFFECT
infiltrates	I-ADVEFFECT
developed	O
in	O
a	O
male	O
60	O
yrs	O
of	O
age	O
,	O
who	O
was	O
treated	O
with	O
oxaliplatinum	B-DRUG
and	O
5-fluorouracil	B-DRUG
for	O
unresectable	O
rectum	O
carcinoma	O
.	O
Diarrhoea	B-ADVEFFECT
,	O
T	B-ADVEFFECT
-	I-ADVEFFECT
CD4	I-ADVEFFECT
+	I-ADVEFFECT
lymphopenia	I-ADVEFFECT
and	O
bilateral	B-ADVEFFECT
patchy	I-ADVEFFECT
pulmonary	I-ADVEFFECT
infiltrates	I-ADVEFFECT
developed	O
in	O
a	O
male	O
60	O
yrs	O
of	O
age	O
,	O
who	O
was	O
treated	O
with	O
oxaliplatinum	B-DRUG
and	O
5-fluorouracil	B-DRUG
for	O
unresectable	O
rectum	O
carcinoma	O
.	O
Diarrhoea	B-ADVEFFECT
,	O
T	B-ADVEFFECT
-	I-ADVEFFECT
CD4	I-ADVEFFECT
+	I-ADVEFFECT
lymphopenia	I-ADVEFFECT
and	O
bilateral	B-ADVEFFECT
patchy	I-ADVEFFECT
pulmonary	I-ADVEFFECT
infiltrates	I-ADVEFFECT
developed	O
in	O
a	O
male	O
60	O
yrs	O
of	O
age	O
,	O
who	O
was	O
treated	O
with	O
oxaliplatinum	B-DRUG
and	O
5-fluorouracil	B-DRUG
for	O
unresectable	O
rectum	O
carcinoma	O
.	O
Diarrhoea	B-ADVEFFECT
,	O
T	B-ADVEFFECT
-	I-ADVEFFECT
CD4	I-ADVEFFECT
+	I-ADVEFFECT
lymphopenia	I-ADVEFFECT
and	O
bilateral	B-ADVEFFECT
patchy	I-ADVEFFECT
pulmonary	I-ADVEFFECT
infiltrates	I-ADVEFFECT
developed	O
in	O
a	O
male	O
60	O
yrs	O
of	O
age	O
,	O
who	O
was	O
treated	O
with	O
oxaliplatinum	B-DRUG
and	O
5-fluorouracil	B-DRUG
for	O
unresectable	O
rectum	O
carcinoma	O
.	O
Diarrhoea	B-ADVEFFECT
,	O
T	B-ADVEFFECT
-	I-ADVEFFECT
CD4	I-ADVEFFECT
+	I-ADVEFFECT
lymphopenia	I-ADVEFFECT
and	O
bilateral	B-ADVEFFECT
patchy	I-ADVEFFECT
pulmonary	I-ADVEFFECT
infiltrates	I-ADVEFFECT
developed	O
in	O
a	O
male	O
60	O
yrs	O
of	O
age	O
,	O
who	O
was	O
treated	O
with	O
oxaliplatinum	B-DRUG
and	O
5-fluorouracil	B-DRUG
for	O
unresectable	O
rectum	O
carcinoma	O
.	O
It	O
is	O
concluded	O
that	O
the	O
aforementioned	O
pathological	O
manifestations	O
were	O
due	O
to	O
chemotherapy	O
and	O
included	O
a	O
pulmonary	B-ADVEFFECT
adverse	I-ADVEFFECT
reaction	I-ADVEFFECT
,	O
a	O
feature	O
never	O
previously	O
associated	O
with	O
oxaliplatinum	B-DRUG
and	O
5-fluorouracil	B-DRUG
regimens	O
.	O
It	O
is	O
concluded	O
that	O
the	O
aforementioned	O
pathological	O
manifestations	O
were	O
due	O
to	O
chemotherapy	O
and	O
included	O
a	O
pulmonary	B-ADVEFFECT
adverse	I-ADVEFFECT
reaction	I-ADVEFFECT
,	O
a	O
feature	O
never	O
previously	O
associated	O
with	O
oxaliplatinum	B-DRUG
and	O
5-fluorouracil	B-DRUG
regimens	O
.	O
BACKGROUND	O
:	O
Accutane	B-DRUG
a	O
teratogenic	B-ADVEFFECT
prescription	O
drug	O
licensed	O
to	O
treat	O
severe	O
,	O
recalcitrant	O
nodular	O
acne	O
.	O
RESULTS	O
:	O
The	O
estimated	O
number	O
of	O
Accutane	B-DRUG
prescriptions	O
for	O
reproductive	O
-	O
aged	O
women	O
has	O
more	O
than	O
doubled	O
in	O
the	O
past	O
10	O
years	O
;	O
it	O
is	O
the	O
most	O
widely	O
used	O
teratogenic	B-ADVEFFECT
drug	O
in	O
the	O
United	O
States	O
,	O
with	O
approximately	O
2.5	O
per	O
1,000	O
reproductive	O
-	O
aged	O
women	O
exposed	O
to	O
Accutane	O
in	O
1999	O
.	O
A	O
62-year	O
-	O
old	O
woman	O
treated	O
with	O
pranlukast	B-DRUG
for	O
2	O
months	O
developed	O
interstitial	B-ADVEFFECT
pneumonitis	I-ADVEFFECT
with	O
a	O
high	B-ADVEFFECT
fever	I-ADVEFFECT
.	O
A	O
62-year	O
-	O
old	O
woman	O
treated	O
with	O
pranlukast	B-DRUG
for	O
2	O
months	O
developed	O
interstitial	B-ADVEFFECT
pneumonitis	I-ADVEFFECT
with	O
a	O
high	B-ADVEFFECT
fever	I-ADVEFFECT
.	O
Acute	O
interstitial	B-ADVEFFECT
pneumonia	I-ADVEFFECT
induced	O
by	O
ONO-1078	B-DRUG
(	O
pranlukast	B-DRUG
)	O
,	O
a	O
leukotriene	O
receptor	O
antagonist	O
.	O
Acute	O
interstitial	B-ADVEFFECT
pneumonia	I-ADVEFFECT
induced	O
by	O
ONO-1078	B-DRUG
(	O
pranlukast	B-DRUG
)	O
,	O
a	O
leukotriene	O
receptor	O
antagonist	O
.	O
An	O
asymptomatic	O
HIV	O
-	O
infected	O
woman	O
experienced	O
right	O
-	O
sided	O
renal	B-ADVEFFECT
colicky	I-ADVEFFECT
pain	I-ADVEFFECT
during	O
treatment	O
with	O
indinavir	B-DRUG
.	O
Indinavir	B-DRUG
-	O
associated	O
nephrolithiasis	B-ADVEFFECT
and	O
chronic	O
interstitial	B-ADVEFFECT
nephritis	I-ADVEFFECT
were	O
the	O
only	O
possible	O
causes	O
identified	O
in	O
this	O
patient	O
.	O
Indinavir	B-DRUG
-	O
associated	O
nephrolithiasis	B-ADVEFFECT
and	O
chronic	O
interstitial	B-ADVEFFECT
nephritis	I-ADVEFFECT
were	O
the	O
only	O
possible	O
causes	O
identified	O
in	O
this	O
patient	O
.	O
Papillary	B-ADVEFFECT
necrosis	I-ADVEFFECT
associated	O
with	O
the	O
HIV	O
protease	O
inhibitor	O
indinavir	B-DRUG
.	O
Physicians	O
should	O
be	O
aware	O
that	O
indinavir	B-DRUG
nephrolithiasis	B-ADVEFFECT
may	O
cause	O
papillary	B-ADVEFFECT
necrosis	I-ADVEFFECT
.	O
Physicians	O
should	O
be	O
aware	O
that	O
indinavir	B-DRUG
nephrolithiasis	B-ADVEFFECT
may	O
cause	O
papillary	B-ADVEFFECT
necrosis	I-ADVEFFECT
.	O
The	O
HIV	O
protease	O
inhibitor	O
indinavir	B-DRUG
may	O
cause	O
nephrolithiasis	B-ADVEFFECT
and	O
interstitial	B-ADVEFFECT
nephritis	I-ADVEFFECT
.	O
The	O
HIV	O
protease	O
inhibitor	O
indinavir	B-DRUG
may	O
cause	O
nephrolithiasis	B-ADVEFFECT
and	O
interstitial	B-ADVEFFECT
nephritis	I-ADVEFFECT
.	O
The	O
renal	O
consequences	O
of	O
indinavir	B-DRUG
-	O
associated	O
nephrotoxicity	B-ADVEFFECT
are	O
uncertain	O
.	O
We	O
report	O
a	O
case	O
of	O
papillary	B-ADVEFFECT
necrosis	I-ADVEFFECT
in	O
a	O
patient	O
treated	O
with	O
indinavir	B-DRUG
.	O
We	O
describe	O
2	O
male	O
patients	O
,	O
a	O
49-year	O
-	O
old	O
with	O
psoriatic	O
arthritis	O
and	O
impaired	O
renal	O
function	O
and	O
a	O
43-year	O
-	O
old	O
renal	O
transplant	O
recipient	O
,	O
who	O
both	O
sustained	O
a	O
marked	O
decline	B-ADVEFFECT
in	I-ADVEFFECT
glomerular	I-ADVEFFECT
filtration	I-ADVEFFECT
rate	I-ADVEFFECT
in	O
conjunction	O
with	O
a	O
selective	O
inhibitor	O
of	O
cyclooxygenase-2	O
(	O
COX-2	O
)	O
,	O
rofecoxib	B-DRUG
.	O
CONCLUSIONS	O
:	O
LTG	B-DRUG
overdose	O
may	O
result	O
in	O
a	O
severe	O
but	O
reversible	O
encephalopathy	B-ADVEFFECT
,	O
a	O
previously	O
undescribed	O
phenomenon	O
.	O
Evaluation	O
revealed	O
elevated	B-ADVEFFECT
serum	I-ADVEFFECT
LTG	I-ADVEFFECT
levels	I-ADVEFFECT
and	O
no	O
other	O
etiology	O
for	O
encephalopathy	B-ADVEFFECT
.	O
METHODS	O
:	O
A	O
55-year	O
-	O
old	O
woman	O
became	O
stuporous	B-ADVEFFECT
after	O
overdose	O
with	O
lamotrigine	B-DRUG
(	O
LTG	B-DRUG
)	O
and	O
valproic	B-DRUG
acid	I-DRUG
(	O
VPA	B-DRUG
)	O
tablets	O
.	O
METHODS	O
:	O
A	O
55-year	O
-	O
old	O
woman	O
became	O
stuporous	B-ADVEFFECT
after	O
overdose	O
with	O
lamotrigine	B-DRUG
(	O
LTG	B-DRUG
)	O
and	O
valproic	B-DRUG
acid	I-DRUG
(	O
VPA	B-DRUG
)	O
tablets	O
.	O
METHODS	O
:	O
A	O
55-year	O
-	O
old	O
woman	O
became	O
stuporous	B-ADVEFFECT
after	O
overdose	O
with	O
lamotrigine	B-DRUG
(	O
LTG	B-DRUG
)	O
and	O
valproic	B-DRUG
acid	I-DRUG
(	O
VPA	B-DRUG
)	O
tablets	O
.	O
METHODS	O
:	O
A	O
55-year	O
-	O
old	O
woman	O
became	O
stuporous	B-ADVEFFECT
after	O
overdose	O
with	O
lamotrigine	B-DRUG
(	O
LTG	B-DRUG
)	O
and	O
valproic	B-DRUG
acid	I-DRUG
(	O
VPA	B-DRUG
)	O
tablets	O
.	O
PURPOSE	O
:	O
To	O
report	O
that	O
acute	O
lamotrigine	B-DRUG
poisoning	O
may	O
result	O
in	O
severe	O
encephalopathy	B-ADVEFFECT
.	O
Stupor	B-ADVEFFECT
from	O
lamotrigine	B-DRUG
toxicity	O
.	O
The	O
cause	O
of	O
death	O
was	O
determined	O
to	O
be	O
acute	B-ADVEFFECT
intoxication	I-ADVEFFECT
by	O
olanzapine	B-DRUG
,	O
and	O
the	O
manner	O
of	O
death	O
was	O
accidental	O
.	O
This	O
article	O
describes	O
the	O
case	O
of	O
a	O
25-year	O
-	O
old	O
man	O
found	O
dead	B-ADVEFFECT
at	O
home	O
who	O
had	O
been	O
prescribed	O
olanzapine	B-DRUG
for	O
schizophrenia	O
.	O
Lichenoid	B-ADVEFFECT
drug	I-ADVEFFECT
eruption	I-ADVEFFECT
to	O
salsalate	B-DRUG
.	O
This	O
eruption	B-ADVEFFECT
emerged	O
after	O
1	O
month	O
of	O
therapy	O
with	O
salsalate	B-DRUG
,	O
persisted	O
for	O
as	O
long	O
as	O
salsalate	B-DRUG
was	O
administered	O
,	O
and	O
cleared	O
within	O
3	O
weeks	O
of	O
discontinuing	O
the	O
medication	O
.	O
We	O
describe	O
a	O
patient	O
who	O
experienced	O
a	O
lichenoid	B-ADVEFFECT
eruption	I-ADVEFFECT
after	O
the	O
initiation	O
of	O
salsalate	B-DRUG
for	O
relief	O
of	O
arthritic	O
pain	O
.	O
Amphotericin	B-DRUG
B	I-DRUG
-	O
induced	O
seizures	B-ADVEFFECT
in	O
a	O
patient	O
with	O
AIDS	O
.	O
CASE	O
SUMMARY	O
:	O
A	O
46-year	O
-	O
old	O
African	O
-	O
American	O
man	O
experienced	O
recurrent	O
grand	B-ADVEFFECT
mal	I-ADVEFFECT
seizures	I-ADVEFFECT
during	O
intravenous	O
infusion	O
of	O
amphotericin	B-DRUG
B	I-DRUG
,	O
then	O
petit	O
mal	O
seizures	B-ADVEFFECT
as	O
the	O
infusion	O
was	O
stopped	O
and	O
the	O
drug	O
concentrations	O
decreased	O
with	O
time	O
.	O
CONCLUSIONS	O
:	O
Amphotericin	B-DRUG
B	I-DRUG
seems	O
to	O
be	O
the	O
probable	O
cause	O
of	O
the	O
seizures	B-ADVEFFECT
.	O
Despite	O
administration	O
of	O
phenytoin	O
and	O
lorazepam	O
,	O
the	O
seizures	B-ADVEFFECT
persisted	O
and	O
occurred	O
only	O
during	O
amphotercin	B-DRUG
B	I-DRUG
administration	O
.	O
Didanosine	B-DRUG
also	O
has	O
a	O
potential	O
for	O
inducing	O
seizures	B-ADVEFFECT
.	O
OBJECTIVE	O
:	O
To	O
report	O
a	O
case	O
of	O
multiple	O
episodes	O
of	O
seizure	B-ADVEFFECT
activity	O
in	O
an	O
AIDS	O
patent	O
following	O
amphotericin	B-DRUG
B	I-DRUG
infusion	O
.	O
The	O
time	O
course	O
of	O
events	O
suggested	O
that	O
amphotericin	B-DRUG
B	I-DRUG
was	O
the	O
cause	O
of	O
the	O
seizures	B-ADVEFFECT
in	O
this	O
AIDS	O
patient	O
.	O
To	O
date	O
,	O
only	O
three	O
cases	O
of	O
seizures	B-ADVEFFECT
associated	O
with	O
amphotericin	B-DRUG
B	I-DRUG
have	O
been	O
reported	O
in	O
the	O
literature	O
,	O
but	O
healthcare	O
providers	O
should	O
be	O
aware	O
of	O
the	O
potential	O
for	O
this	O
rare	O
adverse	O
effect	O
.	O
Vocal	B-ADVEFFECT
cord	I-ADVEFFECT
paralysis	I-ADVEFFECT
as	O
a	O
consequence	O
of	O
peritonsillar	O
infiltration	O
with	O
bupivacaine	B-DRUG
.	O
We	O
present	O
the	O
case	O
of	O
a	O
5-year	O
-	O
old	O
girl	O
who	O
developed	O
bilateral	B-ADVEFFECT
vocal	I-ADVEFFECT
cord	I-ADVEFFECT
paralysis	I-ADVEFFECT
following	O
preoperative	O
peritonsillar	O
bupivacaine	B-DRUG
infiltration	O
.	O
A	O
53	O
year	O
old	O
Greenlandic	O
male	O
was	O
admitted	O
twice	O
over	O
a	O
period	O
of	O
4	O
years	O
with	O
a	O
new	O
complete	O
right	B-ADVEFFECT
bundle	I-ADVEFFECT
branch	I-ADVEFFECT
block	I-ADVEFFECT
after	O
ingestion	O
of	O
10	O
g	O
and	O
4	O
g	O
of	O
carbamazepine	B-DRUG
respectively	O
.	O
Carbamazepine	B-DRUG
induced	O
right	B-ADVEFFECT
bundle	I-ADVEFFECT
branch	I-ADVEFFECT
block	I-ADVEFFECT
in	O
a	O
Greenlandic	O
patient	O
.	O
Cicatricial	B-ADVEFFECT
entropion	I-ADVEFFECT
associated	O
with	O
chronic	O
dipivefrin	B-DRUG
application	O
.	O
CONCLUSIONS	O
:	O
Cicatrization	O
in	O
the	O
substantia	O
propria	O
of	O
the	O
conjunctiva	O
by	O
excessive	O
lymphocytic	O
infiltration	O
after	O
topically	O
administered	O
antiglaucoma	O
drugs	O
including	O
dipivefrin	B-DRUG
is	O
a	O
possible	O
mechanism	O
of	O
action	O
for	O
entropion	B-ADVEFFECT
.	O
Nine	O
eyes	O
from	O
6	O
patients	O
,	O
74	O
years	O
to	O
90	O
years	O
of	O
age	O
,	O
referred	O
by	O
ophthalmologists	O
for	O
repair	O
of	O
cicatricial	B-ADVEFFECT
entropion	I-ADVEFFECT
after	O
at	O
least	O
2	O
years	O
of	O
twice	O
-	O
a	O
-	O
day	O
application	O
of	O
dipivefrin	B-DRUG
.	O
PURPOSE	O
:	O
To	O
report	O
patients	O
who	O
presented	O
to	O
the	O
oculoplastics	O
department	O
for	O
repair	O
of	O
cicatrical	B-ADVEFFECT
entropion	I-ADVEFFECT
after	O
topical	O
use	O
of	O
dipivefrin	B-DRUG
.	O
A	O
34-year	O
-	O
old	O
lady	O
developed	O
a	O
constellation	B-ADVEFFECT
of	I-ADVEFFECT
dermatitis	I-ADVEFFECT
,	O
fever	B-ADVEFFECT
,	O
lymphadenopathy	B-ADVEFFECT
and	O
hepatitis	B-ADVEFFECT
,	O
beginning	O
on	O
the	O
17th	O
day	O
of	O
a	O
course	O
of	O
oral	O
sulphasalazine	B-DRUG
for	O
sero	O
-	O
negative	O
rheumatoid	O
arthritis	O
.	O
A	O
34-year	O
-	O
old	O
lady	O
developed	O
a	O
constellation	B-ADVEFFECT
of	I-ADVEFFECT
dermatitis	I-ADVEFFECT
,	O
fever	B-ADVEFFECT
,	O
lymphadenopathy	B-ADVEFFECT
and	O
hepatitis	B-ADVEFFECT
,	O
beginning	O
on	O
the	O
17th	O
day	O
of	O
a	O
course	O
of	O
oral	O
sulphasalazine	B-DRUG
for	O
sero	O
-	O
negative	O
rheumatoid	O
arthritis	O
.	O
A	O
34-year	O
-	O
old	O
lady	O
developed	O
a	O
constellation	B-ADVEFFECT
of	I-ADVEFFECT
dermatitis	I-ADVEFFECT
,	O
fever	B-ADVEFFECT
,	O
lymphadenopathy	B-ADVEFFECT
and	O
hepatitis	B-ADVEFFECT
,	O
beginning	O
on	O
the	O
17th	O
day	O
of	O
a	O
course	O
of	O
oral	O
sulphasalazine	B-DRUG
for	O
sero	O
-	O
negative	O
rheumatoid	O
arthritis	O
.	O
A	O
34-year	O
-	O
old	O
lady	O
developed	O
a	O
constellation	B-ADVEFFECT
of	I-ADVEFFECT
dermatitis	I-ADVEFFECT
,	O
fever	B-ADVEFFECT
,	O
lymphadenopathy	B-ADVEFFECT
and	O
hepatitis	B-ADVEFFECT
,	O
beginning	O
on	O
the	O
17th	O
day	O
of	O
a	O
course	O
of	O
oral	O
sulphasalazine	B-DRUG
for	O
sero	O
-	O
negative	O
rheumatoid	O
arthritis	O
.	O
It	O
is	O
thought	O
that	O
the	O
clinico	O
-	O
pathological	O
features	O
and	O
chronology	O
of	O
this	O
case	O
bore	O
the	O
hallmarks	O
of	O
the	O
so	O
-	O
called	O
""""	O
3-week	O
sulphasalazine	B-ADVEFFECT
syndrome	I-ADVEFFECT
""""	O
,	O
a	O
rare	O
,	O
but	O
often	O
fatal	B-ADVEFFECT
,	O
immunoallergic	B-ADVEFFECT
reaction	I-ADVEFFECT
to	O
sulphasalazine	B-DRUG
.	O
It	O
is	O
thought	O
that	O
the	O
clinico	O
-	O
pathological	O
features	O
and	O
chronology	O
of	O
this	O
case	O
bore	O
the	O
hallmarks	O
of	O
the	O
so	O
-	O
called	O
""""	O
3-week	O
sulphasalazine	B-ADVEFFECT
syndrome	I-ADVEFFECT
""""	O
,	O
a	O
rare	O
,	O
but	O
often	O
fatal	B-ADVEFFECT
,	O
immunoallergic	B-ADVEFFECT
reaction	I-ADVEFFECT
to	O
sulphasalazine	B-DRUG
.	O
It	O
is	O
thought	O
that	O
the	O
clinico	O
-	O
pathological	O
features	O
and	O
chronology	O
of	O
this	O
case	O
bore	O
the	O
hallmarks	O
of	O
the	O
so	O
-	O
called	O
""""	O
3-week	O
sulphasalazine	B-ADVEFFECT
syndrome	I-ADVEFFECT
""""	O
,	O
a	O
rare	O
,	O
but	O
often	O
fatal	B-ADVEFFECT
,	O
immunoallergic	B-ADVEFFECT
reaction	I-ADVEFFECT
to	O
sulphasalazine	B-DRUG
.	O
It	O
is	O
thought	O
that	O
the	O
clinico	O
-	O
pathological	O
features	O
and	O
chronology	O
of	O
this	O
case	O
bore	O
the	O
hallmarks	O
of	O
the	O
so	O
-	O
called	O
""""	O
3-week	O
sulphasalazine	B-ADVEFFECT
syndrome	I-ADVEFFECT
""""	O
,	O
a	O
rare	O
,	O
but	O
often	O
fatal	B-ADVEFFECT
,	O
immunoallergic	B-ADVEFFECT
reaction	I-ADVEFFECT
to	O
sulphasalazine	B-DRUG
.	O
It	O
is	O
thought	O
that	O
the	O
clinico	O
-	O
pathological	O
features	O
and	O
chronology	O
of	O
this	O
case	O
bore	O
the	O
hallmarks	O
of	O
the	O
so	O
-	O
called	O
""""	O
3-week	O
sulphasalazine	B-ADVEFFECT
syndrome	I-ADVEFFECT
""""	O
,	O
a	O
rare	O
,	O
but	O
often	O
fatal	B-ADVEFFECT
,	O
immunoallergic	B-ADVEFFECT
reaction	I-ADVEFFECT
to	O
sulphasalazine	B-DRUG
.	O
It	O
is	O
thought	O
that	O
the	O
clinico	O
-	O
pathological	O
features	O
and	O
chronology	O
of	O
this	O
case	O
bore	O
the	O
hallmarks	O
of	O
the	O
so	O
-	O
called	O
""""	O
3-week	O
sulphasalazine	B-ADVEFFECT
syndrome	I-ADVEFFECT
""""	O
,	O
a	O
rare	O
,	O
but	O
often	O
fatal	B-ADVEFFECT
,	O
immunoallergic	B-ADVEFFECT
reaction	I-ADVEFFECT
to	O
sulphasalazine	B-DRUG
.	O
The	O
3-week	O
sulphasalazine	B-ADVEFFECT
syndrome	I-ADVEFFECT
strikes	O
again	O
.	O
Interestingly	O
,	O
the	O
use	O
of	O
carboplatin	O
(	O
CBDCA	O
)	O
and	O
VDS	O
in	O
the	O
subsequent	O
treatment	O
course	O
was	O
well	O
tolerated	O
indicating	O
that	O
the	O
SIADH	B-ADVEFFECT
was	O
most	O
likely	O
to	O
have	O
been	O
induced	O
by	O
administration	O
of	O
CDDP	B-DRUG
.	O
Syndrome	B-ADVEFFECT
of	I-ADVEFFECT
inappropriate	I-ADVEFFECT
secretion	I-ADVEFFECT
of	I-ADVEFFECT
ADH	I-ADVEFFECT
(	O
SIADH	B-ADVEFFECT
)	O
following	O
cisplatin	B-DRUG
administration	O
in	O
a	O
pulmonary	O
adenocarcinoma	O
patient	O
with	O
a	O
malignant	O
pleural	O
effusion	O
.	O
Syndrome	B-ADVEFFECT
of	I-ADVEFFECT
inappropriate	I-ADVEFFECT
secretion	I-ADVEFFECT
of	I-ADVEFFECT
ADH	I-ADVEFFECT
(	O
SIADH	B-ADVEFFECT
)	O
following	O
cisplatin	B-DRUG
administration	O
in	O
a	O
pulmonary	O
adenocarcinoma	O
patient	O
with	O
a	O
malignant	O
pleural	O
effusion	O
.	O
We	O
report	O
a	O
patient	O
with	O
pulmonary	O
adenocarcinoma	O
complicated	O
by	O
the	O
syndrome	B-ADVEFFECT
of	I-ADVEFFECT
inappropriate	I-ADVEFFECT
secretion	I-ADVEFFECT
of	I-ADVEFFECT
antidiuretic	I-ADVEFFECT
hormone	I-ADVEFFECT
(	O
SIADH	B-ADVEFFECT
)	O
following	O
systemic	O
chemotherapy	O
with	O
cisplatin	B-DRUG
(	O
CDDP	B-DRUG
)	O
and	O
vindesine	B-DRUG
(	O
VDS	B-DRUG
)	O
.	O
We	O
report	O
a	O
patient	O
with	O
pulmonary	O
adenocarcinoma	O
complicated	O
by	O
the	O
syndrome	B-ADVEFFECT
of	I-ADVEFFECT
inappropriate	I-ADVEFFECT
secretion	I-ADVEFFECT
of	I-ADVEFFECT
antidiuretic	I-ADVEFFECT
hormone	I-ADVEFFECT
(	O
SIADH	B-ADVEFFECT
)	O
following	O
systemic	O
chemotherapy	O
with	O
cisplatin	B-DRUG
(	O
CDDP	B-DRUG
)	O
and	O
vindesine	B-DRUG
(	O
VDS	B-DRUG
)	O
.	O
We	O
report	O
a	O
patient	O
with	O
pulmonary	O
adenocarcinoma	O
complicated	O
by	O
the	O
syndrome	B-ADVEFFECT
of	I-ADVEFFECT
inappropriate	I-ADVEFFECT
secretion	I-ADVEFFECT
of	I-ADVEFFECT
antidiuretic	I-ADVEFFECT
hormone	I-ADVEFFECT
(	O
SIADH	B-ADVEFFECT
)	O
following	O
systemic	O
chemotherapy	O
with	O
cisplatin	B-DRUG
(	O
CDDP	B-DRUG
)	O
and	O
vindesine	B-DRUG
(	O
VDS	B-DRUG
)	O
.	O
We	O
report	O
a	O
patient	O
with	O
pulmonary	O
adenocarcinoma	O
complicated	O
by	O
the	O
syndrome	B-ADVEFFECT
of	I-ADVEFFECT
inappropriate	I-ADVEFFECT
secretion	I-ADVEFFECT
of	I-ADVEFFECT
antidiuretic	I-ADVEFFECT
hormone	I-ADVEFFECT
(	O
SIADH	B-ADVEFFECT
)	O
following	O
systemic	O
chemotherapy	O
with	O
cisplatin	B-DRUG
(	O
CDDP	B-DRUG
)	O
and	O
vindesine	B-DRUG
(	O
VDS	B-DRUG
)	O
.	O
We	O
report	O
a	O
patient	O
with	O
pulmonary	O
adenocarcinoma	O
complicated	O
by	O
the	O
syndrome	B-ADVEFFECT
of	I-ADVEFFECT
inappropriate	I-ADVEFFECT
secretion	I-ADVEFFECT
of	I-ADVEFFECT
antidiuretic	I-ADVEFFECT
hormone	I-ADVEFFECT
(	O
SIADH	B-ADVEFFECT
)	O
following	O
systemic	O
chemotherapy	O
with	O
cisplatin	B-DRUG
(	O
CDDP	B-DRUG
)	O
and	O
vindesine	B-DRUG
(	O
VDS	B-DRUG
)	O
.	O
We	O
report	O
a	O
patient	O
with	O
pulmonary	O
adenocarcinoma	O
complicated	O
by	O
the	O
syndrome	B-ADVEFFECT
of	I-ADVEFFECT
inappropriate	I-ADVEFFECT
secretion	I-ADVEFFECT
of	I-ADVEFFECT
antidiuretic	I-ADVEFFECT
hormone	I-ADVEFFECT
(	O
SIADH	B-ADVEFFECT
)	O
following	O
systemic	O
chemotherapy	O
with	O
cisplatin	B-DRUG
(	O
CDDP	B-DRUG
)	O
and	O
vindesine	B-DRUG
(	O
VDS	B-DRUG
)	O
.	O
We	O
report	O
a	O
patient	O
with	O
pulmonary	O
adenocarcinoma	O
complicated	O
by	O
the	O
syndrome	B-ADVEFFECT
of	I-ADVEFFECT
inappropriate	I-ADVEFFECT
secretion	I-ADVEFFECT
of	I-ADVEFFECT
antidiuretic	I-ADVEFFECT
hormone	I-ADVEFFECT
(	O
SIADH	B-ADVEFFECT
)	O
following	O
systemic	O
chemotherapy	O
with	O
cisplatin	B-DRUG
(	O
CDDP	B-DRUG
)	O
and	O
vindesine	B-DRUG
(	O
VDS	B-DRUG
)	O
.	O
We	O
report	O
a	O
patient	O
with	O
pulmonary	O
adenocarcinoma	O
complicated	O
by	O
the	O
syndrome	B-ADVEFFECT
of	I-ADVEFFECT
inappropriate	I-ADVEFFECT
secretion	I-ADVEFFECT
of	I-ADVEFFECT
antidiuretic	I-ADVEFFECT
hormone	I-ADVEFFECT
(	O
SIADH	B-ADVEFFECT
)	O
following	O
systemic	O
chemotherapy	O
with	O
cisplatin	B-DRUG
(	O
CDDP	B-DRUG
)	O
and	O
vindesine	B-DRUG
(	O
VDS	B-DRUG
)	O
.	O
After	O
extensive	O
neurological	O
'	O
work	O
up	O
'	O
,	O
we	O
realized	O
that	O
the	O
anisocoria	B-ADVEFFECT
was	O
related	O
to	O
the	O
transdermal	O
scopolamine	B-DRUG
patch	O
that	O
we	O
had	O
prescribed	O
for	O
weaning	O
off	O
the	O
opioid	O
.	O
Anisocoria	B-ADVEFFECT
from	O
transdermal	O
scopolamine	B-DRUG
.	O
De	B-ADVEFFECT
novo	I-ADVEFFECT
absence	I-ADVEFFECT
status	I-ADVEFFECT
of	O
late	O
onset	O
following	O
withdrawal	O
of	O
lorazepam	B-DRUG
:	O
a	O
case	O
report	O
.	O
The	O
aim	O
of	O
this	O
report	O
is	O
to	O
describe	O
the	O
clinical	O
and	O
electroencephalographic	O
findings	O
seen	O
in	O
an	O
elderly	O
woman	O
without	O
previous	O
history	O
of	O
seizures	O
who	O
developed	O
a	O
nonconvulsive	B-ADVEFFECT
generalized	I-ADVEFFECT
status	I-ADVEFFECT
epilepticus	I-ADVEFFECT
following	O
acute	O
withdrawal	O
of	O
lorazepam	B-DRUG
.	O
Early	O
recognition	O
of	O
hereditary	O
motor	O
and	O
sensory	O
neuropathy	O
type	O
1	O
can	O
avoid	O
life	B-ADVEFFECT
-	I-ADVEFFECT
threatening	I-ADVEFFECT
vincristine	I-ADVEFFECT
neurotoxicity	I-ADVEFFECT
.	O
Recognizing	O
early	O
signs	O
of	O
HMSN	O
,	O
such	O
as	O
areflexia	O
and	O
pes	O
cavus	O
deformity	O
,	O
can	O
prevent	O
severe	B-ADVEFFECT
neurotoxicity	I-ADVEFFECT
of	O
polychemotherapy	O
by	O
avoiding	O
vincristine	B-DRUG
.	O
The	O
disease	O
predisposes	O
to	O
severe	O
vincristine	B-ADVEFFECT
neurotoxicity	I-ADVEFFECT
.	O
We	O
report	O
a	O
31-year	O
-	O
old	O
women	O
with	O
recurrent	O
Hodgkin	O
's	O
lymphoma	O
and	O
unrecognized	O
HMSN-1	O
who	O
developed	O
severe	B-ADVEFFECT
motor	I-ADVEFFECT
neuropathy	I-ADVEFFECT
3	O
weeks	O
after	O
the	O
first	O
cycle	O
of	O
treatment	O
including	O
2	O
mg	O
of	O
vincristine	B-DRUG
.	O
Acute	O
asymptomatic	B-ADVEFFECT
hepatitis	I-ADVEFFECT
in	O
a	O
healthy	O
normal	O
volunteer	O
exposed	O
to	O
2	O
oral	O
doses	O
of	O
amodiaquine	B-DRUG
and	O
artesunate	B-DRUG
.	O
Acute	O
asymptomatic	B-ADVEFFECT
hepatitis	I-ADVEFFECT
in	O
a	O
healthy	O
normal	O
volunteer	O
exposed	O
to	O
2	O
oral	O
doses	O
of	O
amodiaquine	B-DRUG
and	O
artesunate	B-DRUG
.	O
This	O
report	O
describes	O
an	O
unexpected	O
drug	O
-	O
induced	O
hepatitis	B-ADVEFFECT
in	O
a	O
previously	O
healthy	O
young	O
woman	O
exposed	O
to	O
2	O
doses	O
of	O
amodiaquine	B-DRUG
and	O
artesunate	B-DRUG
.	O
This	O
report	O
describes	O
an	O
unexpected	O
drug	O
-	O
induced	O
hepatitis	B-ADVEFFECT
in	O
a	O
previously	O
healthy	O
young	O
woman	O
exposed	O
to	O
2	O
doses	O
of	O
amodiaquine	B-DRUG
and	O
artesunate	B-DRUG
.	O
Systemic	B-ADVEFFECT
allergic	I-ADVEFFECT
contact	I-ADVEFFECT
dermatitis	I-ADVEFFECT
to	O
8-methoxypsoralen	B-DRUG
(	O
8-MOP	B-DRUG
)	O
.	O
Systemic	B-ADVEFFECT
allergic	I-ADVEFFECT
contact	I-ADVEFFECT
dermatitis	I-ADVEFFECT
to	O
8-methoxypsoralen	B-DRUG
(	O
8-MOP	B-DRUG
)	O
.	O
We	O
describe	O
a	O
patient	O
who	O
had	O
a	O
systemic	B-ADVEFFECT
allergic	I-ADVEFFECT
contact	I-ADVEFFECT
dermatitis	I-ADVEFFECT
to	O
8-MOP	B-DRUG
develop	O
during	O
her	O
second	O
course	O
of	O
PUVA	O
treatment	O
for	O
psoriasis	O
.	O
A	O
33-year	O
-	O
old	O
man	O
with	O
a	O
history	O
of	O
recreational	O
benztropine	B-DRUG
abuse	O
presented	O
to	O
the	O
emergency	O
department	O
with	O
confusion	B-ADVEFFECT
,	O
abdominal	B-ADVEFFECT
pain	I-ADVEFFECT
,	O
and	O
distention	B-ADVEFFECT
.	O
A	O
33-year	O
-	O
old	O
man	O
with	O
a	O
history	O
of	O
recreational	O
benztropine	B-DRUG
abuse	O
presented	O
to	O
the	O
emergency	O
department	O
with	O
confusion	B-ADVEFFECT
,	O
abdominal	B-ADVEFFECT
pain	I-ADVEFFECT
,	O
and	O
distention	B-ADVEFFECT
.	O
A	O
33-year	O
-	O
old	O
man	O
with	O
a	O
history	O
of	O
recreational	O
benztropine	B-DRUG
abuse	O
presented	O
to	O
the	O
emergency	O
department	O
with	O
confusion	B-ADVEFFECT
,	O
abdominal	B-ADVEFFECT
pain	I-ADVEFFECT
,	O
and	O
distention	B-ADVEFFECT
.	O
Agranulocytosis	B-ADVEFFECT
and	O
granulocytopenia	B-ADVEFFECT
associated	O
with	O
quetiapine	B-DRUG
.	O
Agranulocytosis	B-ADVEFFECT
and	O
granulocytopenia	B-ADVEFFECT
associated	O
with	O
quetiapine	B-DRUG
.	O
CONCLUSION	O
:	O
Although	O
a	O
definite	O
association	O
has	O
not	O
been	O
proven	O
,	O
clinicians	O
should	O
be	O
aware	O
of	O
the	O
possibility	O
of	O
agranulocytosis	B-ADVEFFECT
while	O
using	O
quetiapine	B-DRUG
.	O
METHOD	O
:	O
We	O
describe	O
three	O
case	O
-	O
reports	O
concerning	O
haematological	B-ADVEFFECT
adverse	I-ADVEFFECT
effects	I-ADVEFFECT
of	O
quetiapine	B-DRUG
.	O
RESULTS	O
:	O
Quetiapine	B-DRUG
was	O
associated	O
with	O
leucopenia	B-ADVEFFECT
in	O
two	O
patients	O
and	O
clinically	O
apparent	O
agranulocytosis	B-ADVEFFECT
in	O
one	O
patient	O
.	O
RESULTS	O
:	O
Quetiapine	B-DRUG
was	O
associated	O
with	O
leucopenia	B-ADVEFFECT
in	O
two	O
patients	O
and	O
clinically	O
apparent	O
agranulocytosis	B-ADVEFFECT
in	O
one	O
patient	O
.	O
CONCLUSIONS	O
:	O
There	O
is	O
very	O
little	O
published	O
information	O
regarding	O
ofloxacin	B-DRUG
-	O
induced	O
toxic	B-ADVEFFECT
epidermal	I-ADVEFFECT
necrolysis	I-ADVEFFECT
.	O
However	O
,	O
a	O
large	O
case	O
-	O
control	O
study	O
included	O
three	O
cases	O
of	O
either	O
Stevens	B-ADVEFFECT
-	I-ADVEFFECT
Johnson	I-ADVEFFECT
syndrome	I-ADVEFFECT
or	O
toxic	B-ADVEFFECT
epidermal	I-ADVEFFECT
necrolysis	I-ADVEFFECT
associated	O
with	O
ofloxacin	B-DRUG
use	O
,	O
but	O
no	O
details	O
of	O
the	O
cases	O
were	O
given	O
.	O
However	O
,	O
a	O
large	O
case	O
-	O
control	O
study	O
included	O
three	O
cases	O
of	O
either	O
Stevens	B-ADVEFFECT
-	I-ADVEFFECT
Johnson	I-ADVEFFECT
syndrome	I-ADVEFFECT
or	O
toxic	B-ADVEFFECT
epidermal	I-ADVEFFECT
necrolysis	I-ADVEFFECT
associated	O
with	O
ofloxacin	B-DRUG
use	O
,	O
but	O
no	O
details	O
of	O
the	O
cases	O
were	O
given	O
.	O
It	O
is	O
hoped	O
that	O
this	O
case	O
report	O
creates	O
awareness	O
that	O
ofloxacin	B-DRUG
-	O
induced	O
toxic	B-ADVEFFECT
epidermal	I-ADVEFFECT
necrolysis	I-ADVEFFECT
is	O
possible	O
.	O
OBJECTIVE	O
:	O
To	O
report	O
a	O
fatal	O
case	O
of	O
toxic	B-ADVEFFECT
epidermal	I-ADVEFFECT
necrolysis	I-ADVEFFECT
in	O
a	O
man	O
who	O
was	O
treated	O
with	O
oral	O
ofloxacin	B-DRUG
for	O
epididymitis	O
.	O
Ofloxacin	B-DRUG
:	O
a	O
probable	O
cause	O
of	O
toxic	B-ADVEFFECT
epidermal	I-ADVEFFECT
necrolysis	I-ADVEFFECT
.	O
This	O
report	O
rules	O
out	O
other	O
causes	O
of	O
toxic	B-ADVEFFECT
epidermal	I-ADVEFFECT
necrolysis	I-ADVEFFECT
and	O
implicates	O
ofloxacin	B-DRUG
in	O
what	O
appears	O
to	O
be	O
an	O
atypical	O
presentation	O
of	O
drug	O
-	O
induced	O
toxic	B-ADVEFFECT
epidermal	I-ADVEFFECT
necrolysis	I-ADVEFFECT
.	O
This	O
report	O
rules	O
out	O
other	O
causes	O
of	O
toxic	B-ADVEFFECT
epidermal	I-ADVEFFECT
necrolysis	I-ADVEFFECT
and	O
implicates	O
ofloxacin	B-DRUG
in	O
what	O
appears	O
to	O
be	O
an	O
atypical	O
presentation	O
of	O
drug	O
-	O
induced	O
toxic	B-ADVEFFECT
epidermal	I-ADVEFFECT
necrolysis	I-ADVEFFECT
.	O
A	O
boy	O
with	O
chronic	O
neutropenia	O
and	O
recurrent	O
inflammatory	O
skin	O
lesions	O
developed	O
multiple	B-ADVEFFECT
erythematous	I-ADVEFFECT
nodules	I-ADVEFFECT
following	O
administration	O
of	O
G	B-DRUG
-	I-DRUG
CSF	I-DRUG
.	O
A	O
girl	O
with	O
cystic	O
fibrosis	O
and	O
cyclic	O
neutropenia	O
developed	O
an	O
erythematous	B-ADVEFFECT
papular	I-ADVEFFECT
eruption	I-ADVEFFECT
without	O
fever	O
or	O
neutrophilia	O
7	O
months	O
after	O
commencing	O
therapy	O
with	O
G	B-DRUG
-	I-DRUG
CSF	I-DRUG
.	O
Neutrophilic	B-ADVEFFECT
dermatoses	I-ADVEFFECT
in	O
two	O
children	O
with	O
idiopathic	O
neutropenia	O
:	O
association	O
with	O
granulocyte	B-DRUG
colony	I-DRUG
-	I-DRUG
stimulating	I-DRUG
factor	I-DRUG
(	O
G	B-DRUG
-	I-DRUG
CSF	I-DRUG
)	O
therapy	O
.	O
Neutrophilic	B-ADVEFFECT
dermatoses	I-ADVEFFECT
in	O
two	O
children	O
with	O
idiopathic	O
neutropenia	O
:	O
association	O
with	O
granulocyte	B-DRUG
colony	I-DRUG
-	I-DRUG
stimulating	I-DRUG
factor	I-DRUG
(	O
G	B-DRUG
-	I-DRUG
CSF	I-DRUG
)	O
therapy	O
.	O
Painful	O
neutrophilic	B-ADVEFFECT
skin	I-ADVEFFECT
lesions	I-ADVEFFECT
were	O
observed	O
in	O
two	O
children	O
receiving	O
granulocyte	B-DRUG
colony	I-DRUG
-	I-DRUG
stimulating	I-DRUG
factor	I-DRUG
(	O
G	B-DRUG
-	I-DRUG
CSF	I-DRUG
)	O
for	O
treatment	O
of	O
idiopathic	O
neutropenia	O
.	O
Painful	O
neutrophilic	B-ADVEFFECT
skin	I-ADVEFFECT
lesions	I-ADVEFFECT
were	O
observed	O
in	O
two	O
children	O
receiving	O
granulocyte	B-DRUG
colony	I-DRUG
-	I-DRUG
stimulating	I-DRUG
factor	I-DRUG
(	O
G	B-DRUG
-	I-DRUG
CSF	I-DRUG
)	O
for	O
treatment	O
of	O
idiopathic	O
neutropenia	O
.	O
Painful	B-ADVEFFECT
neutrophilic	B-ADVEFFECT
skin	I-ADVEFFECT
lesions	I-ADVEFFECT
were	O
observed	O
in	O
two	O
children	O
receiving	O
granulocyte	B-DRUG
colony	I-DRUG
-	I-DRUG
stimulating	I-DRUG
factor	I-DRUG
(	O
G	B-DRUG
-	I-DRUG
CSF	I-DRUG
)	O
for	O
treatment	O
of	O
idiopathic	O
neutropenia	O
.	O
Painful	B-ADVEFFECT
neutrophilic	B-ADVEFFECT
skin	I-ADVEFFECT
lesions	I-ADVEFFECT
were	O
observed	O
in	O
two	O
children	O
receiving	O
granulocyte	B-DRUG
colony	I-DRUG
-	I-DRUG
stimulating	I-DRUG
factor	I-DRUG
(	O
G	B-DRUG
-	I-DRUG
CSF	I-DRUG
)	O
for	O
treatment	O
of	O
idiopathic	O
neutropenia	O
.	O
We	O
believe	O
that	O
these	O
skin	B-ADVEFFECT
eruptions	I-ADVEFFECT
belong	O
to	O
a	O
spectrum	O
of	O
neutrophilic	B-ADVEFFECT
dermatoses	I-ADVEFFECT
that	O
can	O
be	O
induced	O
or	O
aggravated	O
by	O
G	B-DRUG
-	I-DRUG
CSF	I-DRUG
therapy	O
.	O
We	O
believe	O
that	O
these	O
skin	B-ADVEFFECT
eruptions	I-ADVEFFECT
belong	O
to	O
a	O
spectrum	O
of	O
neutrophilic	B-ADVEFFECT
dermatoses	I-ADVEFFECT
that	O
can	O
be	O
induced	O
or	O
aggravated	O
by	O
G	B-DRUG
-	I-DRUG
CSF	I-DRUG
therapy	O
.	O
There	O
is	O
a	O
putative	O
role	O
of	O
liothyronine	B-DRUG
administration	O
in	O
precipitating	O
or	O
activating	O
hyperthyroidism	B-ADVEFFECT
.	O
Triiodothyronine	B-DRUG
-	O
induced	O
thyrotoxicosis	B-ADVEFFECT
in	O
ophthalmic	O
Graves	O
disease	O
.	O
This	O
case	O
report	O
describes	O
the	O
development	O
of	O
asymptomatic	O
visual	B-ADVEFFECT
field	I-ADVEFFECT
defects	I-ADVEFFECT
(	O
VFDs	B-ADVEFFECT
)	O
in	O
a	O
psychiatric	O
patient	O
with	O
bipolar	O
disorder	O
receiving	O
adjunctive	O
tiagabine	B-DRUG
treatment	O
.	O
This	O
case	O
report	O
describes	O
the	O
development	O
of	O
asymptomatic	O
visual	B-ADVEFFECT
field	I-ADVEFFECT
defects	I-ADVEFFECT
(	O
VFDs	B-ADVEFFECT
)	O
in	O
a	O
psychiatric	O
patient	O
with	O
bipolar	O
disorder	O
receiving	O
adjunctive	O
tiagabine	B-DRUG
treatment	O
.	O
Pulmonary	B-ADVEFFECT
toxicity	I-ADVEFFECT
with	O
mefloquine	B-DRUG
.	O
This	O
is	O
the	O
second	O
report	O
of	O
acute	B-ADVEFFECT
lung	I-ADVEFFECT
injury	I-ADVEFFECT
and	O
diffuse	B-ADVEFFECT
alveolar	I-ADVEFFECT
damage	I-ADVEFFECT
caused	O
by	O
mefloquine	B-DRUG
.	O
This	O
is	O
the	O
second	O
report	O
of	O
acute	B-ADVEFFECT
lung	I-ADVEFFECT
injury	I-ADVEFFECT
and	O
diffuse	B-ADVEFFECT
alveolar	I-ADVEFFECT
damage	I-ADVEFFECT
caused	O
by	O
mefloquine	B-DRUG
.	O
This	O
report	O
presents	O
a	O
case	O
of	O
acute	B-ADVEFFECT
lung	I-ADVEFFECT
injury	I-ADVEFFECT
developing	O
within	O
hours	O
after	O
administration	O
of	O
mefloquine	B-DRUG
for	O
a	O
low	O
-	O
level	O
Plasmodium	O
falciparum	O
malaria	O
,	O
which	O
was	O
persistent	O
despite	O
halofantrine	O
therapy	O
.	O
An	O
adult	O
male	O
presented	O
with	O
central	B-ADVEFFECT
blindness	I-ADVEFFECT
after	O
ingesting	O
methanol	B-DRUG
.	O
Reversal	O
of	O
severe	O
methanol	B-DRUG
-	O
induced	O
visual	B-ADVEFFECT
impairment	I-ADVEFFECT
:	O
no	O
evidence	O
of	O
retinal	O
toxicity	O
due	O
to	O
fomepizole	O
.	O
Extra	O
caution	O
should	O
be	O
taken	O
in	O
using	O
octreotide	B-DRUG
or	O
its	O
long	O
-	O
acting	O
analog	O
in	O
patients	O
otherwise	O
predisposed	O
to	O
intrahepatic	B-ADVEFFECT
bile	I-ADVEFFECT
stasis	I-ADVEFFECT
.	O
Gallstones	B-ADVEFFECT
and	O
bile	O
sludge	O
are	O
common	O
side	O
effects	O
of	O
octreotide	B-DRUG
therapy	O
but	O
rarely	O
become	O
symptomatic	O
or	O
require	O
treatment	O
.	O
Gallstones	B-ADVEFFECT
and	O
bile	O
sludge	O
are	O
common	O
side	O
effects	O
of	O
octreotide	B-DRUG
therapy	O
but	O
rarely	O
become	O
symptomatic	O
or	O
require	O
treatment	O
.	O
Hepatolithiasis	B-ADVEFFECT
(	O
intrahepatic	O
stone	O
)	O
during	O
octreotide	B-DRUG
therapy	O
for	O
acromegaly	O
:	O
a	O
case	O
report	O
.	O
In	O
addition	O
to	O
its	O
known	O
effect	O
on	O
gallbladder	B-ADVEFFECT
stasis	I-ADVEFFECT
,	O
octreotide	B-DRUG
alters	B-ADVEFFECT
bile	I-ADVEFFECT
acid	I-ADVEFFECT
composition	I-ADVEFFECT
and	O
may	O
thus	O
hasten	B-ADVEFFECT
intrahepatic	I-ADVEFFECT
sludge	I-ADVEFFECT
and	O
stone	B-ADVEFFECT
formation	I-ADVEFFECT
.	O
In	O
addition	O
to	O
its	O
known	O
effect	O
on	O
gallbladder	B-ADVEFFECT
stasis	I-ADVEFFECT
,	O
octreotide	B-DRUG
alters	B-ADVEFFECT
bile	I-ADVEFFECT
acid	I-ADVEFFECT
composition	I-ADVEFFECT
and	O
may	O
thus	O
hasten	B-ADVEFFECT
intrahepatic	I-ADVEFFECT
sludge	I-ADVEFFECT
and	O
stone	B-ADVEFFECT
formation	I-ADVEFFECT
.	O
In	O
addition	O
to	O
its	O
known	O
effect	O
on	O
gallbladder	B-ADVEFFECT
stasis	I-ADVEFFECT
,	O
octreotide	B-DRUG
alters	B-ADVEFFECT
bile	I-ADVEFFECT
acid	I-ADVEFFECT
composition	I-ADVEFFECT
and	O
may	O
thus	O
hasten	B-ADVEFFECT
intrahepatic	I-ADVEFFECT
sludge	I-ADVEFFECT
and	O
stone	B-ADVEFFECT
formation	I-ADVEFFECT
.	O
In	O
addition	O
to	O
its	O
known	O
effect	O
on	O
gallbladder	B-ADVEFFECT
stasis	I-ADVEFFECT
,	O
octreotide	B-DRUG
alters	B-ADVEFFECT
bile	I-ADVEFFECT
acid	I-ADVEFFECT
composition	I-ADVEFFECT
and	O
may	O
thus	O
hasten	B-ADVEFFECT
intrahepatic	I-ADVEFFECT
sludge	I-ADVEFFECT
and	O
stone	B-ADVEFFECT
formation	I-ADVEFFECT
.	O
This	O
is	O
the	O
first	O
reported	O
case	O
of	O
hepatolithiasis	B-ADVEFFECT
during	O
octreotide	B-DRUG
therapy	O
.	O
We	O
report	O
a	O
case	O
of	O
hepatolithiasis	B-ADVEFFECT
(	O
intrahepatic	O
stone	O
)	O
complicated	O
by	O
gram	O
-	O
negative	O
sepsis	O
in	O
a	O
37	O
year	O
old	O
male	O
with	O
acromegaly	O
being	O
treated	O
with	O
octreotide	B-DRUG
.	O
However	O
,	O
in	O
the	O
mid	O
-	O
to	O
-	O
late	O
1980s	O
,	O
a	O
series	O
of	O
letters	O
to	O
the	O
editor	O
and	O
case	O
reports	O
announced	O
an	O
association	O
between	O
tamoxifen	B-DRUG
therapy	O
in	O
women	O
with	O
breast	O
cancer	O
and	O
the	O
development	O
of	O
endometrial	B-ADVEFFECT
carcinoma	I-ADVEFFECT
.	O
In	O
this	O
healthy	O
population	O
,	O
the	O
relative	O
risk	O
of	O
developing	O
endometrial	B-ADVEFFECT
carcinoma	I-ADVEFFECT
in	O
the	O
tamoxifen	B-DRUG
arm	O
was	O
2.54	O
,	O
although	O
when	O
stratified	O
by	O
age	O
,	O
in	O
women	O
over	O
50	O
,	O
the	O
risk	O
grew	O
to	O
4.01	O
.	O
INH	B-DRUG
,	O
which	O
is	O
a	O
leading	O
cause	O
of	O
drug	B-ADVEFFECT
eruptions	I-ADVEFFECT
in	O
the	O
above	O
group	O
of	O
drugs	O
was	O
withdrawn	O
.	O
Isonicotinic	B-DRUG
acid	I-DRUG
hydrazide	I-DRUG
induced	O
anagen	B-ADVEFFECT
effluvium	I-ADVEFFECT
and	O
associated	O
lichenoid	B-ADVEFFECT
eruption	I-ADVEFFECT
.	O
Isonicotinic	B-DRUG
acid	I-DRUG
hydrazide	I-DRUG
induced	O
anagen	B-ADVEFFECT
effluvium	I-ADVEFFECT
and	O
associated	O
lichenoid	B-ADVEFFECT
eruption	I-ADVEFFECT
.	O
Such	O
anagen	B-ADVEFFECT
effluvium	I-ADVEFFECT
with	O
lichenoid	B-ADVEFFECT
eruption	I-ADVEFFECT
following	O
INH	B-DRUG
therapy	O
has	O
not	O
been	O
observed	O
previously	O
.	O
Such	O
anagen	B-ADVEFFECT
effluvium	I-ADVEFFECT
with	O
lichenoid	B-ADVEFFECT
eruption	I-ADVEFFECT
following	O
INH	B-DRUG
therapy	O
has	O
not	O
been	O
observed	O
previously	O
.	O
Linear	B-ADVEFFECT
IgA	I-ADVEFFECT
bullous	I-ADVEFFECT
dermatosis	I-ADVEFFECT
occurring	O
after	O
carbamazepine	B-DRUG
.	O
We	O
report	O
a	O
patient	O
who	O
experienced	B-ADVEFFECT
LABD	O
shortly	O
after	O
starting	O
carbamazepine	B-DRUG
therapy	O
.	O
After	O
a	O
second	O
dose	O
of	O
metoclopramide	B-DRUG
,	O
these	O
symptoms	O
recurred	O
and	O
were	O
associated	O
with	O
confusion	B-ADVEFFECT
,	O
agitation	B-ADVEFFECT
,	O
fever	B-ADVEFFECT
,	O
diaphoresis	B-ADVEFFECT
,	O
tachypnea	B-ADVEFFECT
,	O
tachycardia	B-ADVEFFECT
,	O
and	O
hypertension	O
.	O
After	O
a	O
second	O
dose	O
of	O
metoclopramide	B-DRUG
,	O
these	O
symptoms	O
recurred	O
and	O
were	O
associated	O
with	O
confusion	B-ADVEFFECT
,	O
agitation	B-ADVEFFECT
,	O
fever	B-ADVEFFECT
,	O
diaphoresis	B-ADVEFFECT
,	O
tachypnea	B-ADVEFFECT
,	O
tachycardia	B-ADVEFFECT
,	O
and	O
hypertension	O
.	O
After	O
a	O
second	O
dose	O
of	O
metoclopramide	B-DRUG
,	O
these	O
symptoms	O
recurred	O
and	O
were	O
associated	O
with	O
confusion	B-ADVEFFECT
,	O
agitation	B-ADVEFFECT
,	O
fever	B-ADVEFFECT
,	O
diaphoresis	B-ADVEFFECT
,	O
tachypnea	B-ADVEFFECT
,	O
tachycardia	B-ADVEFFECT
,	O
and	O
hypertension	O
.	O
After	O
a	O
second	O
dose	O
of	O
metoclopramide	B-DRUG
,	O
these	O
symptoms	O
recurred	O
and	O
were	O
associated	O
with	O
confusion	B-ADVEFFECT
,	O
agitation	B-ADVEFFECT
,	O
fever	B-ADVEFFECT
,	O
diaphoresis	B-ADVEFFECT
,	O
tachypnea	B-ADVEFFECT
,	O
tachycardia	B-ADVEFFECT
,	O
and	O
hypertension	O
.	O
After	O
a	O
second	O
dose	O
of	O
metoclopramide	B-DRUG
,	O
these	O
symptoms	O
recurred	O
and	O
were	O
associated	O
with	O
confusion	B-ADVEFFECT
,	O
agitation	B-ADVEFFECT
,	O
fever	B-ADVEFFECT
,	O
diaphoresis	B-ADVEFFECT
,	O
tachypnea	B-ADVEFFECT
,	O
tachycardia	B-ADVEFFECT
,	O
and	O
hypertension	O
.	O
After	O
a	O
second	O
dose	O
of	O
metoclopramide	B-DRUG
,	O
these	O
symptoms	O
recurred	O
and	O
were	O
associated	O
with	O
confusion	B-ADVEFFECT
,	O
agitation	B-ADVEFFECT
,	O
fever	B-ADVEFFECT
,	O
diaphoresis	B-ADVEFFECT
,	O
tachypnea	B-ADVEFFECT
,	O
tachycardia	B-ADVEFFECT
,	O
and	O
hypertension	O
.	O
After	O
a	O
second	O
dose	O
of	O
metoclopramide	B-DRUG
,	O
these	O
symptoms	O
recurred	O
and	O
were	O
associated	O
with	O
confusion	B-ADVEFFECT
,	O
agitation	B-ADVEFFECT
,	O
fever	B-ADVEFFECT
,	O
diaphoresis	B-ADVEFFECT
,	O
tachypnea	B-ADVEFFECT
,	O
tachycardia	B-ADVEFFECT
,	O
and	O
hypertension	O
.	O
CONCLUSIONS	O
:	O
Clinicians	O
should	O
be	O
aware	O
of	O
a	O
risk	O
of	O
serotonin	B-ADVEFFECT
syndrome	I-ADVEFFECT
with	O
serious	O
extrapyramidal	B-ADVEFFECT
reactions	I-ADVEFFECT
in	O
patients	O
receiving	O
sertraline	B-DRUG
or	O
venlafaxine	B-DRUG
when	O
metoclopramide	B-DRUG
is	O
coadministered	O
even	O
in	O
a	O
single	O
,	O
conventional	O
dose	O
.	O
CONCLUSIONS	O
:	O
Clinicians	O
should	O
be	O
aware	O
of	O
a	O
risk	O
of	O
serotonin	B-ADVEFFECT
syndrome	I-ADVEFFECT
with	O
serious	O
extrapyramidal	B-ADVEFFECT
reactions	I-ADVEFFECT
in	O
patients	O
receiving	O
sertraline	B-DRUG
or	O
venlafaxine	B-DRUG
when	O
metoclopramide	B-DRUG
is	O
coadministered	O
even	O
in	O
a	O
single	O
,	O
conventional	O
dose	O
.	O
CONCLUSIONS	O
:	O
Clinicians	O
should	O
be	O
aware	O
of	O
a	O
risk	O
of	O
serotonin	B-ADVEFFECT
syndrome	I-ADVEFFECT
with	O
serious	O
extrapyramidal	B-ADVEFFECT
reactions	I-ADVEFFECT
in	O
patients	O
receiving	O
sertraline	B-DRUG
or	O
venlafaxine	B-DRUG
when	O
metoclopramide	B-DRUG
is	O
coadministered	O
even	O
in	O
a	O
single	O
,	O
conventional	O
dose	O
.	O
CONCLUSIONS	O
:	O
Clinicians	O
should	O
be	O
aware	O
of	O
a	O
risk	O
of	O
serotonin	B-ADVEFFECT
syndrome	I-ADVEFFECT
with	O
serious	O
extrapyramidal	B-ADVEFFECT
reactions	I-ADVEFFECT
in	O
patients	O
receiving	O
sertraline	B-DRUG
or	O
venlafaxine	B-DRUG
when	O
metoclopramide	B-DRUG
is	O
coadministered	O
even	O
in	O
a	O
single	O
,	O
conventional	O
dose	O
.	O
CONCLUSIONS	O
:	O
Clinicians	O
should	O
be	O
aware	O
of	O
a	O
risk	O
of	O
serotonin	B-ADVEFFECT
syndrome	I-ADVEFFECT
with	O
serious	O
extrapyramidal	B-ADVEFFECT
reactions	I-ADVEFFECT
in	O
patients	O
receiving	O
sertraline	B-DRUG
or	O
venlafaxine	B-DRUG
when	O
metoclopramide	B-DRUG
is	O
coadministered	O
even	O
in	O
a	O
single	O
,	O
conventional	O
dose	O
.	O
CONCLUSIONS	O
:	O
Clinicians	O
should	O
be	O
aware	O
of	O
a	O
risk	O
of	O
serotonin	B-ADVEFFECT
syndrome	I-ADVEFFECT
with	O
serious	O
extrapyramidal	B-ADVEFFECT
reactions	I-ADVEFFECT
in	O
patients	O
receiving	O
sertraline	B-DRUG
or	O
venlafaxine	B-DRUG
when	O
metoclopramide	B-DRUG
is	O
coadministered	O
even	O
in	O
a	O
single	O
,	O
conventional	O
dose	O
.	O
OBJECTIVE	O
:	O
To	O
report	O
2	O
cases	O
of	O
serotonin	B-ADVEFFECT
syndrome	I-ADVEFFECT
with	O
serious	O
extrapyramidal	B-ADVEFFECT
movement	I-ADVEFFECT
disorders	I-ADVEFFECT
occurring	O
when	O
metoclopramide	B-DRUG
was	O
coadministered	O
with	O
sertraline	B-DRUG
or	O
venlafaxine	B-DRUG
.	O
OBJECTIVE	O
:	O
To	O
report	O
2	O
cases	O
of	O
serotonin	B-ADVEFFECT
syndrome	I-ADVEFFECT
with	O
serious	O
extrapyramidal	B-ADVEFFECT
movement	I-ADVEFFECT
disorders	I-ADVEFFECT
occurring	O
when	O
metoclopramide	B-DRUG
was	O
coadministered	O
with	O
sertraline	B-DRUG
or	O
venlafaxine	B-DRUG
.	O
OBJECTIVE	O
:	O
To	O
report	O
2	O
cases	O
of	O
serotonin	B-ADVEFFECT
syndrome	I-ADVEFFECT
with	O
serious	O
extrapyramidal	B-ADVEFFECT
movement	I-ADVEFFECT
disorders	I-ADVEFFECT
occurring	O
when	O
metoclopramide	B-DRUG
was	O
coadministered	O
with	O
sertraline	B-DRUG
or	O
venlafaxine	B-DRUG
.	O
OBJECTIVE	O
:	O
To	O
report	O
2	O
cases	O
of	O
serotonin	B-ADVEFFECT
syndrome	I-ADVEFFECT
with	O
serious	O
extrapyramidal	B-ADVEFFECT
movement	I-ADVEFFECT
disorders	I-ADVEFFECT
occurring	O
when	O
metoclopramide	B-DRUG
was	O
coadministered	O
with	O
sertraline	B-DRUG
or	O
venlafaxine	B-DRUG
.	O
OBJECTIVE	O
:	O
To	O
report	O
2	O
cases	O
of	O
serotonin	B-ADVEFFECT
syndrome	I-ADVEFFECT
with	O
serious	O
extrapyramidal	B-ADVEFFECT
movement	I-ADVEFFECT
disorders	I-ADVEFFECT
occurring	O
when	O
metoclopramide	B-DRUG
was	O
coadministered	O
with	O
sertraline	B-DRUG
or	O
venlafaxine	B-DRUG
.	O
OBJECTIVE	O
:	O
To	O
report	O
2	O
cases	O
of	O
serotonin	B-ADVEFFECT
syndrome	I-ADVEFFECT
with	O
serious	O
extrapyramidal	B-ADVEFFECT
movement	I-ADVEFFECT
disorders	I-ADVEFFECT
occurring	O
when	O
metoclopramide	B-DRUG
was	O
coadministered	O
with	O
sertraline	B-DRUG
or	O
venlafaxine	B-DRUG
.	O
Serotonin	B-ADVEFFECT
syndrome	I-ADVEFFECT
caused	O
by	O
selective	O
serotonin	O
reuptake	O
-	O
inhibitors	O
-	O
metoclopramide	B-DRUG
interaction	O
.	O
She	O
was	O
administered	O
metoclopramide	B-DRUG
because	O
of	O
nausea	O
and	O
,	O
within	O
2	O
hours	O
,	O
developed	O
agitation	B-ADVEFFECT
,	O
dysarthria	B-ADVEFFECT
,	O
diaphoresis	B-ADVEFFECT
,	O
and	O
a	O
movement	B-ADVEFFECT
disorder	I-ADVEFFECT
.	O
She	O
was	O
administered	O
metoclopramide	B-DRUG
because	O
of	O
nausea	O
and	O
,	O
within	O
2	O
hours	O
,	O
developed	O
agitation	B-ADVEFFECT
,	O
dysarthria	B-ADVEFFECT
,	O
diaphoresis	B-ADVEFFECT
,	O
and	O
a	O
movement	B-ADVEFFECT
disorder	I-ADVEFFECT
.	O
She	O
was	O
administered	O
metoclopramide	B-DRUG
because	O
of	O
nausea	O
and	O
,	O
within	O
2	O
hours	O
,	O
developed	O
agitation	B-ADVEFFECT
,	O
dysarthria	B-ADVEFFECT
,	O
diaphoresis	B-ADVEFFECT
,	O
and	O
a	O
movement	B-ADVEFFECT
disorder	I-ADVEFFECT
.	O
She	O
was	O
administered	O
metoclopramide	B-DRUG
because	O
of	O
nausea	O
and	O
,	O
within	O
2	O
hours	O
,	O
developed	O
agitation	B-ADVEFFECT
,	O
dysarthria	B-ADVEFFECT
,	O
diaphoresis	B-ADVEFFECT
,	O
and	O
a	O
movement	B-ADVEFFECT
disorder	I-ADVEFFECT
.	O
She	O
was	O
admitted	O
following	O
a	O
fall	O
and	O
,	O
after	O
being	O
given	O
metoclopramide	B-DRUG
,	O
developed	O
movement	B-ADVEFFECT
disorder	I-ADVEFFECT
and	O
a	O
period	O
of	O
unresponsiveness	B-ADVEFFECT
.	O
She	O
was	O
admitted	O
following	O
a	O
fall	O
and	O
,	O
after	O
being	O
given	O
metoclopramide	B-DRUG
,	O
developed	O
movement	B-ADVEFFECT
disorder	I-ADVEFFECT
and	O
a	O
period	O
of	O
unresponsiveness	B-ADVEFFECT
.	O
